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RESUMO  
 
Embora a epilepsia seja reconhecida há vários séculos como uma das 
doenças neurológicas mais prevalentes, a sua base celular e molecular não é ainda 
completamente conhecida. Contudo, acredita-se que a sua causa seja multifatorial 
e envolva um desequilíbrio entre a neurotransmissão GABAérgica e 
glutamatérgica. Cerca de 30% dos doentes epiléticos são refratários à terapia 
medicamentosa e a maioria destes doentes sofre de epilepsia do lobo mesial 
temporal (MTLE). Apenas uma fração dos doentes resistentes aos fármacos 
atualmente disponíveis pode ser submetida a cirurgia como tratamento de último 
recurso. Os restantes doentes permanecem com um limitado recurso ao tratamento 
médico. Isto realça a necessidade de encontrar novas ferramentas farmacológicas, 
capazes de controlar as convulsões e/ou o processo epileptogénico. 
Os transportadores de elevada afinidade para o GABA e o glutamato, são 
proteínas chave no controlo da excitabilidade no sistema nervoso central. 
Considerando o seu papel crucial no controlo dos níveis extracelulares de 
neurotransmissores, torna-se evidente que a sua atividade deva ser fortemente 
regulada. O trifosfato de adenosina (ATP) e a adenosina surgem como potenciais 
candidatos capazes de modular o transporte dos neurotransmissores rápidos, uma 
vez que os níveis extracelulares de ambos aumentam rapidamente no cérebro 
durante um estímulo neuronal de elevada frequência ou em situações patológicas, 
permitindo a coabitação espacial e temporal destas duas purinas com os 
neurotransmissores, GABA e glutamato. Tendo em consideração trabalhos 
anteriores que sugerem que o recetor P2X7, sensível ao ATP, é um alvo potencial 
para o controlo das crises epiléticas e que a ativação deste recetor é capaz de 
modular os níveis extracelulares dos neurotransmissores aminoacídicos, este 
estudo focou-se no papel do recetor P2X7 na modulação sincronizada da captação 
de GABA e glutamato na epilepsia refratária ao tratamento medicamentoso. 
Assim, os objetivos deste trabalho visaram avaliar: (1) o papel dos recetores 
P2X7 no transporte de elevada afinidade de GABA e glutamato em terminais 
nervosos (sinaptossomas) isolados do cérebro humano (controlos cadavéricos) e 
de ratazanas Wistar; (2) a via de sinalização subjacente à modulação do transporte 
de GABA e de glutamato mediada pela ativação do recetor P2X7; e (3) as 
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alterações causadas pela variação da densidade e localização do recetor P2X7 no 
transporte de elevada afinidade de GABA e glutamato em indivíduos epiléticos – 
quer em ratazanas com epilepsia induzida por injecção de pilocarpina, quer em 
doentes com epilepsia refratária ao tratamento medicamentoso (MTLE e não-
MTLE). Além disso, avaliou-se se a densidade e a localização de outros recetores 
purinérgicos estaria alterada em amostras de cérebro humano de doentes MTLE, 
em comparação com dadores cadavéricos, a fim de inferir sobre o seu envolvimento 
na epilepsia. Uma vez que a MTLE afeta o hipocampo e o neocórtex adjacente, 
estas duas estruturas cerebrais foram incluídas sempre que possível nas análises 
realizadas neste trabalho.  
A acumulação de GABA e de glutamato (marcados radioativamente) foi 
avaliada por espectrometria de cintilação líquida. A densidade e distribuição dos 
recetores purinérgicos no tecido cerebral foram avaliadas por Western blotting e 
por imunofluorescência acoplada à microscopia confocal, respetivamente. 
Os resultados obtidos mostram que a ativação de recetores P2X7 modula 
negativamente a captação de GABA e de glutamato por terminais nervosos 
isolados do neocórtex humano e de ratazanas Wistar. O mecanismo subjacente à 
modulação negativa da captação desencadeada pela ativação do recetor P2X7 
parece ser comum a ambos os neurotransmissores e envolve o colapso parcial do 
gradiente de Na+ – a força motriz para a captação de aminoácidos – que é causado 
pelo influxo de Na+ através do recetor P2X7. Esta conclusão foi alcançada, uma 
vez que: (1) o efeito inibitório do agonista do recetor P2X7, BzATP, na captação de 
aminoácidos foi mimetizado por dois ionóforos de Na+; (2) o aumento da 
concentração intracelular de Na+, bem como a diminuição da concentração 
extracelular de Na+, diminuíram a captação de ambos os neurotransmissores, como 
previsto pelas alterações nos potenciais de reversão dos transportadores; (3) o 
efeito inibitório do BzATP foi atenuado quando o gradiente transmembranar de Na+ 
foi diminuído; (4) a ativação do recetor P2X7 aumentou significativamente os níveis 
de intracelulares de Na+; e (5) o bloqueio seletivo da entrada de Na+ através do 
recetor P2X7 impediu o efeito inibitório de BzATP na captação de glutamato e de 
GABA. Além disso, os resultados obtidos em sinaptossomas de córtex de ratazana 
mostram que, paralelamente à diminuição da captação de GABA e de glutamato 
quando o Ca2+ extracelular se encontra diminuído, a ativação do recetor P2X7 
também promove a libertação de ambos os neurotransmissores, embora a 
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magnitude e o mecanismo subjacente à libertação de GABA e de glutamato sejam 
significativamente diferentes: a ativação do recetor P2X7 promove a libertação de 
pequenas quantidades de GABA através da reversão do transportador GAT1, 
enquanto o glutamato é libertado em maiores quantidades através do próprio 
recetor P2X7. 
Contrariamente às nossas expectativas, não foram encontradas diferenças 
na densidade nem na função do recetor P2X7 em terminais nervosos isolados do 
córtex de ratazanas epiléticas comparativamente com os animais controlo. Estes 
resultados contrastam com os resultados obtidos em terminais nervosos isolados 
do neocórtex cerebral de doentes epiléticos refratários à medicação, nos quais o 
recetor P2X7 se encontra aumentado, estando este aumento correlacionado com 
uma maior potência do BzATP (agonista dos recetores P2X7) para inibir a captação 
de GABA, mas não a captação de glutamato. 
Dado que a atividade epilética também origina grandes quantidades de 
adenosina e que os recetores A2A da adenosina têm sido implicados tanto no 
controlo dos níveis sinápticos de GABA e glutamato como na epilepsia, foi avaliado, 
pela primeira vez, a densidade e localização destes recetores em amostras de 
cérebro humano de doentes epiléticos refratários à medicação. Contrariamente à 
localização pré-sináptica dos receptores P2X7, os resultados obtidos mostraram 
que os recetores A2A são principalmente expressos em astrócitos, estando a sua 
densidade aumentada de forma significativa em amostras do cérebro de doentes 
MTLE. É muito provável que a modulação negativa da captação de glutamato 
promovida pelo colapso do gradiente de Na+ transmembranar após a ativação do 
recetor A2A astrocítico, tal como descrito na literatura, seja bastante semelhante à 
descrita neste estudo para a modulação da captação de glutamato e GABA devida 
à ativação do recetor P2X7, e que ambas possam estar aumentadas em doentes 
epiléticos. 
No seu conjunto, os resultados deste trabalho sugerem que a ativação 
transitória de recetores P2X7 e A2A – motivada pelo aumento da quantidade 
extracelular de ATP libertado aquando de um estímulo nervoso de elevada 
frequência e o subsequente catabolismo extracelular deste nucleótido em 
adenosina – poderá facilitar não só a neurotransmissão glutamatérgica, mas 
também, a neurotransmissão GABAérgica cuja atividade promove a neuro-inibição 
tónica após estímulo intenso. Embora esta modulação fina pareça ser 
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fisiologicamente relevante para a formação da memória e a aprendizagem através 
da potenciação da neurotransmissão, a sobre expressão dos recetores P2X7 e A2A 
no cérebro epilético (respetivamente nos terminais nervosos e astrócitos) poderá 
ser perigosa e fomentar as crises epiléticas. Isto pode ser explicado pelo facto do 
aumento da densidade dos recetores P2X7 e A2A promover, para além da 
sustentação da sinalização glutamatérgica excitatória, a persistência da 
neurotransmissão GABAérgica, devido à diminuição da captação deste 
neurotransmissor, que poderá culminar no rundown GABAérgico, um processo 
através do qual o efeito inibitório do GABA é convertido num efeito pró-convulsivo 
promovendo assim a hiperexcitabilidade neuronal, em vez da neuro-inibição. 
Em suma, este estudo vem preencher uma lacuna na compreensão do 
cérebro epilético humano, em relação ao papel pro-epileptogénico do ATP e da 
adenosina em condições em que os níveis sinápticos destas purinas aumentam 
rapidamente, como por exemplo durante estímulos de elevada frequência. Assim 
sendo, o uso de antagonistas seletivos dos recetores P2X7 neuronais e dos 
recetores A2A nos astrócitos poderá constituir uma alternativa terapêutica nova e 
valiosa para controlar a epilepsia refratária. Para além do contexto da epilepsia, 
existe um aumento significativo de resultados que indiciam o envolvimento de 
ambos os recetores, P2X7 e A2A, na fisiopatologia de vários distúrbios neurológicos, 
nos quais o antagonismo destes dois subtipos de recetores purinérgicos poderá 
também apresentar benefícios clínicos através do controlo dos "sinais perigosos" 
provenientes da sua disfunção.  
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ABSTRACT 
 
Although epilepsy is recognized for centuries as one of the most prevalent 
neurological disorders, its cellular and molecular basis is still largely unknown. It is, 
however, believed that the cause is multifactorial and involves an unbalance 
between GABAergic and glutamatergic neurotransmission. About 30% of epilepsy 
patients remain drug-refractory and the majority of them suffer from Mesial 
Temporal Lobe Epilepsy (MTLE). Only a fraction of these patients can be submitted 
to surgery as a last resource treatment, leaving remaining patients with an unmet 
medical need. This highlights the need to search for new pharmacological tools 
controlling seizures and/or epileptogenesis. 
High-affinity transporters of fast neurotransmitters, like γ-aminobutyric acid 
(GABA) and glutamate, are key proteins in the control of excitability in the central 
nervous system (CNS). Given their major role in the control of neurotransmitters 
levels in the extracellular space, it became clear that these transporters must be 
highly regulated. Adenosine triphosphate (ATP) and adenosine emerge as potential 
candidates to modulate neurotransmitters transport since their extracellular levels 
rapidly increase in the brain during high-frequency neuronal firing or under 
pathological conditions allowing the spatial and temporal cohabitation of these two 
purines with GABA and glutamate neurotransmitters. Taking into consideration 
previous findings suggesting that the ATP-sensitive P2X7 receptor, may be a 
potential target to control seizures and that this receptor is able to modulate the 
extracellular levels of amino acid neurotransmitters, we focus our attention on the 
study of the role of the P2X7 receptor on synchronized modulation of GABA and 
glutamate uptake in drug-resistant epilepsy. 
Therefore, the goals of this work were to evaluate: (1) the role of the ATP-
sensitive P2X7 receptor on high-affinity transport of GABA and glutamate into nerve 
terminals (synaptosomes) isolated from brain samples from Wistar rats and human 
cadaveric controls; (2) the signaling pathway underlying the P2X7 receptor-
mediated modulation of GABA and glutamate transport; (3) the changes in the 
expression and cellular localization of the P2X7 receptor, as well as the P2X7 
receptor-mediated modulation of high-affinity transport of amino acid, in epileptic 
individuals – both rats injected with pilocarpine and human drug-refractory epileptic 
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patients (MTLE and non-MTLE). In addition, we also evaluated if the expression and 
the localization of other purinoceptors were altered in human brain samples from 
MTLE patients as compared with cadaveric controls in order to infer about their 
involvement in epilepsy. Since the MTLE disorder affects the hippocampus and 
adjacent neocortex, these two regions were included whenever possible in the 
analysis performed in this study.  
Radiolabeled GABA and glutamate accumulation was evaluated by liquid 
scintillation spectrometry. Brain tissue density and distribution of purinoceptors were 
assessed by Western blot analysis and immunofluorescence confocal microscopy, 
respectively. 
Results clearly show that activation of the pre-synaptic P2X7 receptor 
downregulates [3H]GABA and [14C]glutamate uptake by nerve terminals of the 
neocortex of human and Wistar rats. The mechanism underlying downmodulation 
of the uptake of amino acids triggered by activation of the P2X7 receptor seems to 
be common for both neurotransmitters and it involves the partial collapse of the Na+ 
driving-force for neurotransmitters uptake caused by the influx of Na+ through the 
P2X7 receptor channel. This conclusion was achieved, since: 1) the inhibitory effect 
of the P2X7 receptor agonist, 2’(3’)-O-(4-Benzoylbenzoyl)ATP (BzATP), on amino 
acids uptake was mimicked by two Na+ ionophores; (2) the increase in intracellular 
Na+ concentration, as well as the decrease in extracellular Na+ concentration 
downmodulated the uptake of both neurotransmitters, as predicted by the changes 
in transporter reversal potentials; (3) the inhibitory effect of BzATP was attenuated 
when transmembrane Na+ gradient was decreased; (4) the activation of the P2X7 
receptor significantly increased intrasynaptosomal Na+ levels; and (5) the selective 
blockade of Na+ entry through the P2X7 receptor prevented the inhibitory effect of 
BzATP on GABA and glutamate uptake. Additionally, obtained data using rat cortical 
synaptosomes show that besides decreasing GABA and glutamate uptake under 
low Ca2+ conditions, activation of the P2X7 receptor also favors the release of both 
neurotransmitters, although the magnitude and the mechanisms underlying GABA 
and glutamate release differ significantly: P2X7 receptor activation causes the 
outflow of small amounts of GABA through reversal of GAT1 transporter, while 
glutamate is released in higher quantities through the P2X7 receptor pore.    
 Contrary to our expectations, we found no differences in the P2X7 receptor 
expression and function on rat cortical nerve terminals of pilocarpine-induced 
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epileptic rats, compared to their control littermates. These findings contrast with our 
data using nerve terminals isolated from human cerebral neocortices obtained from 
drug-resistant epileptic patients, where the P2X7 receptor was upregulated and the 
increase in the P2X7 receptor density correlates with a higher potency of the P2X7 
receptor agonist, BzATP, concerning inhibition of GABA, but not glutamate uptake 
by nerve terminals of the neocortex of MTLE patients.  
 Since epileptic activity also produce large amounts of adenosine and that 
adenosine A2A receptors have been implicated both in controlling synaptic levels of 
GABA and glutamate and in epilepsy, we assessed, for the first time, the density 
and localization of A2A receptors in human brain samples of drug-resistant epileptic 
patients. In contrast to the pre-synaptic localization of the P2X7 receptor, data from 
this study show that A2A receptors are mainly expressed in astrocytes being its 
density significantly increased in brain samples from MTLE patients. It is highly 
possible that the downmodulation of glutamate uptake promoted by the partial 
collapse of the transmembrane Na+ gradient described in the literature is owed to a 
surplus in astrocytic A2A receptor activation and may be enhanced in epileptic 
patients. This is quite similar to what we have found in the modulation of GABA and 
glutamate uptake by the activation of the P2X7 receptor. 
All together, results from this study suggest that transient activation of P2X7 
and A2A receptors by massive quantities of ATP released under high-frequency 
nerve firing and its subsequent extracellular catabolism into adenosine, may 
facilitate the glutamatergic neurotransmission while promoting the endurance of 
GABAergic neurotransmission ensuring, therefore, tonic neuro-inhibition following 
an intense period of stimulation. While this fine-tuning modulation may be 
physiologically relevant under conditions of memory formation and learning by 
potentiating neurotransmission, the overexpression of P2X7 and A2A purinoceptors 
(respectively in nerve terminals and astrocytes) in the epileptic brain may be 
dangerous and foment epileptic discharges. This may be explained by the fact that 
the increase in the levels of P2X7 and A2A receptors promotes, besides the 
endurance of excitatory glutamatergic signaling, the persistence of GABA-mediated 
neurotransmission, due to a decrease in GABA uptake, that may result in 
GABAergic rundown, a process by which GABAergic inhibition is converted into a 
pro-convulsive action by promoting neuronal hyperexcitability, instead of inhibition.  
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In summary, this study fills a gap in the understanding of the human epileptic 
brain, regarding the pro-epileptic role of both ATP and adenosine in the extracellular 
milieu, in conditions where the synaptic levels of these purines rapidly increase, 
such as during intense neuronal discharges. Taking this into account, 
pharmacological targeting of neuronal P2X7 and astrocytic A2A receptors with 
selective antagonists may constitute a novel and valuable therapeutic alternative to 
control drug-resistant epilepsy in humans. Outside the epilepsy context, there is an 
explosion of data indicating that both P2X7 and A2A receptors are involved in the 
pathophysiology of several neurological syndromes, where the blockage of both 
purinoceptors may also present clinical benefits to curb “dangerous signals” 
emanating from an underlying dysfunction of these two purinoceptors. 
 
 
 
 
 
Purinergic modulation of neurotransmitter transporters in human MTLE 
Introduction 
13 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION
Purinergic modulation of neurotransmitter transporters in human MTLE 
Introduction 
14 
 
 
 
 
Epilepsy: an old disorder still unsolved 
Epilepsy was first described by Hippocrates in the 5th century BC. It is 
estimated that over 50 million people around the world suffer from epilepsy 
nowadays. This makes this disease one of the world’s oldest recognized disorders, 
the second most common neurological disease after stroke, and a major burden for 
public health systems (Madsen et al., 2010; Pitkänen and Lukasiuk, 2011). 
Epilepsy is a chronic and heterogeneous neurological disorder that 
is characterized by the propensity of the brain to generate spontaneous recurrent 
seizures having severe impact on patients’ quality of life due to devastating 
behavioral, social and occupational consequences. Epileptic seizures arise from an 
excessively synchronous and sustained discharge of a group of neurons and 
reflects periods of enhanced excitability (Engelborghs et al., 2000).  Its clinical 
presentation depends on the brain region in which the seizures start and spread, 
and can vary from light and nearly undetectable symptoms to loss of consciousness 
and severe convulsions culminating in status epilepticus (SE), a state of continuous 
seizures that is considered the most extreme form of seizure (Trinka et al., 2015). 
Regarding its etiology, epilepsy can be classified into three groups: 
structural/metabolic, genetic and unknown (Berg and Scheffer, 2011). In the 
structural/metabolic epilepsy, there is a distinct structural or metabolic condition of 
disease that has been demonstrated to be associated with a substantially increased 
risk of developing epilepsy. When of genetic origin, there is a separate disorder 
interposed between the gene defect and the epilepsy. The genetic epilepsy is, as 
best as understood, the direct result of a known or presumed genetic defect(s) in 
which seizures are the core symptom of the disorder. In the unknown epilepsy, as 
the name suggests, the nature of the underlying cause is unidentified. It is also 
called idiopathic epilepsy. 
Although epilepsy has been (and continue to be) one of the most studied 
neurological disorders, its cellular and molecular basis are still largely unknown 
(O'Dell et al., 2012; Pavlov et al., 2013) and there is still no cure for this disorder. 
Nevertheless, it is believed that the cause of epilepsy is multifactorial and involves 
several mechanisms, namely an imbalance between glutamatergic and GABAergic 
neurotransmission, changes in function and/or composition of the ionotropic 
receptors – which promote alterations of ionic gradients of Na+, Ca2+, Cl- or K+ – or 
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deficiency in endogenous neurotransmitters and neuromodulators (Engelborghs et 
al., 2000; Miles et al., 2012; Lerche et al., 2013; Pavlov et al., 2013; Waszkielewicz 
et al., 2013). The enormous complexity of this neurological disorder makes it 
impossible to fully understand the mechanisms underlying epileptogenesis and 
seizure generation only through clinical evaluation of human patients. Therefore the 
researchers developed rodent animal models in which the induced pathology 
resembles some aspects of the human pathology. There are several animal models 
of epilepsy currently being used, which are induced by neurochemical agents (e.g. 
pilocarpine and kainic acid), electrical stimulation protocols (e.g. electroshock-
induced seizures, afterdischarges and kindling), hyperthermal or hypoxic insults, 
traumatic injuries, optogenetics and rodent strains with idiopathic or audiogenic-
induced seizures (Curia et al., 2008; Pitkänen et al., 2011; O'Dell et al., 2012; 
Kandratavicius et al., 2014). The diversity of animal models to study epilepsy reflects 
the existence of not only one type of epilepsy, but the existence of different forms of 
epilepsy or epileptic syndromes. Therefore, the use of an appropriate animal model 
is essential when studying a particular form of epilepsy. One must, however, bear 
in mind that resemblance of any animal model with human pathology is associated 
with many limitations (Kandratavicius et al., 2014), namely, by (1) the anatomical 
and functional differences between species, (2) the chronicity of the disorder –  the 
evolution of epilepsy in humans occurs in several years whereas in animal models 
occurs in only a few weeks –  and (3) the origin and neuronal network adaptation to 
the initial cause of the disease. 
Most of the antiepileptic drugs (AEDs) currently used as primary therapy for 
epilepsy were discovered by screening, without a rationale regarding to the 
mechanism of action (Engelborghs et al., 2000). The posterior finding of the 
mechanism of action of such drugs clarified that most of AEDs exert their 
antiepileptic properties through only a few neurochemical mechanisms. Basically, 
most AEDs decrease membrane excitability through the interaction with ionic 
channel conductance – mainly Na+ (e.g. phenytoin and carbamazepin), K+ (e.g. 
retigabine) and Ca2+ (e.g. ethosuximide) channels – or with neurotransmitters 
receptors – essentially by the promotion of inhibitory neurotransmission (e.g. 
barbiturates and benzodiazepines) or by the inhibition of excitatory 
neurotransmission (e.g. lamotrigine and felbamate) (Engelborghs et al., 2000; Beck 
and Yaari, 2012; O'Dell et al., 2012). Some of these AEDs, such as valproate, exert 
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their action by acting on two or more different targets. In addition to the antiepileptic 
properties, a few novel AEDs, such as levetiracetam – which may affect exocytosis 
upon binding selectively to synaptic vesicle protein SV2A (Lynch et al., 2004; Yan 
et al., 2005; Russo et al., 2010) –, seem to have also some effects in the prevention 
or modification of epileptogenesis (Yan et al., 2005; Russo et al., 2010; Löscher, 
2012). Recently, some authors have emphasized neuronal cell transplantation as 
an alternative therapy for restraining spontaneous recurrent seizures in drug-
resistant epileptic individuals due to their ability for giving rise to neurons 
synthesizing the inhibitory neurotransmitter GABA, thereby recovering the neuronal 
loss and the adverse effects resulting therefrom (Shetty, 2012). 
Despite the intense research of the last decades, few new AEDs were 
approved to clinical practice and only 50% of the patients are adequately treated for 
their symptoms with the currently available AEDs (Madsen et al., 2010). Of the 
remaining patients, 20% are treated at expense of severe side effects, while about 
30% of patients are refractory to medication continuing to have spontaneous 
seizures, even when treated with three or more different drugs (Beck and Yaari, 
2012). Currently, in these refractory epilepsies the most promising treatment is the 
complete surgical removal of ‘‘the minimum amount of tissue that must be resected 
to produce seizure freedom’’, also known as epileptogenic zone, or the complete 
disconnection of this zone (Rosenow and Lüders, 2001). To define the location and 
boundaries of the epileptogenic zone, epileptologists use various diagnostic tools, 
such as electrophysiological recordings, analysis of seizure semiology, functional 
testing and neuroimaging techniques. However, only a subset of patients, in which 
the seizures are generated over a well-localized area that can be removed safely, 
are able to profit from this type of treatment, leaving the remaining patients with an 
unmet medical need. In this context, the research of new potential pharmacological 
targets able to control seizures is an urgent need. In addition to controlling seizures, 
the identification of a therapy that could prevent or modify epileptogenesis would 
represent a major advance over the majority of current treatment options.  
 
MTLE as an unmet medical need 
MTLE is the most common and devastating form of human intractable 
epilepsy. This chronic disease is characterized by a dynamic process that 
progressively alters neuronal excitability, establishes critical interconnections and 
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develops structural and biochemical changes (Henshall et al., 2013) that affect the 
hippocampus (O'Dell et al., 2012) – being MTLE frequently associated with 
hippocampal sclerosis characterized by neuronal loss of the Ammon’s horn or Cornu 
Ammonis (CA; hence the subdivisions CA1 through CA4) and concomitant 
astrogliosis (Cendes et al., 2014; Thom, 2014) – as well as the affection of several 
neocortical regions (Doherty et al., 2003; Bartolomei et al., 2005; Scanlon et al., 
2011; Alhusaini et al., 2012; Biagini et al., 2013; Di Maio, 2014; Kandratavicius et 
al., 2014). These pathological features often acquired over decades of disease limit 
the possibility of successful therapeutic approaches, often rendering the disease 
refractory and increasing the incapacitating nature of this specific epileptic disorder 
(Di Maio, 2014). 
The disease is normally initiated by a traumatic event, also defined as primary 
insult – including febrile seizures, SE, trauma or infection – after which the disease 
remains invisible during 5–15 years. This period is characterized by freedom of 
symptoms or complications and it is called latency period (Sharma et al., 2007; 
O'Dell et al., 2012; Di Maio, 2014). After this period, the patient begins to suffer from 
spontaneous seizures, which at the onset are controllable with medication (silent 
period; O’Dell et al., 2012). As the disease progresses, patients commonly develop 
intractable symptoms that cannot be managed with the available AEDs. At this time 
and when the epileptogenic zone is conveniently detected, amygdalo-
hypocampectomy surgery appears as the only available treatment of last resource.  
The irreversible structural and biochemical changes are thought to occur 
during the latent period. However, several authors propose that these changes 
continue to accumulate with each new insult over the course of the disease (Yang 
et al., 2010). These changes can include neurodegeneration, neurogenesis, 
astroglial scar and astrogliosis, aberrant sprouting of mossy fiber or granule cell 
axon, dendritic plasticity, blood-brain barrier damage, recruitment of inflammatory 
cells into brain tissue, reorganization of the extracellular matrix, and reorganization 
of the molecular architecture of individual brain cells (de Lanerolle et al., 2003; 
Sharma et al., 2007; Bae et al., 2010; Yang et al., 2010; Pitkänen and Lukasiuk, 
2011; O'Dell et al., 2012).  
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GABA and glutamate neurotransmission in CNS 
Glutamatergic neurotransmission: an overview 
Although glutamate effects in mammalian CNS were known for more than 75 
years, it was only in 1984 that this non-essential amino acid was really 
acknowledged as fulfilling the criteria of a neurotransmitter (reviewed by Niciu et al., 
2012). Currently it is known that glutamate is the main excitatory neurotransmitter 
in the CNS, playing an important role in many essential brain functions including 
cognition, memory and learning. Although the brain contains huge amounts of 
glutamate, normally only a small fraction of this neurotransmitter is present in the 
extracellular space (3-10 µM) (Danbolt, 2001). This high concentration gradient of 
glutamate across the plasma membrane is due to the fact that elevated 
concentrations of extracellular glutamate are toxic to neurons and may promote 
neuronal death in a process now referred as “excitotoxicity” (Niciu et al., 2012; 
Willard and Koochekpour, 2013).  
Glutamate cannot permeate the blood-brain barrier and, therefore, this amino 
acid must be synthesized from local precursors, such as glucose or glutamine. 
Neurons cannot perform the synthesis of glutamate from glucose, since these cells 
lack both the glutamine synthesizing and the pyruvate carboxylase enzymes 
(Rowley et al., 2012). Astrocytes, on the other hand, express both of these enzymes 
and are therefore essential for maintaining a supply of glutamine to neurons 
(Kersanté et al., 2013). Glutamine produced in glial cells is then transported to nerve 
terminals, where it is metabolized to glutamate, a process known as the glutamate-
glutamine cycle (Danbolt, 2001).  
Once synthesized in nerve terminals, glutamate is actively transported into 
synaptic vesicles by vesicular glutamate transporters (VGLUT) and then it is 
released by exocytosis of synaptic vesicles, in a Ca2+-dependent manner. Although 
most of the focus has been on synaptic release of glutamate from nerve terminals 
by exocytosis, this is not the only mechanism responsible to supply the extracellular 
fluid with glutamate (Danbolt, 2001; Zhou and Danbolt, 2014). In fact, there are 
several non-vesicular and non-exocytotic mechanisms through which glutamate can 
be released to extracellular space, namely through: glutamate-cystine antiporter 
(xCT; slc7a11), anion channels, reversal of high-affinity glutamate transporters, gap 
junctions (connexins and pannexins) and ATP-sensitive P2X7 receptors (Danbolt, 
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2001; Marcoli et al., 2008; Niciu et al., 2012; Zhou and Danbolt, 2014; Orellana et 
al., 2015). In addition, growing evidences show that brain astrocytes also contribute 
to the supply of extracellular glutamate, being the mechanisms of release similar to 
those found in neurons (Malarkey and Parpura, 2008; Orellana et al., 2011; Zhou 
and Danbolt, 2014). 
The released glutamate exerts its signaling by acting on ionotropic and 
metabotropic receptors which are located on the surface of cells expressing them 
(Willard and Koochekpour, 2013; Martinez-Lozada and Ortega, 2015). It is 
interesting to note that most cells in the CNS express at least one type of glutamate 
receptor. Ionotropic glutamate receptors can be subdivided into three groups of 
receptors, according to their selective agonist: N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate. All of 
these receptors are ligand-gated non-selective cation channel that induce a rapid 
excitatory postsynaptic current (EPSC), being NMDA family also gated by voltage. 
In contrast to ionotropic receptors, the responses mediated by metabotropic 
glutamate receptors are slower, since these receptors are G-protein coupled 
receptors (GPCR). Based on sequence homology, G-protein coupled and 
pharmacology, metabotropic glutamate receptors can be categorized in three 
groups. The receptors of group I (mGluR1 and mGluR5) are generally expressed 
on postsynaptic cells and are coupled to Gq protein promoting neuronal excitation 
through the activation of phospholipase C (PLC) and consequent release of inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). The receptors of group II 
(mGluR 2 and mGluR 3) and group III (mGluR 4 and mGluR 6-8) are mostly 
expressed on presynaptic cells and are coupled to a Gi protein promoting neuronal 
inhibition through the inhibition of adenylate cyclase (AC) and consequent decrease 
of cyclic AMP (cAMP) levels (Willard and Koochekpour, 2013). In general, it appears 
that both families of glutamate receptors – ionotropic and metabotropic – play crucial 
roles in the synaptic plasticity, a term used to describe changes in synaptic strength 
and efficacy either due to physiological alterations in neuronal activity (as in memory 
and learning) as well as due to pathological disturbances (Niciu et al., 2012): a long-
lasting increase in synaptic strength is known as long-term potentiation (LTP), while 
its counterpart is termed long-term depression (LTD). Several glutamate receptors 
have been largely implicated in several neurological disorders, such as 
Schizophrenia, Alzheimer’s disease, Parkinson’s disease, epilepsia and anxiety 
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(Willard and Koochekpour, 2013; Pitsikas, 2014; Crépel and Mulle, 2015; Nicoletti 
et al., 2015).  
After dissociation from the receptor, glutamate is transported back into the 
presynaptic nerve terminal or into surrounding astrocytes via high-affinity glutamate 
transporters (see section Neurotransmitter transporters) thereby terminating 
glutamate's excitatory action. Other mechanisms such as glutamate diffusion and 
binding to transporters also contributes to the control the extracellular concentration 
of glutamate (Danbolt, 2001; Fontana, 2015). 
 
GABAergic neurotransmission: an overview 
GABA is the main inhibitory neurotransmitter in the mammalian CNS, playing 
a fundamental role in the control of neuronal excitability, neuronal plasticity and 
network synchronization in tandem with glutamate (see previous section). The 
synthesis of GABA occurs by decarboxylation of glutamate through the enzyme 
glutamate decarboxylase, which is almost exclusively expressed in GABAergic 
neurons (Schousboe et al., 2014). The fact that GABA synthesis is closely 
connected with glutamate synthesis makes it very difficult to affect the synthesis of 
one neurotransmitter without affecting the synthesis of the other.  
After synthesis, GABA is transported into synaptic vesicles via a vesicular 
inhibitory amino acid transporter (VIAAT) and it is released in response to a specific 
stimulus through a Ca2+-dependent mechanism or by other Ca2+-independent 
pathways, namely by the reversal of the Na+-coupled high-affinity GABA 
transporters or through ATP-sensitive P2X7 receptor (Wang et al., 2002; Richerson 
and Wu, 2003; Papp et al., 2004; Wu et al., 2007; Lee et al., 2011). 
Released GABA exerts its function through the activation of widely distributed 
ionotropic (GABAA and GABAC) and metabotropic (GABAB) receptors. GABAB 
receptors are coupled to Gi/0 protein and mediate slow and prolonged inhibitory 
transmission. Presynaptic GABAB receptors inhibit the release of GABA (GABAB 
auto-receptors) and other neurotransmitters (GABAB hetero-receptors), such as 
glutamate and noradrenaline, via blockage of Ca2+ channels and second 
messenger-mediated effects downstream of Ca2+ entry, while postsynaptic GABAB 
receptors diminish excitability by the activation of inwardly rectifying potassium (Kir) 
channels (Kumar et al., 2013; Wu and Sun, 2015). Ionotropic GABA receptors are 
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ligand-gated receptors that mediate the hyperpolarization of the cell through Cl- 
influx (Madsen et al., 2010).  
The most important inhibitory receptor in the CNS is the ionotropic GABAA 
receptor (Sigel and Steinmann, 2012). This receptor is permeable to Cl- and HCO3- 
in a proportion of 5:1 and it is localized at the synaptic level, as well as, outside the 
synapse, being in this case referred to as perisynaptic or as extrasynaptic (Kaila et 
al., 1993; Miles et al., 2012; Sigel and Steinmann, 2012; Braat and Kooy, 2015; 
Schipper et al., 2015). Synaptically located GABAA receptors have low affinity for 
GABA and mediate fast inhibitory transmission (also referred as phasic or transient 
inhibition) in response to high concentrations (low micromolar) of intermittently 
released GABA, whereas extrasynaptic GABAA receptors display high-affinity for 
GABA, sensing low ambient GABA concentrations in the extracellular space in order 
to generate a form of tonic (persistent) inhibition (Brickley and Mody, 2012; Sigel 
and Steinmann, 2012; Braat and Kooy, 2015). Extrasynaptic GABAA receptors show 
no, or very little, desensitization in contrast to their synaptic counterparts (Madsen 
et al., 2010). Thus, tonic inhibitory currents are due to GABA that is not captured 
synaptically and produce a slow temporal inhibition by persistent activation of 
extrasynaptic GABAA receptors. Regarding its structure, GABAA receptor consists of 
heteromeric pentamers made up of various combinations of different subunits – α1-
6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3 – resulting in a complex heterogeneity of receptors 
with distinct physiological and pharmacological profiles (Braat and Kooy, 2015). It is 
believed that specific subunits are characteristic of extrasynaptic GABAA receptors, 
while other subunits are expressed only in synaptic GABAA receptors. For instance, 
synaptic GABAA receptors contain an α1-3, βn and γ2 subunits – being γ2 critical for 
the maintenance of receptors at the synapse – and extrasynaptic GABAA receptors 
contain α4-6 and δ subunit (Semyanov et al., 2004; Palma et al., 2007; Braat and 
Kooy, 2015). 
After dissociation from the receptor, and similarly to glutamate, GABA is 
transported back into presynaptic nerve endings or to astrocytes via Na+-coupled 
high-affinity GABA transporters (see section Neurotransmitter transporters) or it is 
diffused, thus terminating GABA's action. Most of the GABA taken up into nerve 
terminals is reutilized as a neurotransmitter, after its incorporation into synaptic 
vesicles.  A small amount of neuronal GABA, as well GABA taken up by astrocytes 
is metabolized into succinate, through the concerted action of GABA transaminase 
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(GABAT) and succinic semialdehyde dehydrogenase (Rowley et al., 2012; 
Schousboe et al., 2014). 
As previously said, GABA is the main inhibitory neurotransmitter. However, 
this only seems to be true in mature tissue (adult), since different studies have 
shown that, during the early development, GABA acting on GABAA receptors is 
depolarizing and often excitatory (Köhling, 2002; Ben-Ari et al., 2012; Ben-Ari, 2014; 
Wu and Sun, 2015). The “polarity” of GABA action (Figure 1) seems to be dependent 
on the intracellular Cl- concentration (Ben-Ari et al., 2012) and has been associated 
with two major cation-chloride transporters that regulates the intracellular Cl- 
concentration:  the inwardly directed mediated by Na+-K+-Cl- cotransporter (NKCC1) 
– largely responsible for the high intracellular Cl- concentration – and the Cl- 
extruding K+-Cl- cotransporter (KCC2). The expression of NKCC1 is high in the 
developing and postnatal brain, while the expression of KCC2 is low, thus promoting 
high intracellular Cl- concentration at this period (Blaesse et al., 2009; Ben-Ari, 
2014). Under these circumstances, the activation of GABAA receptors promotes Cl- 
efflux (Figure 1A) causing membrane depolarization and the excitatory GABA effect 
(Sigel and Steinmann, 2012; Ben-Ari, 2014; Braat and Kooy, 2015; Wu and Sun, 
2015). The “GABA effect shift”, i.e., the change in the GABA effect from depolarizing 
in developing brain to hyperpolarizing in the adult brain (Figure 1) is due to a decline 
in intracellular Cl- concentration mediated by increased expression of KCC2 in a 
developmentally time-dependent manner (Wu and Sun, 2015). In these conditions 
of low intracellular Cl- concentration, the activation o GABAA receptors promotes Cl- 
influx (Figure 1B) triggering membrane hyperpolarization and the conventional 
inhibitory GABA effect (Ben-Ari, 2014; Braat and Kooy, 2015; Wu and Sun, 2015). 
Moreover, some authors have proposed that the “GABA shift” may even occur in 
adult tissue, being involved in several neurological disorders characterized by 
neuronal excitability, such as epilepsy (Cohen et al., 2002; Köhling, 2002; Huberfeld 
et al., 2007; Blaesse et al., 2009; Lagostena et al., 2010; Viitanen et al., 2010; Miles 
et al., 2012; Pavlov et al., 2013). In this case, the “GABA shift” has been largely 
associated with a decrease in the expression of KCC2  and with an increase in the 
expression of NKCC1 (Miles et al., 2012; Ben-Ari et al., 2014),(Miles et al., 2012) 
leading to an effect of GABA that may easily switch from hyperpolarizing  into 
depolarizing.   
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Figure 1 – Schematic diagram of “GABA shift” along the development and its relation with changes 
in intracellular Cl- concentration. Panel A shows the high intracellular Cl- concentration in immature 
brain due to the high expression of NKCC1, which determines the efflux of Cl- upon GABAA receptor 
activation and the consequent membrane depolarization and promotion of neuronal excitability. In 
panel B it is shown the low intracellular Cl- concentration in adult brain due to the predominant 
expression of KCC2, causing the influx of Cl- into the cell upon GABAA receptor activation, membrane 
hyperpolarization and neuronal inhibition. Adapted from Ben-Ari (2014). 
 
Neurotransmitter transporters: key proteins in the regulation of neuronal 
excitability 
The actions of GABA and glutamate in the brain highlight the need to maintain 
the balance between the extracellular levels of these neurotransmitters at synapses. 
The maintenance of low levels of glutamate is crucial to prevent overexcitation of 
brain neurons, while the regulation of extracellular GABA levels controls the 
excitability of cells. If neurotransmitters are not rapidly removed from the synaptic 
cleft (in a millisecond time scale), receptors will be in a desensitized or persistently 
activated status and brain function compromised (Niciu et al., 2012).  
There are no extracellular enzymes that can metabolize glutamate or GABA 
with significance. Hence, when these neurotransmitters are released they must be 
rapidly and efficiently cleared from the extracellular space through high-affinity 
amino acid transporters (Danbolt, 2001; Conti et al., 2004; Zhou and Danbolt, 2013; 
Scimemi, 2014). Both GABA and glutamate transporters belong to a large family of 
sodium symporters. These transporters are widely expressed throughout the brain 
and they are mainly located in plasma membranes of neurons and glia, essentially 
in close apposition to the synapse (Allen et al., 2004; Kanner, 2006; Scimemi, 2014) 
to more effectively shape synaptic transmission. The transport of amino acid 
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neurotransmitters across the plasma membrane is electrogenic and it is performed 
against very high concentration gradients of GABA or glutamate using the power 
from ion gradients maintained by Na+/K+-ATPase, i.e., high extracellular Na+ 
concentration and high intracellular K+ concentration (secondary active transport) 
(Kanner, 2006; Scimemi, 2014). Ionic requirement for the transport depends on the 
amino acid being taken up into the cell and it is schematically represented in Figure 
2.  
 
 
Figure 2 – Schematic representation of ionic fluxes coupled to glutamate (panel A) and GABA (panel 
B) uptake. Adapted from Kanner (2006). 
 
To date, five distinct subtypes of glutamate transporters have been identified: 
excitatory amino acid transporters (EAAT) 1-5. These transporters belong to a 
solute carrier 1 (slc1) family – gene name approved by HUGO Gene Nomenclature 
Committee (HGNC) (Hediger et al., 2013) – and mediate co-transport of glutamate, 
Na+ and H+ with counter-transport of K+ (Figure 2A) in the proportion of 1Glutamate-
:3Na+:1H+:1K+ (Kanner, 2006; Zhou and Danbolt, 2014), thus allowing the 
maintenance of high glutamate concentration gradient across the membrane. EAAT 
are widely distributed throughout the brain and their cellular and subcellular 
localization is summarized in Table 1. EAAT2 (also known as GLT-1) is the most 
important glutamate transporter, since it accounts for more than 80% of the total 
glutamate transport activity (Danbolt, 2001; Fontana, 2015; Takahashi et al., 2015). 
Although it was thought that EAAT2 was exclusively expressed in astrocytes, a 
number of recent studies have suggested that this glutamate transporter is also 
expressed in nerve terminals of some neurons (Beart and O'Shea, 2007; Bjornsen 
et al., 2007; Holmseth et al., 2012; Fontana, 2015). Only 6% of the EAAT2-
immunoreactivity was detected in the plasma membrane of nerve terminals, 
however the EAAT2 in nerve terminals account for more than half of the uptake of 
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exogenous glutamate by hippocampal slice preparation (Schmitt et al., 2002; 
Furness et al., 2008), suggesting that terminal EAAT2 is more active than astroglial 
EAAT2. In turn, EAAT1 (also known as GLAST) seems to be exclusively expressed 
in brain astrocytes, while EAAT3 (also known as EAAC1) and EAAT4 are mostly 
expressed in neurons (Kim et al., 2011; Holmseth et al., 2012; Zhou and Danbolt, 
2013). The expression of EAAT5 in the brain is very low, being these transporters 
preferentially expressed in the Müller cells of retina (Héja et al., 2006).  
Contrarily to other EAAT’s that are mainly present at the plasma membrane, 
EAAT3 is mainly intracellular and its targeting to the cytoplasmic membrane seems 
to be rapidly regulated by several mechanisms, such as protein kinase C (PKC) 
activation (Beart and O'Shea, 2007; Bianchi et al., 2013).  It is believed that the 
function of EAAT3 is related to the subtle regulation of glutamatergic transmission 
through the prevention of the spillover of glutamate at excitatory synapses and it is 
important for the production of intracellular glutathione and subsequent protection 
from oxidative stress, since these transporters also can transport cysteine (Bianchi 
et al., 2013). 
 
Table 1 – Nomenclature and localization of the different subtypes of glutamate 
transporters. 
Subtypes 
Other 
names 
Gene 
symbol * 
Cellular localization Sub-cellular localization 
EAAT1 GLAST slc1a3 Astrocytes Astrocytic plasma membrane  
EAAT2 GLT-1 slc1a2 
Mainly  astrocytes, some 
neurons 
Astrocytic plasma membrane, 
Axon terminals 
EAAT3 EAAC1 slc1a1 
Mainly neurons, some 
oligodendrocytes 
Soma, dendrites 
EAAT4 _ slc1a6 
Mainly neurons, some 
astrocytes 
Soma, Dendrites, Spines, 
Astrocytic plasma membrane 
EAAT5 _ slc1a7 Müller cells   Plasma membrane endfeet 
* An abbreviated form of the gene name approved by HGNC. Adapted from Héja et al. (2006), Kim 
et al. (2011), Bianchi et al. (2013), Zhou and Danbolt (2013) and  Šerý et al. (2015) . 
 
Until now, four subtypes of GABA transporters (GATs) are known: GAT1, 
GAT2, GAT3 and betaine-GABA transporter (BGT1). The nomenclature of GABA 
transporters between mice, rat and human is different and somewhat confusing (see 
the summary in Table 2) and for simplicity, it will be used the same terminology 
regardless of the species being investigated. GABA transporters belong to a solute 
carrier 6 family (slc6; gene name approved by HGNC) and they catalyze the co-
transport of GABA, Na+ and Cl- (Figure 2B) with the stoichiometry of 
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1GABA:2Na+:1Cl- (Richerson and Wu, 2003; Kanner, 2006; Hediger et al., 2013; 
Scimemi, 2014). GAT1 and GAT3 are expressed exclusively in the brain, whereas 
GAT2 and BGT1 are expressed in multiple other organs (Madsen et al., 2010). The 
cellular and subcellular localization of GABA transporters is summarized in Table 2.  
GAT1 was the first molecularly identified GABA transporter and it is the most 
important transporter for the removal of synaptically released GABA, given its main 
localization at nerve terminals. Additionally, GAT1 is also found in astrocytes (Zhou 
and Danbolt, 2013; Melone et al., 2015), as well as, in neuronal cell bodies for a 
short time during development (Zhou and Danbolt, 2013). In contrast to GAT1, 
GAT3 is predominantly expressed in astrocytes throughout the CNS, although it is 
also expressed in nerve terminals (Melone et al., 2015). The expression of GAT2 
and BGT1 in brain is scarce, being these transporters more expressed in 
hepatocytes in the liver and kidney. Within the brain, the expression of GAT2 is 
higher in the leptomeninges and some large blood vessels and the expression of 
BGT1 is higher in the leptomeninges (Zhou and Danbolt, 2013; Scimemi, 2014). 
Additionally, BGT1 has been found also in the cortex and hippocampus where it is 
located in an extrasynaptic region involving, to a large extent, astrocytes (Madsen 
et al., 2010). 
 
Table 2 – Nomenclature and localization of the different subtypes of plasma 
membrane GABA transporters. 
Subtypes Other names 
Gene 
symbol * 
Cellular 
localization 
Sub-cellular 
localization 
GAT1 _ slc6a1 
Mainly neurons, 
some astrocytes 
Axon terminals, 
Astrocytic plasma 
membranes 
GAT2 
Rat GAT2, human GAT2, 
mouse GAT3 
slc6a13 
Hepatocytes, 
leptomeningeal 
cells and some 
blood vessel cells 
Plasma membranes 
GAT3 
Rat GAT3, human GAT3, 
mouse GAT4,GAT-B 
slc6a11 
Mainly astrocytes, 
some neurons 
Distal astrocytic 
processes, nerve 
terminals 
BGT1 
Rat BGT1, rat NTBE, rat 
GAT-4, human GAT-4, 
mouse GAT-2 
scl6a12 
Hepatocytes, 
leptomeningeal 
cells and some 
astrocytes  
Plasma membranes  
* An abbreviated form of the gene name approved by the HGNC. Adapted from Héja et al. (2006), 
Madsen et al. (2010), Melone et al. (2015) and Zhou and Danbolt (2013). 
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It has long been recognized that the action of high-affinity transporters for 
GABA and glutamate can be highly modified via short- and longer-term 
mechanisms. In fact, several studies have demonstrated that amino acid 
transporters are regulated, not only by kinases/phosphatases and scaffolding 
proteins, but also by diverse influences that seem to affect trafficking of the 
transporters: platelet-derived growth factor, thyroid hormone, trophic factors – e.g. 
brain derived neurotrophic factor (BDNF) – among others (Casado et al., 1993; 
Corey et al., 1994; Gonçalves et al., 1997; Quick et al., 1997; Beckman et al., 1998; 
Cordeiro et al., 2000; Beart and O'Shea, 2007; Hu and Quick, 2008; Cristóvão-
Ferreira et al., 2009; Vaz et al., 2011; Melo et al., 2013; Yu et al., 2015). Short-term 
mechanisms include: (1) changes in ionic concentrations and membrane potential 
responsible for the transport, (2) changes in the trafficking of transporters through 
dynamic redistribution of these proteins between intracellular space and the plasma 
membrane, (3) changes in transporters lateral mobility via interaction with other 
synaptic proteins, and (4) post-translational modifications, such as phosphorylation. 
Longer-term mechanisms are due to altered expression and abundance of GABA 
and glutamate transporters. However, it remains unclear how these changes in the 
expression, mobility and activity of GABA and glutamate transporters affect the time 
course and spatial spread of GABAergic and glutamatergic signals in the brain. 
As previously seen, the transport of neurotransmitters depends on the 
electrochemical gradients across the plasma membrane. The implication is that, as 
already mentioned, an alteration of the ionic gradients can promote an alteration of 
the transporter function. Interestingly, disruption of the electrochemical gradients 
can, on its own, be sufficient to reverse the transporter function and promote the 
translocation of GABA and glutamate from the cytoplasm back into the extracellular 
space, instead of the uptake into the cell (Richerson and Wu, 2003; Allen et al., 
2004; Héja et al., 2006; Wu et al., 2006; Scimemi, 2014). In the last few years, the 
reverse mode function of the transporters has been described under depolarizing 
conditions, where electrochemical gradients are sufficiently weakened, i.e., when 
there is a decrease of the ratio between extracellular Na+ concentration and 
intracellular K+ concentration and/or when there is an increase in the ratio between 
intracellular Na+ and extracellular K+ concentrations (Fontana, 2015). Such loss of 
energy supply due to ionic gradient disruption may occur under acute pathological 
states – such as during epileptic seizures or ischemia. The reverse mode of amino 
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acid transporters function and the consequent augmentation of extracellular GABA 
and glutamate levels have been described in these pathologies (Allen et al., 2004). 
Some studies reach the conclusion that reversion of neurotransmitter transporters 
mode may be critical for neurotransmitters release under such conditions, as this 
can be the main pathway for the translocation of amino acids outwards (Héja et al., 
2006; Zhou and Danbolt, 2013). Furthermore, it has been shown the reversal of 
some transporters in response to physiologically relevant stimuli. This is the case of 
GABA transporters, for which a small increase in the extracellular K+ concentration 
to 12 mM, which may be achieved during high-frequency neuronal firing, is sufficient 
to revert the transport. GABA transporters revert easier than glutamate transporters 
(Richerson and Wu, 2003; Allen et al., 2004; Wu et al., 2007), since they are 
powered by co-transport of only 2 Na+ ions, while glutamate transporters co-
transport 3 Na+ ions. This is in keeping with theoretical calculations showing a close 
relation between the reversal potential of GABA transporters and resting membrane 
potential of neurons (Richerson and Wu, 2003; Allen et al., 2004; Wu et al., 2006). 
The emerging view of reverse function of neurotransmitter transporters adds 
complexity to the traditional and simplistic view of transporters as “tiny vacuum 
cleaners”  (Richerson and Wu, 2003). 
The field of transport biology of GABA and glutamate has tremendously 
grown over the past years and is nowadays recognized as playing an important role 
in the manifestation and even in the treatment of several neurological disorders, 
including cerebral ischemia, traumatic brain injury, Parkinson’s disease, Alzheimer’s 
disease, Huntington’s disease and epilepsy (O'Shea, 2002; Sheldon and Robinson, 
2007; Madsen et al., 2010; Vizi et al., 2010; Hediger et al., 2013). 
 
Dysfunction of GABAergic and glutamatergic neurotransmission in 
epilepsy: focusing on high-affinity transporters 
The imbalance between GABAergic and glutamatergic neurotransmission 
that leads to aberrant neuronal excitability has long been considered to be the 
hallmark of epileptic conditions. The crucial role of high-affinity transporters in the 
regulation of the extracellular levels of GABA and glutamate and consequent 
prevention of neuronal damage has attracted much attention in the last years 
highlighting these transporters as hopeful therapeutic targets to control seizures 
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and/or epileptogenesis (Sheldon and Robinson, 2007; Madsen et al., 2010; Tian et 
al., 2010; Rowley et al., 2012; Schousboe et al., 2014; Fontana, 2015).  
Increased levels of extracellular glutamate have been extensively found in 
epilepsy conditions (Janjua et al., 1992; During and Spencer, 1993; Soukupova et 
al., 2015) and have been associated with a dysfunction of the EAAT (Danbolt, 2001; 
Beart and O'Shea, 2007). However we are facing “the chicken or egg” dilemma, 
since we do not know whether the changes in the expression/function of these 
transporters contribute to the pathogenesis of epilepsy or they result from epilepsy.  
The glutamate transporter that has been more extensively studied is the 
EAAT2 (Takahashi et al., 2015), given its dominant role in glutamate uptake. 
Different studies have shown that the expression of EAAT2 was decreased in rodent 
models of epilepsy (Sakurai et al., 2015), as well as in patients with intractable 
temporal lobe epilepsy (Proper et al., 2002; Sarac et al., 2009). Additionally, the 
development of lethal spontaneous seizures that exacerbates brain injury was 
observed in mice lacking EAAT2 (Tanaka et al., 1997; Petr et al., 2015), EAAT2 
downregulation was correlated with thalamic neuronal death following kainic acid-
induced SE (Sakurai et al., 2015) and a neuroprotection phenotype was conferred 
by the increased EAAT2 expression (Kong et al., 2012; Kong et al., 2014). These 
observations lead to the hypothesis that overexpression or simple activation of 
EAAT2 could be a promising therapeutic approach through the inhibition of 
excitotoxicity (Takahashi et al., 2015). However some authors have called attention 
to the fact that effects obtained with the promotion of EAAT2 activity may be contrary 
to the desired effect due to the reversion of transporter during pathological 
excitotoxic conditions (Danbolt, 2001; Richerson and Wu, 2003; Allen et al., 2004; 
Sheldon and Robinson, 2007; Fontana, 2015). So, the clarification of whether the 
EAAT2 activation under excitotoxic conditions will facilitate glutamate clearance or, 
instead, intensify reverse transport is a question still unanswered.  
Similarly to EAAT2, EAAT1 is also decreased in patients with intractable 
temporal lobe epilepsy (Proper et al., 2002; Sarac et al., 2009), the generalized 
seizure duration of amygdala-kindled seizures in mice lacking EAAT1 was 
significantly prolonged in these animals (Watanabe et al., 1999) and EAAT1 
knockout mice showed more severe stages of pentylenetetrazol-induced seizures 
than wild type mice (Watanabe et al., 1999).   
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EAAT3 involvement in epilepsy is controversial. While some studies show 
that, similarly to EAAT2 and EAAT1, the expression of EAAT3 is decreased in 
human neocortical epileptic loci (Rakhade and Loeb, 2008), as well as  in epileptic 
models induced by kainate (Simantov et al., 1996) and in brain malformations 
(Harrington et al., 2007), other studies show that this transporter is increased in 
intractable temporal lobe epilepsy (Crino et al., 2002; Proper et al., 2002) as well as 
in acute seizures induced by 4-aminopyridine (Medina-Ceja et al., 2012), pilocarpine 
or kainate (Ross et al., 2011). Furthermore genetic deletion of the EAAT3 decreases 
seizure-induced neuronal death after pilocarpine-induced SE (Lane et al., 2014).  
There are growing evidences that GABAergic signaling is altered in refractory 
temporal lobe epilepsy (Loup et al., 2000; Cohen et al., 2002; D’Antuono et al., 2004; 
Ragozzino et al., 2005; Palma et al., 2007; Loup et al., 2009; Mazzuferi et al., 2010; 
Miles et al., 2012; Pallud et al., 2014).  Since GATs are responsible for termination 
of GABA action, it is possible that these transporters are altered in epilepsy and, 
therefore, its targeting may constitute a valuable therapeutic approach.  
Among GABA transporters the most studied is GAT1. However, studies 
relating its alteration in epilepsy are not consistent. While in a rat model of seizures 
induced with corticotropin-releasing hormone GAT1 seems to be overexpressed, 
the same is not true for a rat model of seizures induced by hyperthermia (Orozco-
Suarez et al., 2000). In a model of acute seizures induced by 4-aminopyridine, the 
expression of GAT1 increases 60 min after the induction and it decreases 120 min 
later (Medina-Ceja et al., 2012). Studies performed in human epileptic brain tissue 
resected from drug-resistant patients have shown a reduction of GAT1, in both 
neocortex and hippocampus (Lee et al., 2006; Aronica et al., 2007).  
In the last years, several studies have showed that the promotion of 
GABAergic signaling by inhibition of GABA transporters may be beneficial to 
decrease neuronal excitability. In this way, pharmacological approaches were 
designed to inhibit GABA transport and consequently increase extracellular levels 
of this inhibitory neurotransmitter. Tiagabine is one inhibitor of GABA transporters, 
inhibiting preferentially GAT1 rather than GAT2 or GAT3, which has demonstrated 
clinical anticonvulsant efficacy and has been approved for clinical use in the 
treatment of epilepsy (Nielsen et al., 1991; Engelborghs et al., 2000; Madsen et al., 
2010). However, tiagabine is associated with severe adverse effects and it is not 
recommended in some seizure types where the effect obtained is opposite to the 
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desired neuro-inhibition (Madsen et al., 2010). Some authors suggest that unwanted 
effects obtained with the blockage of GABA transporters may be explained by less 
GABA being released via reversal of GABA transporters when neurons depolarize 
(Richerson and Wu, 2003; Allen et al., 2004). On the contrary, others authors have 
suggested that the blockage of GABA transporters and the consequent 
augmentation of extracellular GABA concentration by decreasing the uptake is not 
always the best strategy since “friendly” inhibitory GABA may become “foe” due to 
GABAA rundown (Köhling, 2002). 
 Actually, several authors have proposed that the “GABAergic rundown” is 
responsible for the promotion of synchronous neuronal discharges underlying focal 
seizures in refractory temporal lobe epilepsy (Cohen et al., 2002; D’Antuono et al., 
2004; Ragozzino et al., 2005; Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 
2012; Pallud et al., 2014). This phenomenon could be (1) due to desensitization of 
GABAA receptor upon repetitive stimulation producing a reduction of the evoked 
GABA current in an use-dependent manner (Ragozzino et al., 2005; Palma et al., 
2007; Mazzuferi et al., 2010), or even (2) due to depolarization and excitatory 
actions stemming from changes in intracellular concentration of Cl- promoted 
essentially by the downregulation of KCC2 – responsible for Cl- extrusion, a situation 
that has been observed in epileptic tissue (D’Antuono et al., 2004; Huberfeld et al., 
2007; Blaesse et al., 2009; Ben-Ari et al., 2012; Miles et al., 2012).  This implies that 
instead of GABAergic signaling counterbalancing the depolarizing effects of 
glutamate, it may also contribute to the excitatory tone. The doubts over the anti- or 
pro-epileptic roles of GABAergic signaling in epilepsy suggest that treatments 
targeting the cell firing control and the consequent reduction of intrinsic neuronal 
excitability should be carefully examined, since these treatments may beneficially 
restrain sudden surges in network activity according to whether GABA is a “friend” 
or “foe” at this time (Köhling, 2002; Pavlov et al., 2013).  
 
 
Purinergic signaling  
Research during the last decades has shown that ATP is not only a 
component of nucleic acids and the principal fuel inside the cell, but also has a great 
importance in cellular communication. The concept of purinergic neurotransmission 
in which extracellular purines (namely ATP and adenosine) and pyrimidines act as 
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signaling molecules was introduced in 1972 by Burnstock (reviewed by Abbrachio 
et al., 2009; Burnstock et al., 2011a;  Burnstock et al., 2011b). Subsequently, ATP 
was identified as a co-transmitter in sympathetic and parasympathetic nerves, and 
it is now recognized that ATP acts either as sole transmitter or a co-transmitter in 
most nerves in both peripheral and central nervous systems (Abbracchio et al., 
2009; Burnstock et al., 2011a). Growing evidences have shown that purinergic 
signaling appears to play important roles in neurodegeneration, neuroprotection and 
neuroregeneration (Burnstock, 2015). 
In basal physiological conditions, intracellular concentration of ATP is high 
(5-8 millimolar) while the extracellular concentration of ATP is low (nanomolar to 
micromolar range). However under physiological high-frequency stimulation 
conditions and under pathological conditions, such as epilepsy and cellular injury, 
the extracellular concentration of ATP increases reaching millimolar levels (Cunha 
et al., 1996b; Frenguelli et al., 2007; Dale and Frenguelli, 2009; Heinrich et al., 2012; 
Sáez-Orellana et al., 2015). Under these conditions, ATP is released, or co-released 
with other classical neurotransmitters (such as glutamate and GABA) by several 
mechanisms (Figure 3A), that involve constitutive and regulated exocytosis (Ca2+-
dependent), ATP-binding cassette proteins, pannexins, connexins, ATP-sensitive 
P2X7 receptor and osmolytic transporters linked to anion channels (Lazarowski, 
2012; Sáez-Orellana et al., 2015). Additionally, it has been suggested that a leak in 
events of cell membrane damage could contribute to hugely increase extracellular 
ATP levels, conditioning in this way the synaptic activity (Sáez-Orellana et al., 2015). 
After ATP being released, it is rapidly metabolized by a cascade of plasma 
membrane-bound enzymes, known as ectonucleotidases (Figure 3B). This process 
is physiologically relevant since it controls the lifetime of ATP, produce ATP 
metabolites that also act as signaling molecules and protect some purinergic 
receptors from desensitization (Cardoso et al., 2015). According to substrate 
specificity and products formation, ectonucleotidases are divided into four major 
families, which are all expressed in the brain (Abbracchio et al., 2009; Sáez-Orellana 
et al., 2015): ectonucleoside triphosphate diphosphohydrolases (E-NTPDases), 
ectonucleotide pyrophosphatase and/or phosphodiesterases (E-NPPs), alkaline 
phosphatases, and ecto-5'-nucleotidase (CD73). E-NTPDases and E-NPPs 
hydrolyze ATP and adenosine diphosphate (ADP) to adenosine monophosphate 
(AMP), which is then hydrolyzed to adenosine by CD73. Alkaline phosphatases 
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equally hydrolyze nucleoside tri, di and monophosphates. Dinucleoside 
polyphosphates, nicotinamide adenine dinucleotide (NAD+) and uridine diphosphate 
(UDP) sugars, are substrates exclusively for E-NPPs (Abbracchio et al., 2009).  
 
  
Figure 3 – Schematic representation of ATP release and its metabolism. Panel A illustrates the 
different mechanisms of ATP release. Panel B represents the metabolism of ATP, inside and outside 
of the cell. 
 
Although adenosine is produced from the extracellular catabolism of ATP 
(Figure 3B), it can also be released as such into the extracellular medium by 
equilibrative nucleoside transporters (Bonan, 2012; Heinrich et al., 2012; Wall and 
Dale, 2013; Sims and Dale, 2014). In addition, there is increasing evidence for other 
mechanisms of adenosine release, including exocytotic release and retrograde 
signaling (Dale and Frenguelli, 2009). When in the extracellular milieu, adenosine 
is metabolized to inosine by adenosine deaminase (ADA) or taken up by cells via 
nucleoside transporters (Correia-de-Sá and Ribeiro, 1996). The driving motor for 
adenosine uptake by cells via equilibrative nucleoside transporters is the 
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phosphorylation of the nucleoside into AMP by high-affinity intracellular adenosine 
kinase (AK). 
As discussed above, the metabolism of ATP originates several extracellular 
ubiquitous nucleotides and nucleosides, which exert signaling effects through the 
activation of purinoceptors (see next section). 
 
Purinoceptors 
Purinergic receptors are a family of membrane receptors expressed in a wide 
variety of tissues, including the brain. These receptors were defined for the first time 
in 1976 and were subdivided 2 years later into two types of purinoceptors, classified 
as adenosine-sensitive P1 and nucleotide-activated P2 (Figure 4; reviewed by 
Burnstock et al., 2007) . P2 receptors were then subdivided into ionotropic P2X and 
metabotropic P2Y receptors (Figure 4) based on their mechanism of action, 
pharmacology and molecular cloning (Ralevic and Burnstock, 1998; Abbracchio et 
al., 2009).  
 
 
Figure 4 – Schematic representation of the three different families of purinergic receptors: 
metabotropic P1 receptors, ionotropic P2X receptors and metabotropic P2Y receptors. 
 
P1 receptors 
P1 receptors comprise four types of GPCR, A1, A2A, A2B and A3, displaying 
distinct pharmacological and functional properties. In common with other GPCR, P1 
receptors contain seven transmembrane domains, an extracellular N-terminus and 
an intracellular C-terminus (Figure 4). Activation of A1 and A3 receptors favors (1) 
the inhibition of AC, (2) the activation of several types of K+ channels, (3) the 
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inactivation of Ca2+ channels, and (4) the activation of PLC-β (Burnstock et al., 
2011a). In contrast, activation of A2A and A2B receptors stimulates AC resulting in 
the production of cAMP. Despite of this dominant pathway, A2A and A2B receptors 
may also be associated with intracellular Ca2+ mobilization (Burnstock et al., 2011a).  
The A1 and A2A receptors are the most relevant receptors in the brain 
(Burnstock, 2007; Boison, 2008). The A1 receptor is the most expressed adenosine 
receptor under physiological conditions. The latter receptor is highly expressed in 
the hippocampus (Burnstock et al., 2011a), while the A2A receptor is expressed at 
low levels in this structure (Schiffmann et al., 1991; Dixon et al., 1996), but this 
balance can change with ageing (Cunha et al., 1995; Rebola et al., 2003). 
The key agonists and antagonists of the P1 adenosine receptor subtypes are 
summarized in Table 3. 
 
Table 3 – Characteristics of P1 receptors 
Receptor Transduction pathway Main agonists Antagonists 
A1 Gi/G0: ↓ cAMP CCPA; R-PIA 
DPCPX, N-040, 
MRS1754 
A2A Gs: ↑ cAMP NECA; CGS21680 
KF17837, SCH58261, 
ZM241385 
A2B Gs: ↑ cAMP NECA  
Enprofylline, MRE2029- 
F20, MRS17541 
A3 
Gi/G0, Gq/G11: ↓ cAMP, PLC-β 
activation 
IB-MECA, NECA, 2-
Cl-IB-MECA 
MRS1220, L-268605, 
MRS1191, MRS1523 
Adapted from IUPHAR and Burnstock (2007) 
 
In the last couple of years, the A2A receptor has been implicated in neuronal 
excitability and synaptic plasticity (Kanno and Nishizaki, 2012; Matos et al., 2012; 
Valadas et al., 2012; Matos et al. 2013), as well as in diverse pathological conditions 
of the CNS, such as Parkinson’s disease (Uchida et al., 2015), Alzheimer’s disease 
(Orr et al., 2015) and epilepsy (see section Purinergic signaling and epilepsy). 
Initially it was believed that the A2A receptor was mostly located in neurons, both 
pre- and post-synaptically (Rebola et al., 2005; Rodrigues et al., 2015). However, 
growing evidences have shown that this receptor is also expressed in glial cells 
(Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013; Orr et al., 2015), 
where the A2A receptor is critical for glutamate transport modulation (Kanno and 
Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013) and memory formation (Orr 
et al., 2015). 
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P2X receptors 
P2X receptors are ligand-gated ion channels that promote fast cell 
depolarization through the influx of Na+ and Ca2+ ions (Figure 4). These receptors 
are composed by three individual subunits and are designated as P2X1 to P2X7 
according to the historical order of cloning. P2X receptors share a common topology 
(see Figure 4) with two transmembrane domains, a glycosylated extracellular ligand 
binding loop with several conserved cysteines connecting the two transmembrane 
domains, and intracellular N- and C-termini (North, 2002; Abbracchio et al., 2009; 
Baroja-Mazo et al., 2013). Trimeric P2X receptors are assembled in the 
endoplasmic reticulum, and then trafficked to the cell membrane (Sáez-Orellana et 
al., 2015). With the exception of P2X6 subunit, all subunits undergo 
homotrimerization (Abbracchio et al., 2009; Sáez-Orellana et al., 2015). The key 
agonists and antagonists of the homomeric P2X receptors are summarized in Table 
4. 
 
Table 4 – Characteristics of P2X receptors 
Receptor Transduction pathway Main agonists Antagonists 
P2X1 Ion channel (Ca2+ and Na+) ATP, 2-MeSATP 
TNP-ATP, IP5I, NF023, 
NF449 
P2X2 Ion channel (mainly Ca2+) ATP, ATPγS 
Suramin, isoPPADS, 
RB2, NF770, NF279 
P2X3 Ion channel 2-MeSATP, ATP 
TNP-ATP, PPADS, 
A317491, NF110, Ip5I, 
P2X4 Ion channel (mainly Ca2+) 
ATP,  Ivermectin 
potentiation 
5-BDBD,  TNP-ATP, 
BBG  
P2X5 Ion channel 
ATP,   2-MeSATP,  
ATPγS 
Suramin, PPADS, BBG 
P2X6 Ion channel _ _ 
P2X7 
Ion channel and large pore 
with prolonged activation 
BzATP, ATP 
A-438079, O-ATP,  
A-740003 
Adapted from IUPHAR and Burnstock (2007). 
 
One atypical member of the P2X family is the homomeric P2X7 receptor, 
since this receptor displays unusually large ionic conductance, high EC50 for ATP 
(>100 µM) and slow desensitization (Khakh and North, 2006; Jarvis and Khakh, 
2009; Pankratov et al., 2009). In contrast to other P2X receptors, the P2X7 receptor 
has a long intracellular C-terminus (239 amino acids) and upon repeated or 
prolonged activation it opens a non-selective pore that allows the permeation of 
organic cations with large molecular weight (600-800 Da) (North, 2002; Sperlágh 
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and Illes, 2014). Another peculiar characteristic of P2X7 receptor is the increase of 
its activity by reducing the concentration of divalent ions, like Ca2+ and Mg2+ (Virginio 
et al., 1997; North, 2002; Jiang, 2009; Yan et al., 2011). Growing evidences 
implicate P2X7 receptor in crucial physiological phenomena, such as LTP (Chu et 
al., 2010), as well as in the pathophysiology  of several neurological syndromes, 
namely neurotrauma (Kimbler et al., 2012), multiple sclerosis (Gu et al., 2015), 
amyotrophic lateral sclerosis (Yiangou et al., 2006), Alzheimer’s disease (McLarnon 
et al., 2006; Miras-Portugal et al., 2015; Sáez-Orellana et al., 2015), Huntington’s 
disease (Díaz-Hernández et al., 2009), psychiatric mood disorders (Kongsui et al., 
2014) and epilepsy (see section Purinergic signaling and epilepsy). 
Recent studies have shown that the P2X subunits can form hetero-trimers 
due to the assembly of at least two different individual subunits leading to the 
existence of a large number of P2X receptor phenotypes (North, 2002; Burnstock 
and Kennedy, 2011; Baroja-Mazo et al., 2013). To date, seven functional hetero-
trimers have been reported: P2X2/3, P2X4/6, P2X1/5, P2X2/6, P2X1/4, P2X1/2 and 
P2X4/7 (Burnstock and Kennedy, 2011). The most physiologically relevant of these 
heteromeric receptors are the P2X1/2, P2X2/3, P2X1/4 and P2X1/5 receptors 
(Baroja-Mazo et al., 2013). 
 
P2Y receptors 
P2Y receptors belong to GPCR family and share the common topology of 
seven transmembrane domains, an extracellular N-terminus and an intracellular C-
terminus (Figure 4). The first P2Y receptor (P2Y1) was cloned in 1993 (Baroja-Mazo 
et al., 2013) and so far, eight subtypes of metabotropic P2Y are described: P2Y1, 
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14.  
P2Y receptors can be activated by adenine and uridine nucleotides – ATP, 
ADP, UTP and UDP (Figure 4, Table 5) – and therefore they are frequently grouped 
according to their preferential endogenous agonist. P2Y1, P2Y11, P2Y12 and P2Y13 
receptors are only activated by adenine nucleotides: P2Y1, P2Y12 and P2Y13 
receptors preferentially bind ADP and P2Y11 has a high-affinity for ATP (Baroja-
Mazo et al., 2013). The P2Y2 receptor and rodent P2Y4 receptor can be activated 
by either adenine or uridine nucleotides, while the human P2Y4 and P2Y6 receptors 
are selective for uridine nucleotides. In contrast to P2Y2 and P2Y4 receptors that 
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use mainly triphosphate nucleotides, P2Y6 receptor binds preferentially to UDP 
(Baroja-Mazo et al., 2013). The P2Y14 receptor subtype is activated by UDP sugars: 
UDP-glucose and UDP-galactose (Weisman et al., 2012; Baroja-Mazo et al., 2013). 
The key agonists and antagonists of the P2Y receptors are summarized in Table 5. 
 
Table 5 – Characteristics of P2Y receptors 
Receptor Transduction pathway Main agonists Antagonists 
P2Y1 
Gq/G11, Gi/G0: PLC-β 
activation, ion channel (K+ 
and Ca2+) 
MRS2365, 2-MeSADP, 
ADPβS 
MRS2179, MRS2500 
 
P2Y2 
Gq/G11 and possibly Gi/G0: 
PLC-β activation 
2-thio-UTP, UTP, ATP 
Suramin, RB-2, AR-
C126313 
P2Y4 
Gq/G11 and possibly Gi: PLC-
β activation, PLA2 stimulation 
UTP,ATP RB2,  Suramin 
P2Y6 Gq/G11: PLC-β activation, 
3-Phenacyl-UDP, 
UDPβS, UDP 
MRS2578 
P2Y11 
Gq/G11 and Gs: PLC-β 
activation, ↑ cAMP 
AR-C67085MX, 
BzATP,  ATPγS 
Suramin, RB-2, NF157 
P2Y12 Giα: ↓ cAMP 
2-MeSATP, 2-
MeSADP, ADP 
CT50547, INS49266, 
AZD6140, PSB0413, 
ARL66096 
P2Y13 Gi/G0: ↓ cAMP ADP, 2-MeSADP MRS2211, 2-MeSAMP 
P2Y14 
Gi/G0: ↓ cAMP, PLC 
stimulation 
UDP-glucose, UDP-
galactose 
_ 
Adapted from IUPHAR and Burnstock (2007) 
 
Moreover, P2Y receptors can also be grouped according to the phylogenetic 
similarity and coupling to specific G proteins. (1) Gq protein-coupled receptors 
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) activate PLC-β; (2) Gi protein-coupled receptors 
(P2Y12, P2Y13, P2Y14) inhibit AC and regulate ion channels; and (3) the Gs protein-
coupled receptor (P2Y11) activates AC and regulates ion fluxes. Note that P2Y11 
receptor is coupled to different G proteins, Gq and Gs, evidencing an agonist-specific 
signaling pathway (White et al., 2003). 
P2Y receptors can homodimerize or heterodimerize with other P2Y 
receptors, as well as with other transmitter receptors, including the adenosine A1 
receptor (Abbracchio et al., 2009). 
 
Purinergic signaling and epilepsy 
Several lines of evidence led to the conclusion that ATP exerts a pro-epileptic 
role by activating P2 purinoceptors, leading to the hypothesis that purinergic 
signaling could be a target for the treatment of drug-refractory epilepsy. It has been 
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evidenced that (1) microinjection of ATP analogues into the pre-piriform cortex can 
induce generalized motor seizures (Knutsen and Murray, 1997); (2) adenine 
nucleotides modulate epileptiform activity in hippocampal slices (Ross et al., 1998); 
(3) ATP participates in the pathophysiology of pilocarpine-induced temporal lobe 
epilepsy (Vianna et al., 2002), and (4) extracellular levels of ATP and adenosine 
rapidly increase during high-frequency neuronal firing, as well as upon noxious brain 
conditions such as epilepsy-associated seizures (Dale and Frenguelli, 2009; 
Heinrich et al., 2012; Wall and Dale, 2013; Sims and Dale, 2014) Different P2 
receptors, mostly excitatory ionotropic P2X receptors activated by ATP, were 
identified as putative targets to control seizures, (Burnstock and Kennedy, 2011; 
Henshall et al., 2013; North and Jarvis, 2013; Sáez-Orellana et al., 2015).  
The P2X7 receptor has been considered the P2 receptor more committed to 
epilepsy, although controversy still exists in the literature regarding its pro- or 
anticonvulsant effects in distinct animal models. For instance, pilocarpine-induced 
seizures were increased in mice lacking the P2X7 receptor, although no such effect 
was observed in the kainate epilepsy model (Kim and Kang, 2011). In vitro studies 
also argue that the P2X7 receptor activation can be inhibitory. These include a 
report showing that presynaptic P2X7 receptor reduce neurotransmitter release in 
hippocampal slices (Armstrong et al., 2002). On the other hand, it has been shown 
that the P2X7 receptor is upregulated in both hippocampus and cerebral cortex of 
rodents with temporal lobe epilepsy (either induced with pilocarpine or kainate); 
these findings were observed both in acute and chronic phases of the disorder 
(Avignone et al., 2008; Doná et al., 2009; Jimenez-Pacheco et al., 2013). Despite 
this, the expression of P2X7 receptor may transiently decrease to control levels in 
the latent phase of the disease (Doná et al., 2009) and this finding may complicate 
interpretation of the results obtained by various research groups. An increase in the 
density of the P2X7 receptor was also observed in the neocortex from patients with 
drug-resistant temporal lobe epilepsy (Jimenez-Pacheco et al., 2013). Manipulation 
of the P2X7 receptor tone with the selective antagonist, A-438079, exerts an 
anticonvulsant effect in rodent models of epilepsy (Engel et al., 2012a; Engel et al., 
2012b; Henshall et al., 2013; Jimenez-Pacheco et al., 2013). The apparently 
contradictory findings regarding the role of P2X7 receptor in epilepsy suggest that 
the contribution of this receptor may change along disease stages and the 
underlying epileptogenic process.  
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Despite P2X4 and P2X7 subunits may form functional heterotrimers the 
involvement of P2X4 subunits in epilepsy is less studied, but the results obtained 
are also controversial. Doná et al. (2009) found no changes in the P2X4 receptor 
expression and function in the epileptic hippocampus of rats injected with 
pilocarpine. Conversely, Ulmann et al. (2013) using a model of kainate-induced SE 
detected increased levels of the P2X4 receptor in activated glial cells of the 
hippocampus. 
The ATP metabolite, adenosine, has long been considered an endogenous 
antiepileptic substance acting via inhibitory A1 receptors. This is why some authors 
propose the augmentation of extracellular adenosine as a solution to resolve drug-
refractory epilepsies (Boison, 2007, 2012; Boison and Stewart, 2009). Nevertheless, 
one must not forget that adenosine may also activate excitatory A2A receptors in 
certain brain regions (e.g. hippocampus) besides the predominant inhibitory A1 
receptor (Boison, 2008). In this regard, it should be noticed that excitatory A2A 
receptors become more abundant in epileptic animals (Chen et al., 2007; 
Hosseinmardi et al., 2007; El Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim 
et al., 2011; Li et al., 2012; Huicong et al., 2013; Orr et al., 2015). Experimental 
results in rodents demonstrate that adenosine A2A receptor antagonists may offer 
protection against diverse epileptic syndromes, including temporal lobe epilepsy, 
leading several authors to propose that the adenosine A2A receptor may be an 
attractive pharmacological target for treatment of epilepsy (Hosseinmardi et al., 
2007; El Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Li et 
al., 2012; Huicong et al., 2013; Orr et al., 2015). 
 
 
Interplay between GABA, glutamate and purines in epilepsy: 
clinical relevance of this study 
As discussed previously, epilepsy is largely characterized by an imbalance 
between GABAergic and glutamatergic neurotransmission and nowadays only 50% 
of the epileptic patients are adequately treated for their symptoms with currently 
available AEDs. High-affinity transporters have a key role in the maintenance of 
synaptic transmission and growing evidences indicates the pharmacological 
modulation of GABA and glutamate transporters as relevant therapeutic targets 
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(Madsen et al., 2010; Rowley et al., 2012; Schousboe et al., 2014; Zhou and 
Danbolt, 2014). As a matter of fact, several efforts have been made to increase brain 
network inhibitory tone or decrease excitation by targeting GABA and glutamate 
transporters. Additionally, the approved clinical use of the GAT1 inhibitor, tiagabine, 
for the therapeutic management of epilepsy (Nielsen et al., 1991; Madsen et al., 
2010) makes us to believe that the “fine-tuning” modulation of amino acid 
transporters by fast endogenous regulators, namely ATP, may be a promising 
strategy through promotion of appropriate concentrations of GABA and glutamate 
in the right places at the right time. ATP emerges as a potential candidate, since it 
is co-released with neurotransmitters GABA and glutamate and its extracellular 
levels increase significantly during high-frequency neuronal firing (Cunha et al., 
1996b; Frenguelli et al., 2007; Heinrich et al., 2012). Furthermore, ATP co-inhabits 
with GABA and glutamate at the synapse, being this nucleotide in the right place to 
rapidly modulate the extracellular levels of GABA and glutamate.  
Besides the ATP and given that this nucleotide is extracellularly metabolized 
by a cascade of ectonucleotidases into adenosine resulting in high extracellular 
concentrations of adenosine, it is probable that adenosine is also able to modulate 
the extracellular levels of GABA and glutamate. In fact, several works have shown 
that adenosine, through the activation of A2A receptors, can modulate the 
extracellular levels of GABA and glutamate, altering both the uptake and the release 
of these amino acid neurotransmitters (Gonzalez et al., 2006; Cristóvão-Ferreira et 
al., 2009; Vaz et al., 2011; Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et 
al., 2013; Vaz et al., 2015). Although it is already known that the A2A receptor is 
increased in rodent models of epilepsy (Chen et al., 2007; Hosseinmardi et al., 2007; 
El Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Li et al., 2012; 
Huicong et al., 2013; Orr et al., 2015), no attempts have been made to investigate 
alterations in the A2A receptor density in human brain samples from drug-resistant 
epileptic patients. Likewise, there are no studies, to our knowledge where the 
modulation of extracellular levels of GABA and glutamate by adenosine A2A receptor 
activation has been tested in epileptic conditions. 
So, in this work, we aim at contributing to find new drug therapies to control 
seizures through the finding of “fine-tuning” modulatory mechanisms that rapidly 
regulate the extracellular levels of GABA and glutamate in accordance with the 
needs of a balanced synapse. Besides its value in controlling seizure activity in 
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epileptic patients, it is possible that these drugs acting selectively on GABA and/or 
on glutamate transporters, by modulating its activity, may constitute a potential 
therapeutic candidate for the treatment of other neurological and psychiatric 
diseases associated with the GABAergic/glutamatergic balance, such as anxiety, 
sleep disorders, among many others. 
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Given that, as discussed above (see section Purinergic signaling and 
epilepsy), (1) the excitatory P2X7 receptor has been proposed as a target to control 
seizures, (2) the opening of the P2X7 receptor channel by ATP increases Na+-influx 
that is characteristic of increased brain activity (Lo et al., 2008; Yu et al., 2010), and 
(3) GABA and glutamate transporters are crucially dependent on the 
transmembrane Na+ gradient, we decided to investigate the modulatory role of ATP 
acting via the P2X7 receptor on the uptake of GABA and glutamate by isolated nerve 
terminals measured in parallel. Our hypothesis is that full opening of the P2X7 
receptor channel leads to extensive Na+-influx, which might dissipate the Na+ 
gradient across the plasma membrane and, thus, decrease the transport driving 
force for GABA and glutamate. Since energy modulation by changing the 
transmembrane Na+ gradient may affect both GABA and glutamate transport 
systems and given the overall effects of these two neurotransmitters on neuronal 
networking, it seems necessary to study the uptake of the two amino acids in 
parallel, i.e. under the same modulatory conditions, in order to appreciate putative 
differential effects caused by activation of the P2X7 receptor in control and epileptic 
brain tissue. Our hypothesis that the activation of the P2X7 receptor may alter 
neurotransmitters uptake was borne out by studies conducted in the RBA-2 type-2-
like astrocytic cell line showing that the P2X7 receptor stimulation increases 
intracellular Na+ concentration and, thereby, causes downmodulation of the 
glutamate transport (Lo et al., 2008). In keeping with hypothesis, other authors 
showed (1) that the P2X7 receptor activation may modulate the uptake of glutamate 
in microglial cells via the activation of a cascade of extracellular signal-regulated 
kinases and the production of oxidants (Morioka et al., 2008), and (2) that P2X 
receptors are associated with increases in the amount of GABA in the extracellular 
milieu due to a reduction of its uptake in the rat retina (Neal et al., 1998). In this 
context, the specific aims of this study were to investigate: (1) the role of the ATP-
sensitive P2X7 receptor on high-affinity GABA and glutamate transport in brain 
tissues from Wistar rats and Human controls (cadaveric organ donors), (2) the 
molecular pathway underlying modulation of GABA and glutamate transport 
operated by the P2X7 receptor activation, and (3) whether the expression and 
cellular localization of P2X7 receptors and the P2X7 receptor-mediated modulation 
of amino acid transporters change in epileptic individuals, both rats injected with 
pilocarpine and human MTLE and non-MTLE patients that underwent neurosurgical 
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ablation of the epileptic focus at Centro Hospitalar do Porto – Hospital Geral de 
Santo António. The use of the animal model allowed us to test extensively our 
hypothesis that ATP acting via the P2X7 receptor could modulate GABA and 
glutamate uptake by changing the transmembrane Na+ gradient before going to 
brain samples from Human controls and patients with drug-refractory epilepsy, 
which for obvious reasons are more difficult to obtain. Given the similarity of the 
results obtained with nerve terminals isolated from brain samples of both species, 
we are now in conditions to say that the pilocarpine-injected epileptic rat model is 
suitable for testing the role of purines in the context of amino acid uptake modulation, 
which was a secondary goal of the present study.  
Changes in the P2X7 receptor-mediated downmodulation of GABA and 
glutamate uptake were mostly assessed in the absence of extracellular Ca2+ in order 
to mimic conditions that occur under high-frequency neuronal firing and/or 
pathologic brain activity, such as prolonged or repeated seizures (Engel et al., 
2012a). Under these conditions the extracellular Ca2+ concentration falls up to 90% 
(Heinemann et al., 1977; Rusakov and Fine, 2003; Engel et al., 2012a; Torres et al., 
2012; Jimenez-Pacheco et al., 2013) and Na+-conductance through the P2X7 
receptor is largely enhanced, as this receptor is highly sensitive to changes in the 
extracellular concentration of divalent cations (Virginio et al., 1997; Yan et al., 2011). 
Performing experiments in low extracellular Ca2+ conditions also excludes the 
involvement of Ca2+-regulation of amino acid transporters (directly or via 
plasmalemmal and mitochondrial Na+/Ca2+ exchangers), as well as the interference 
of Ca2+-activated neurotransmitter release (Cordeiro et al., 2000; Cordeiro et al., 
2003; Ashpole et al., 2013; Romei et al., 2015).   
Additionally, we also evaluated if the expression of other purinergic receptors 
was altered in Human brain samples of MTLE patients as compared with cadaveric 
organ donors. Besides the P2X7 receptor (see above), the excitatory adenosine A2A 
receptor that is expressed in epileptic region targets, both cerebral cortex and 
hippocampus, called our attention by the additional following reasons: (1) the A2A 
receptor is a metabotropic receptor whose function has been associated with the 
ability to modulate GABA and glutamate transport (Nishizaki et al., 2002; Vaz et al., 
2011; Kanno and Nishizaki, 2012; Matos et al., 2012), (2) several studies 
demonstrate that the A2A receptor expression may be altered in rodent models of 
epilepsy (Chen et al., 2007; Hosseinmardi et al., 2007; El Yacoubi et al., 2008, 2009; 
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Fukuda et al., 2011; Rosim et al., 2011; Li et al., 2012; Huicong et al., 2013; Orr et 
al., 2015) and 3) it has been shown that A2A receptor antagonists can offer protection 
against diverse epileptic syndromes induced in rodents (Hosseinmardi et al., 2007; 
El Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Li et al., 2012; 
Huicong et al., 2013). 
It is worth noting that, since the MTLE disorder affects both brain regions 
hippocampus and neocortex (Doherty et al., 2003; Bartolomei et al., 2005; Scanlon 
et al., 2011; Alhusaini et al., 2012; O'Dell et al., 2012; Biagini et al., 2013; Di Maio, 
2014; Kandratavicius et al., 2014), this study was performed whenever possible 
using to the two cerebral regions according to the availability of human tissue. 
The ultimate goal of this study is to contribute to unravel the “mysteries” of 
drug-resistant epilepsies, such as MTLE, in order to prompt for novel and more 
accurate drugs targeting the purinergic signaling cascade, which might be deeply 
involved both in epileptogenesis and in neuronal damage secondary to prolonged 
or repetitive seizures. 
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Abstract 
Sodium-dependent high-affinity amino acid transporters play crucial roles in 
terminating synaptic transmission in the CNS. However, there is a lack of 
information about the mechanisms underlying the regulation of amino acid transport 
by fast-acting neuromodulators, like ATP. Here, we investigated whether activation 
of the ATP-sensitive P2X7 receptor modulates Na+-dependent GABA and glutamate 
uptake into nerve terminals (synaptosomes) of the rat cerebral cortex. Radiolabeled 
neurotransmitter accumulation was evaluated by liquid scintillation spectrometry. 
The cell-permeant sodium selective fluorescent indicator, SBFI-AM, was used to 
estimate Na+ influx across plasma membrane. BzATP, 3-300µM, a prototypic P2X7 
receptor agonist, concentration-dependently decreased [3H]GABA (14%) and 
[14C]glutamate (24%) uptake; BzATP decreased transport Vmax without affecting the 
Km values. The selective P2X7 receptor antagonist, A-438079 (3µM), prevented 
inhibition of [3H]GABA and [14C]glutamate uptake by BzATP (100µM). The inhibitory 
effect of BzATP coincided with its ability to increase intracellular Na+ and was 
mimicked by Na+ ionophores, like gramicidin and monensin. Increases in 
intracellular Na+ (with veratridine or ouabain) or substitution of extracellular Na+ by 
NMDG+ all decreased [3H]GABA and [14C]glutamate uptake and attenuated BzATP 
effects. Uptake inhibition by BzATP (100 µM) was also attenuated by calmidazolium, 
which selectively inhibits Na+ currents through the P2X7 receptor pore. In 
conclusion, disruption of the Na+ gradient by P2X7 receptor activation 
downmodulates high-affinity GABA and glutamate uptake into rat cortical 
synaptosomes. Interference with amino acid transport efficacy may constitute a 
novel target for therapeutic management of cortical excitability.   
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Introduction 
GABA and glutamate are key neurotransmitters in CNS where they play a 
fundamental role in controlling neuronal excitability, information processing and 
neuronal plasticity. Therefore, maintenance of the balance between GABAergic 
inhibition and glutamatergic excitation in the brain is crucial under normal and 
pathological conditions. Under physiological conditions, Na+-dependent high-affinity 
transporters rapidly clear amino acid neurotransmitters from the extracellular space. 
These transporters are located in the plasma membrane of both neurons and glia 
exhibiting high density at the synaptic regions (Kanner, 2006). In order to adapt 
transport function to the synaptic environment, transporters should be rapidly 
modulated. However, little is known about the signaling molecules responsible for 
fast regulation of GABA and glutamate transport. 
ATP is a likely candidate, as the nucleotide is co-released with 
neurotransmitters from both neurons and glia under physiologic and pathologic 
conditions, such as during epileptic seizures (Khakh and North, 2006; Pankratov et 
al., 2009; Burnstock et al., 2011b). ATP controls cerebral functions through the 
activation of ionotropic P2X and metabotropic P2Y receptors. The slowly-
desensitizing homomeric P2X7 receptor channel is a unique member of the ATP-
gated P2X receptor family with a characteristic long intracellular C-terminus (239 
amino acids), which displays unusually large ionic conductance and high EC50 for 
ATP (>100 µM) (Jarvis and Khakh, 2009; Jiang, 2009; Pankratov et al., 2009). P2X7 
receptors are widely expressed in the CNS in many cell types including neurons and 
glial cells (Khakh and North, 2006; Henshall et al., 2013). These purinoceptors have 
been implicated in LTP phenomena (Chu et al., 2010) and in many pathological 
conditions, including epilepsy (Engel et al., 2012a; Henshall et al., 2013; Jimenez-
Pacheco et al., 2013; Sperlágh and Illes, 2014). 
The driving-force for high-affinity GABA and glutamate transport is crucially 
dependent on Na+-gradient across the plasma membrane (Wonnemann et al., 2000; 
Richerson and Wu, 2003; Allen et al., 2004; Kanner, 2006). Brain activity is 
accompanied by significant Na+-influx from the extracellular space, through a variety 
of paths including permeation via ligand-gated cation channels, like P2X 
purinoceptors (Lo et al., 2008; Yu et al., 2010). Activation of the P2X7 receptor 
results in intense Na+-influx that may alter the Na+ equilibrium and lead to GABA 
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and glutamate uptake downmodulation by lowering the transport driving-force. This 
rationale was borne out from studies conducted in the RBA-2 type-2-like astrocytic 
cell line showing that P2X7 receptor stimulation increase intracellular Na+ 
concentration and induce the downregulation of glutamate transport (Lo et al., 
2008).  
Although P2X7 receptors display low affinity for ATP (Jarvis and Khakh, 
2009), high levels of ATP released during high-frequency stimuli (Cunha et al., 
1996b; Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 2013) are able 
to activate this receptor in vivo under physiological conditions, thus promoting 
spatio-temporal coincidence of ATP with GABA and glutamate. Under conditions of 
high-frequency neuronal firing, there is also a decline in extracellular Ca2+ 
(Heinemann et al., 1977; Borst and Sakmann, 1999; Engelborghs et al., 2000; 
Stanley, 2000; Massimi and Amzica, 2001; Rusakov and Fine, 2003; Engel et al., 
2012a; Torres et al., 2012; Jimenez-Pacheco et al., 2013) that can both trigger ATP 
release from astrocytes (Torres et al., 2012) and increase the activity of P2X7 
receptors, since divalent ions (like Ca2+) are negative modulators of this 
purinoceptor subtype (Virginio et al., 1997; Jiang, 2009; Yan et al., 2011) rendering 
P2X7 receptor activation an intense but short-lived modulatory capacity over Na+-
coupled high-affinity transport energy. Such low-affinity high-capacity mechanism 
may precede other forms of modulation involving activation of adenosine receptors 
following extracellular ATP breakdown (Nishizaki et al., 2002; Cristóvão-Ferreira et 
al., 2009) as well as low intracellular Ca2+ concentration (micromolar levels) 
modulation of both GABA and glutamate high-affinity transporters through 
enzymatic signaling cascades (Casado et al., 1993; Corey et al., 1994; Gonçalves 
et al., 1997; Beckman et al., 1998; Cordeiro et al., 2000; Cordeiro et al., 2003; 
Ashpole et al., 2013). It is, therefore, tempting to focus our research efforts on the 
energetic component of Na+-coupled transport by performing most of the 
experiments in the absence of extracellular Ca2+.  
Since Na+-coupled transport energy modulation may affect both GABA and 
glutamate transporters and given the antagonistic effects of GABA and glutamate 
on neuronal networks, added to evidences suggesting these neurotransmitter 
transporters may act concertedly to regulate extracellular levels of 
neurotransmitters, it seems necessary to study these in parallel, under the same 
modulatory conditions. Hence, the purpose of this study was to investigate whether 
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the stimulation of ATP-sensitive P2X7 receptors, in the absence of extracellular Ca2+ 
ions, modulates Na+-dependent high-affinity GABA and glutamate uptake into 
synaptosomes of the rat cerebral cortex. 
 
Experimental procedures 
Drugs and solutions 
HEPES and triton X-100 were from Merck Millipore (Darmstadt, Germany). 
GABA, SDS (sodium dodecyl sulphate), 2-mercaptoethanol, sodium deoxycholate, 
Tris (trizma-base), BSA (bovine serum albumin), bromophenol blue, carbenoxolone, 
glycerol, tween 20, BzATP, ouabain, EGTA (ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid), monensin sodium salt, NMDG (N-methyl-D-glucamine), 
aminooxyacetic acid (AOAA) and BAPTA-AM (1,2-bis(2-aminophenoxy)ethane-
N,N,N’,N’-tetraacetic acid tetrakis (acetoxymethyl ester)) were obtained from 
Sigma-Aldrich (St. Louis, MO). L-Glutamic acid, A-438079, DL-TBOA (DL-threo-β-
benzyloxyaspartic acid), H1152 ((S)-(+)-2-Methyl-1-[(4-methyl-5-iso-
quinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride), veratridine and 
TTX (tetrodotoxin) were obtained from Tocris Bioscience (Bristol, UK); SBFI-AM 
(1,3-benzenedicarboxylic acid, 4,4'-[1,4,10-trioxa-7,13-diazacyclopentadecane-
7,13-diylbis (5-methoxy-6,12- benzofurandiyl)]bis-, tetrakis[(acetyloxy)methyl] 
ester) and Pluronic F-127 were from Invitrogen (Carlsbad, CA); gramicidin was from 
Life Technologies (Carlsbad, CA); SKF89976A hydrochloride (1-(4,4-diphenyl-3-
butenyl)-3-piperidinecarboxylic acid hydrochloride) and calmidazolium (3-[bis(4-
chlorophenyl)methyl]-1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy) 
ethyl] -1H-imidazolium chloride) were from Abcam (Cambridge, UK); [14C]Glutamate 
and [3H]GABA were from American Radiolabeled Chemicals, Inc. (St. Louis, MO). 
All stock solutions were stored as frozen aliquots. Dilutions of stock solutions were 
made daily and appropriate solvent controls were done. No statistically significant 
differences between control experiments, made in the absence or in the presence 
of the solvents at the maximal concentrations used, were observed. 
 
Animals 
Animal care and experimental procedures were carried out in accordance 
with the UK Animals (Scientific Procedures) Act 1986 and followed the European 
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Communities Council Directive of 24 November 1986 (86/609/EEC) and the 
National Institutes of Health Guide for Care and Use of Laboratory animals (NIH 
Publications No. 80-23) revised 1996. All studies involving animals are reported in 
accordance with ARRIVE guidelines for reporting experiments involving animals 
(McGrath et al., 2010). All efforts were made to minimize animal suffering and to 
reduce the number of animals used. Wistar rats (150-200 g) of either sex (Charles 
River, Barcelona, Spain) were kept at a constant temperature (21 ºC) and a regular 
light (06.30–19.30 h)–dark (19.30–06.30 h) cycle, with food and water ad libitum.  
 
Preparation of synaptosomes from the rat cerebral cortex 
Synaptosomes were isolated as previously described by Helme-Guizon et al. 
(1998)  and then modified by Bancila et al. (2009). Briefly, the cerebral cortex was 
dissected out and gently homogenized in cold oxygenated (95% O2 and 5% CO2) 
Krebs solution (in mM: glucose 5.5, NaCl 136, KCl 3, MgCl2 1.2, Na2HPO4 1.2, 
NaHCO3 16.2, CaCl2 0.5, pH 7.40). Homogenates were filtered through a nylon filter 
(mesh size 100 µm). The filtrate was left to sit during 30–45 min until formation of a 
pellet, which was re-suspended into Krebs solution and left at room temperature. 
Protein concentration determined by the BCA method (bicinchoninic acid; PierceTM, 
Thermoscientific, Rockford USA) was adjusted to 6.25 mg protein mL-1 (uptake and 
release experiments) or to 6 mg protein mL-1 (Na+-influx measurement 
experiments). 
 
 [3H]GABA and [14C]glutamate uptake experiments 
[3H]GABA uptake by synaptosomes was measured as described elsewhere 
(Cordeiro et al., 2003). [3H]GABA (0.25 μCi mL-1; 70 Ci mmol-1) uptake reactions 
were initiated by adding [3H]GABA (0.5 μM, except otherwise specified) to media 
containing synaptosomes (final concentration 0.25 mg protein mL-1), at 30 ºC. 
Unless otherwise indicated, uptake reactions were performed in media containing 
(in mM) NaCl 128, MgCl2 1.2, KCl 3, glucose 10, HEPES–Na 0.01 (pH 7.4), EGTA 
0.1 and AOAA 0.01 (used to prevent GABA metabolism by GABAT). Experiments 
were performed in the absence of extracellular Ca2+ (except otherwise specified), in 
order to focus research on the energetics of Na+-coupled transport. The reactions 
were stopped by rapid filtration through glass fibre prefilters (Merck Millipore, Cork, 
IRL), prewashed with cold sucrose 320 mM, Tris–HCl 10 mM (pH 7.4) and EGTA 
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0.1 mM. The filters were then washed with the same medium and plunged into vials 
containing scintillation cocktail (Insta-Gel Plus, Perkin Elmer, Boston, USA) for 
radioactivity measurement by liquid scintillation spectrometry (TriCarb2900TR, 
Perkin Elmer, Boston, USA). The values for [3H]GABA taken up by synaptosomes 
were expressed as pmol mg protein-1 after subtraction of blank values obtained by 
filtering reaction medium aliquots. [14C]Glutamate uptake (0.25 μCi mL-1; 0.270 Ci 
mmol-1) by synaptosomes was measured as described above for [3H]GABA uptake 
but using [14C]glutamate (10 μM) without adding AOAA (10 μM) to the medium. 
Unless stated otherwise, uptake assays were carried out during 90 seconds since 
this time is in the linear phase of [3H]GABA and [14C]Glutamate accumulation (see 
e.g. Figure 6). 
All modifier drugs tested were allowed to equilibrate with the synaptosomes 
at least for 10 min before adding the test drug, which was applied 10 min before 
addition of the radioactive neurotransmitter. Control samples were incubated for the 
same amount of time in the absence of drugs. To assess synaptosomal integrity 
before and after incubation with the P2X7 receptor agonist (BzATP) we evaluated 
the activity of the intracellular enzyme, lactate dehydrogenase (LDH, EC 1.1.1.27), 
in the incubation medium by the method of Stolzenbach and Kaplan (1976). 
 
 [3H]GABA and [14C]glutamate release experiments 
[3H]GABA release by synaptosomes was measured after loading the 
synaptosomes with [3H]GABA (0.25 μCi mL-1; 70 Ci mmol-1; 0.5 μM) during 10 min, 
at 30 ºC. Aliquots of a synaptosomal suspension containing 0.5 mg protein mL-1 
were layered onto glass fiber filters (Merck Millipore, Cork, IRL), which were 
mounted in 365 µL chambers of a semi-automated 12-sample superfusion system 
(SF-12 Suprafusion 1000, Brandel, Gaithersburg, MD, USA). Filters containing the 
synaptosomes were superfused (flow rate of 0.5 mL min-1) with a Ca2+-free 
physiological solution (in mM: NaCl 128, MgCl2 1.2, KCl 3, glucose 10, HEPES–Na 
0.01 (pH 7.4), EGTA 0.1 and AOAA 0.01), at 30 ºC. After a 26–min equilibration 
period, 2-min fractions of the superfusate were automatically collected using the SF-
12 suprafusion system; this procedure was prolonged for 34 min. Ten-min after 
beginning fraction collection, synaptosomes were challenged with BzATP (100 or 
300 µM) or veratridine (10 µM) during 2 min by changing the inlet tube from one 
flask to another containing the test drug. The P2X7 receptor antagonist, A-438079 
Purinergic modulation of neurotransmitter transporters in human MTLE  
Original research papers 
56 
 
 
 
(3 µM), was added to the superfusion solution 10 min before BzATP. The radioactive 
content of collected fractions and that remaining in the filters at the end of the 
experimental protocol was measured by liquid scintillation spectrometry 
(TriCarb2900TR, Perkin Elmer, Boston, USA). [14C]Glutamate release (0.25 μCi mL-
1; 0.270 Ci mmol-1; 10 μM) by synaptosomes was measured as described for 
[3H]GABA without adding AOAA (10 μM) to the superfusion solution. 
 
Experiments to measure Na+-influx by synaptosomes  
Measurements of Na+ influx into synaptosomes was performed as described 
previously (Tretter et al., 1998), with minor modifications. Synaptosomes (6 mg 
protein mL-1) were incubated in Na+-free medium (in mM: NMDG 128, MgCl2 1.2, 
CaCl2 0.1, KCl 3, glucose 10 and HEPES–Na 0.01; pH 7.4) with the cell-permeant 
sodium selective fluorescent indicator, SBFI-AM (15 μM), for 60 min at 37 °C. After 
sedimentation and washing with Na+-free medium, the pellet was re-suspended in 
the same medium, and 20 μL aliquots were used in wells of a 96-well plate 
containing 180 μL of reaction medium (in mM: NaCl 128, MgCl2 1.2, CaCl2 0.1, KCl 
3, glucose 10 and HEPES–Na 0.01; pH 7.4) in a final concentration of 6 mg mL-1. 
SBFI-AM fluorescence trapped within synaptosomes was measured using a multi 
detection microplate reader (Synergy HT, BioTek Instruments Inc., Winooski, VT, 
USA) according to manufacturer’s instructions. After a 5 min equilibrium period, 
synaptosomes were stimulated with medium (control) or BzATP and SBFI 
fluorescence was allowed to reach a new steady-state. Thereafter, the Na+ 
ionophore, gramicidin (10 μM), was applied to provide maximum SBFI signal. When 
the influence of a modifier drug over the BzATP was assayed, modifier drug was 
allowed to equilibrate with the synaptosomes for 10 min before the addition of 
BzATP. Control samples were incubated for the same amount of time in the absence 
of drugs.  
 
Immunofluorescence staining and confocal microscopy  
Brain slices  
Brain samples were fixed in 4% paraformaldehyde in phosphate-buffered 
saline (PBS; in mM: NaCl 137, KCl 2.6, Na2HPO4 4.3, KH2PO4 1.5; pH=7.4) for 
about 48 h (4 ºC), cryopreserved in 30% sucrose in PBS and stored in a tissue 
freezing medium at -80 ºC. 
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Free floating 30 μm brain slices were incubated for 1 h, at room temperature, 
with blocking buffer I (foetal bovine serum 10%, BSA 1%, triton X-100 0.5%, NaN3 
0.05%) and subsequently incubated overnight, at 4 ºC, with the following primary 
antibodies; rabbit anti-P2X7 receptor (1:50, #APR004, Alomone, Jerusalem, Israel), 
goat anti-synaptic vesicle-associated membrane protein 1 (VAMP-1 or 
synaptobrevin 1; 1:20, R&D Systems, Minneapolis, MN), mouse anti-glial fibrillary 
acidic protein (GFAP; 1:350, Chemicon, Temecula, CA), mouse anti-S-100 clone 
15E2E2 (1:200; Chemicon, Temecula, CA) and mouse anti-CD11b (1:50, Santa 
Cruz Biotechnology, Dallas, TX) diluted in blocking buffer II (foetal bovine serum 
5%, BSA 0.5%, triton X-100 0.5%, NaN3 0.05% in PBS). Sections were rinsed in 
PBS supplemented with triton X-100 0.5% (3 cycles of 10 min) and incubated for 
120 min with species specific secondary antibodies conjugated with fluorescent 
dyes (donkey anti-rabbit IgG Alexa Fluor 488, donkey anti-mouse IgG Alexa Fluor 
568; donkey anti-goat Alexa 633) diluted in blocking buffer II, at room temperature. 
After rinsing in PBS, slices were mounted on optical-quality glass slides using 
VectaShield (Vector Labs, Peterborough, UK) as mounting media. Observations 
were performed with a laser scanning confocal microscopy (Olympus FV1000, 
Tokyo, Japan). Controls were performed by following the same procedure but 
replacing the primary antibodies with the same volume of blocking buffer II. Images 
were analyzed using the Olympus Fluoview 4.2 Software (Olympus FV1000, Tokyo, 
Japan). Co-localization was assessed by calculating the staining overlap and the 
Pearson’s coefficient (ρ) for each confocal micrograph stained with two fluorescent 
dyes. Overlap between two stainings gives a value between +1 and 0 inclusive, 
where 1 is total overlap and 0 is no overlap. ρ is a measure of the linear correlation 
between two variables (stainings), giving a value between +1 and −1 inclusive, 
where 1 is total positive correlation, 0 is no correlation, and −1 is total negative 
correlation.  
 
Cortical synaptosomes  
The immunocytochemical analysis in cortical synaptosomes was performed 
as previously described (Miras-Portugal et al., 2003; Rodrigues et al., 2005; Marcoli 
et al., 2008). Briefly, synaptosomes were placed onto chamber slides coated with 
poly-D-lysine (Sigma-Aldrich, St. Louis, MO), fixed with 4% paraformaldehyde in 
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PBS for 15 min, and washed twice with PBS. Synaptosomes were permeabilized in 
PBS with 0.2% triton X-100 for 10 min and then blocked for 1h in PBS with 3% BSA 
and 5% foetal bovine serum. The synaptosomes were then washed twice with PBS 
and incubated overnight, at 4 ºC, with the following primary antibodies diluted in 3% 
BSA in PBS: rabbit anti-P2X7 receptor (1:50, #APR004, Alomone, Jerusalem, 
Israel) and goat anti-VAMP-1 (1:20, R&D Systems, Minneapolis, MN). Then, 
synaptosomes were rinsed with 3% BSA in PBS (3 cycles of 10 min) and incubated 
1h at room temperature with species specific secondary antibodies conjugated with 
fluorescent dyes: donkey anti-rabbit IgG Alexa Fluor 488 and donkey anti-goat IgG 
Alexa Fluor 568. After rinsing in PBS and mounting on slices using VectaShield 
(Vector Labs, Peterborough, UK) as mounting media, the synaptosomes were 
observed with a laser scanning confocal microscope (Olympus FV1000, Tokyo, 
Japan). Controls were performed by following the same procedure but replacing the 
primary antibodies by the same volume of 3% BSA in PBS. Images were also 
analyzed using Olympus Fluoview 4.2 Software (Olympus FV1000, Tokyo, Japan). 
Co-localization was assessed by calculating the staining overlap and the ρ for each 
confocal micrograph stained with two fluorescent dyes.  
 
SDS-PAGE and Western blot analysis  
Total membrane lysates and synaptosomes of the rat cerebral cortex were 
homogenized in Radio-Immunoprecipitation Assay (RIPA) buffer containing: Tris-
HCl (pH 7.6) 25 mM, NaCl 150 mM, sodium deoxycholate 1%, triton-X-100 1%, SDS 
0.1%, EDTA 5 mM and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). 
The protein content of the samples was evaluated using the BCA method. Samples 
were solubilized at 70 °C in SDS reducing buffer (Tris-HCl (pH 6.8) 125 mM, SDS 
4%, bromophenol blue 0.005%, glycerol 20%, and 2-mercaptoethanol 5%) for 10 
min, subjected to electrophoresis in 12.5% SDS-polyacrylamide gels and 
electrotransferred onto polyvinylidene difluoride (PVDF) membranes (Merck 
MilliPore, Temecula, CA). Membranes were blocked for 1 h in Tris-buffered saline 
(TBS; in mM: Tris-HCl 10 (pH 7.6), NaCl 150) containing Tween 20 0.05% and BSA 
5% and, subsequently, incubated overnight, at 4 ºC, with primary antibodies: rabbit 
anti-P2X7 receptor (1:300, #APR004, Alomone, Jerusalem, Israel), rabbit anti-β-
actin antibody (1:2500, Abcam, Cambridge, UK), mouse anti-synaptophysin 
(1:1000, Chemicon, Temecula, CA) and mouse anti-GFAP (1:500, Chemicon, 
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Temecula, CA). Membranes were washed three times for 10 min in 0.05% Tween 
20 in TBS and then incubated with horseradish anti-rabbit or anti-mouse peroxidase-
conjugated secondary antibodies for 120 min, at room temperature. The antigen-
antibody complexes were visualized by chemiluminescence with the Immun-Star 
WesternC Kit (Biorad Laboratories, Hercules, CA) using the ChemiDoc MP imaging 
system (Bio-Rad Laboratories, Hercules, CA). To test for specificity of the bands 
corresponding to P2X7 the anti-P2X7 receptor antibody was pre-adsorbed with a 
control peptide antigen corresponding to the amino acid residues 576-595 of the 
intracellular C-terminus of the rat P2X7 receptor, before incubation with the 
membrane. Gel band image densities were quantified with Image J (National 
Institute of Health, USA). 
 
Data presentation and statistical analysis 
The uptake of [3H]GABA, [14C]glutamate and Na+ by synaptosomes of the rat 
cerebral cortex was expressed as a percentage of control values obtained in the 
same synaptosomal batch without adding any drug. The release of [3H]GABA and 
[14C]glutamate by synaptosomes was expressed as the ratio of the peak area 
obtained with test drug and the peak area obtained with a reference compound, 
veratridine. Results are expressed as mean ± SEM, with n (showed in graphs) 
indicating the number of individual experiments performed in a given situation. 
Because of limited inter-individual variation, randomly chosen groups of at least 
three animals of the same strain and weight (Wistar rats of 150-200 g) were 
considered sufficient to replicate each experimental protocol; individual experiments 
were performed in triplicate (uptake experiments) or in duplicate (release 
experiments and Na+ measurement experiments).  Statistical analysis of data was 
carried out using GraphPad Prism 6.04 software (La Jolla, CA, USA). Unpaired 
Student’s t-test with Welch correction was used for statistical analysis when 
parametric data was considered. For multiple comparisons, one-way analysis of 
variance (ANOVA) followed by Bonferroni's Multiple Comparison Test was used. P 
< 0.05 (two tailed) values were considered to show significant differences between 
means.  
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Results 
Synaptosomes of the rat cerebral cortex are enriched in synaptophysin-
positive nerve terminals  
In order to confirm that the synaptosomal fraction of the rat cerebral cortex 
(see Materials and Methods) is enriched in nerve terminals, we analyzed the relative 
protein density of synaptophysin and GFAP, which are well-recognized markers 
respectively of synaptic nerve terminals and astrocytic glial cells, in total lysates and 
synaptosomal fractions by Western blot. Figure 5 shows that cortical synaptosomal 
fractions are highly (~60-fold) enriched in synaptophysin compared to total lysates, 
where the protein density difference between synaptophysin and GFAP is less 
evident. This indicates that, under the present experimental conditions, the 
functional results obtained with synaptosomes of the rat cerebral cortex are most 
likely to be attributed to synaptic nerve terminal enrichment, with a residual (if at all) 
participation of glial subcellular particles (gliosomes, see Figure 5B;  Milanese et al., 
2009;  Carney et al., 2014).  
 
 
Figure 5 – Western blot analysis of synaptophysin and GFAP contents in synaptosomal fractions 
and total lysates of the rat cerebral cortex. Panel (A), shows representative immunoblots of five 
distinct animals loaded with three different protein amounts (10, 17.5 and 25 µg). In Panel (B), shown 
are “Box and Whiskers” plots representing the ratios between synaptophysin and GFAP protein 
densities obtained in total lysates and synaptosomal fractions of five distinct animals; in each box 
represented is the minimum, the 25th percentile, the median, the 75th percentile, and the maximum. 
*P<0.05 (unpaired Student’s t-test with Welch correction) represents significant differences as 
compared to total lysates. Please note that under the present experimental conditions the 
synaptosomal fraction is highly enriched in synaptophysin-immunoreactive synaptic nerve terminals, 
whereas the negative GFAP immunodetection denotes very little (if at all) contamination of this 
fraction by glial subcellular particles (gliosomes). 
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GABA and glutamate uptake is mediated by Na+-dependent high-affinity 
transporters in synaptosomes of the rat cerebral cortex 
Before evaluating the influence of any drug on the accumulation of GABA 
and glutamate by synaptosomes of the rat cerebral cortex, experiments were 
designed to assess the accumulation of both neurotransmitters over time and to 
determine the most adequate time of incubation with [3H]GABA and [14C]glutamate 
for the subsequent experiments. Under the present experimental conditions, the 
time course of [3H]GABA and [14C]glutamate uptake by synaptosomes of the rat 
cerebral cortex (Figure 6A and 6B) was similar to that previously described (Rauen 
et al., 1992; Cordeiro et al., 2003). All subsequent experiments were performed with 
a 90s incubation time so that [3H]GABA and [14C]glutamate uptake were measured 
in the linear accumulation phase.  
 
 
Figure 6 – Rat cortical synaptosomes take up GABA and glutamate through Na+-dependent high-
affinity transporters. Illustrated is the accumulation of [3H]GABA (A) and [14C]glutamate (B) into rat 
cortical synaptosomes over time (0-20 min). Panels (C) and (D) show that the accumulation of 
[3H]GABA and [14C]glutamate (t=90 s) occurs through Na+-dependent high-affinity transporters since 
the incubation of synaptosomes with inhibitors of transporters, SKF489976A (40 µM; GAT1 selective 
inhibitor) and DL-TBOA (100 µM; non-specific EAAT inhibitor), abolished neurotransmitter uptake, 
respectively. The results are expressed as mean ± SEM; the vertical bars represent SEM and are 
shown when they exceed the symbols in size; the n number of individual experiments is shown in 
the graphs. *P<0.05 (unpaired Student’s t-test with Welch correction) represents significant 
differences as compared to the control situation. SKF 489976A and DL-TBOA were incubated 20 
min before addition of [3H]GABA or [14C]Glutamate, respectively. 
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We observed that [3H]GABA accumulation was significantly inhibited 
(96.4±0.2%) in the presence of a potent inhibitor of GABA transporter 1 (GAT1) 
SKF89976A (40 µM) (Figure 6C). Likewise, [14C]glutamate uptake was significantly 
inhibited (89.3±1.1%) in the presence of DL-TBOA (100 µM) (Figure 6D); here, we 
used a non-selective inhibitor because subtype-specific glutamate transport 
inhibitors are still missing. Data suggest that the uptake of both neurotransmitters 
by synaptosomes occurs almost exclusively through high-affinity transporters, 
making unlikely the participation of other membrane translocation mechanisms for 
GABA and glutamate, like connexin hemichannels, that are expected to open in the 
absence of extracellular Ca2+; GAT1 seems to be the dominant GABA transporter 
in synaptosomes of the rat cerebral cortex.  
 
P2X7 receptor activation downmodulates high-affinity [3H]GABA and 
[14C]glutamate uptake  
To evaluate the role of the P2X7 purinoceptor in the modulation of GABA and 
glutamate uptake, cortical synaptosomes were incubated with the prototypic P2X7 
receptor agonist, BzATP (3-300 µM), during 10 minutes before the addition of 
[3H]GABA and [14C]glutamate. BzATP concentration-dependently decreased the 
uptake of [3H]GABA (Figure 7A) and [14C]glutamate (Figure 7B) by synaptosomes 
of the rat cerebral cortex. The inhibitory effects produced by 100 µM BzATP 
(15.6±1.0% and 24.0±0.8%, respectively for GABA and glutamate) were 
significantly (P<0.05) attenuated by a selective P2X7 receptor antagonist, A-438079 
(3 µM; Figure 7A and 7B); on its own A-438079 (3 µM) did not affect the uptake of 
neurotransmitters. These results suggest that activation of the P2X7 purinoceptor 
negatively modulates the uptake of GABA and glutamate by cortical synaptosomes. 
The amplitude of glutamate uptake downmodulation by P2X7 was greater than that 
of GABA.  
We, then, assessed the influence of the P2X7 receptor activation on the 
kinetics of amino acid transporters by evaluating changes in the Michaelis-Menten 
constant (Km) and in the maximum uptake velocity (Vmax). As can be concluded from 
the saturation curves depicted in Figure 7, BzATP (100-300 µM) decreased the Vmax 
of [3H]GABA (Figure 7C) and [14C]glutamate (Figure 7D) uptake in a concentration-
dependent manner, with minor changes in Km values, contributing to the decrease 
in transport efficiency; 100 and 300 µM BzATP decreased (P<0.05) Vmax values for 
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the uptake of [3H]GABA from 2158±38 to 1783±34 and to 1626±49  pmol mg protein-
1 min-1 and for the uptake of [14C]glutamate from 1873±29 to 1646±37 and to 
1593±26 pmol mg protein-1 min-1, respectively.  
 
 
Figure 7 - Activation of the P2X7 receptor downmodulates Na+-dependent high-affinity GABA and 
glutamate transport into synaptosomes of the rat cerebral cortex. Illustrated is the inhibition of 
[3H]GABA (A) and [14C]glutamate (B) uptake triggered by activation of the P2X7 receptor with BzATP 
(3-300 µM), a prototypical P2X7 receptor agonist. The inhibitory effect of 100 µM BzATP was 
prevented by the P2X7 receptor antagonist, A-438079 (3 µM). On its own, A-438079 (3 µM) did not 
influence GABA nor glutamate uptake.  Panels (C) and (D) show the saturation curves depicting the 
amount of [3H]GABA and [14C]glutamate, respectively, taken up as a function of the concentration of 
neurotransmitter. The tables below each panel show the Km (µM) and Vmax (pmol.mg protein-1.min-1) 
values determined from the saturation curves obtained in the absence and in the presence of BzATP 
(100-300 µM),using the GraphPad Prism 6.04 software (La Jolla, CA, USA). Data are expressed as 
mean ± SEM; the vertical bars represent SEM and are shown when they exceed the symbols in size; 
the n number of individual experiments is shown in the graphs. *P<0.05 (one way ANOVA followed 
by Bonferroni’s multiple comparison test) represents significant differences as compared to the 
control situation where no drugs were added; #P<0.05 (one way ANOVA followed by Bonferroni’s 
multiple comparison test) represents significant differences as compared to the effect of BzATP 100 
µM applied alone. BzATP was incubated for 10 min before addition of [3H]GABA or [14C]Glutamate 
and A-438079 was added 10 min before the P2X7 receptor agonist. 
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BzATP (100 µM) did not significantly (P>0.05) change the activity of LDH in 
the incubation fluid of rat cortical synaptosomes (0.27±0.02 mU mL-1, n=3) 
compared to the control situation in the absence of the ATP analogue (0.29±0.06 
mU mL-1, n=3). Data indicate that rat cortical synaptosomes keep their integrity after 
being exposed to BzATP, a situation that is in clear contrast with the findings 
obtained after disrupting synaptosomal membranes with 1% of triton X-100, which 
leads to extrusion of intrasynaptosomal content increasing LDH activity in the 
extracellular media to 3.27±0.10 mU mL-1 (P<0.05 , n=3). 
 
The P2X7 receptor is expressed predominantly on nerve terminals of the rat 
cerebral cortex  
The presence of functional P2X7 receptors on cortical nerve terminals 
(synaptosomes) of the rat has been demonstrated by measuring fluorescent 
intracellular Ca2+ signals and by immunocytochemistry staining (Miras-Portugal et 
al., 2003; Alloisio et al., 2008; Marcoli et al., 2008; Marín-García et al., 2008). Here, 
we used slices of the rat cerebral cortex stained with an antibody that specifically 
reacts with the P2X7 receptor in the brain (Messemer et al., 2013) to evaluate the 
distribution of this receptor among distinct neuronal cells by immunofluorescence 
confocal microscopy (Figure 8A). To this end, we labelled the cells with antibodies 
directed towards: (1) a synaptic nerve terminal marker, the VAMP-1; (2) two 
astrocytic markers, the Ca2+ binding protein A1/B1 (S-100, clone 15E2E2) and 
GFAP; and (3) a microglial cell marker, the alpha M integrin (CD11b). Figure 8A 
shows that the highly specific antibody directed against the C-terminal of the rat 
P2X7 receptor (#APR-004, green) co-localize extensively (staining overlap of 
0.73±0.04; ρ=0.59±0.04) with the synaptic nerve terminal marker, VAMP-1 (red), 
giving the final yellow labelling when merging the two fluorescence channels. The 
P2X7 receptor labelling was also observed in some CD11b positive (red) microglial 
cells of the rat cerebral cortex (staining overlap of 0.46±0.04; ρ=0.32±0.06), but no 
color merge was detected with GFAP (staining overlap of 0.07±0.01; ρ=0.01±0.01) 
nor with S-100 (staining overlap of 0.16±0.02; ρ=-0.01±0.01) astrocytic cells (Figure 
8A). Likewise, co-localization of P2X7 (green) and VAMP-1 (red) staining was also 
observed in synaptosomes isolated from the rat cerebral cortex (staining overlap of 
0.62±0.04; ρ=0.61±0.04) (Figure 8B), which is in agreement with findings from 
electron microscopy and immunofluorescence labelling of P2X7 receptors found in 
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the literature (Deuchars et al., 2001.; Sperlágh et al., 2002; Miras-Portugal et al., 
2003; Cavaliere et al., 2004).  
 
 
Figure 8 - The P2X7 receptor is present predominantly on nerve terminals of the rat cerebral cortex. 
Panel (A) shows the immunolocalization of the P2X7 receptor in confocal micrographs of rat cortical 
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slices. Synaptic nerve terminals are stained with VAMP-1; astrocytes are labelled with the Ca2+ 
binding protein A1/B1 (S-100, clone 15E2E2) and GFAP, whereas CD11b was used to stain 
microglial cells. A negative control resulting from the incubation with the anti-rabbit secondary 
antibody without previous addition of the rabbit anti-P2X7 receptor primary antibody (#APR004) is 
also shown; differential interference contrast (DIC) image is shown for comparison in the latter 
situation. Confocal micrographs shown in Panel (B), show that VAMP-1-positive synaptosomes (red) 
of the rat cerebral cortex are endowed with the P2X7 receptor (green). Yellow staining denotes co-
localization of P2X7 receptors (green) and type-specific cell markers (red). Fluorescence intensity 
scatter plots shown on the right-hand side of the figure were used to estimate co-localization by 
calculating the staining overlap and the Pearson´s Coefficient (ρ). Scale bars = 50 µm. In Panel (C), 
shown are representative immunoblots of the P2X7 receptor in cortical synaptosomes from eight 
rats; gels were loaded with 25, 50 and 75 µg of protein. Please note that rat cortical synaptosomes 
express the P2X7 receptor as a double band at ~ 72 kDa; both bands are specific as they 
disappeared after pre-adsorption of antibody with the control peptide antigen corresponding to the 
amino acid residues 576-595 of the intracellular C-terminus of the rat P2X7 receptor (negative 
control; lane 4). β-actin was used as a reference protein.  
 
In addition, Western blot analysis confirmed that rat cortical synaptosomes 
express the P2X7 receptor at the protein level (Figure 8C). Please note that rat 
cortical synaptosomes expressed the P2X7 receptor as a double band at ~72 kDa 
(Künzli et al., 2007; Jimenez-Pacheco et al., 2013; Yu et al., 2013), which densities 
increase with the amount of protein (25-75 µg) loaded to the gels. Both bands 
disappeared after pre-adsorption of synaptosomal membranes with the control 
peptide antigen corresponding to the amino acid residues 576-595 of the 
intracellular C-terminus of the rat P2X7 receptor (Figure 8C). Taken together, these 
results support our pharmacological data implicating the P2X7 receptor in the 
negative control of [3H]GABA (Figure 7A) and [14C]glutamate (Figure 7B) uptake by 
nerve terminals (synaptosomes) of the rat cerebral cortex.  
 
Downmodulation of [3H]GABA and [14C]glutamate transport by P2X7 receptor 
activation correlates with drug-induced shifts in the synaptosomal Na+ 
concentration 
Experiments were designed to unravel the mechanism(s) underlying 
downmodulation of GABA and glutamate uptake by activation of the P2X7 
purinoceptor.  
Knowing that P2X7 receptor activation promotes the influx of Na+ and Ca2+ 
from the extracellular milieu and taking into account that extracellular Ca2+ was 
removed from the reaction medium (see Materials and Methods), it was 
hypothesized that Na+-entry through the P2X7 receptor channel and subsequent 
dissipation of the Na+-gradient may be responsible for the negative modulation of 
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high-affinity GABA and glutamate transport, which is crucially dependent on the Na+-
gradient. 
To test the validity of this hypothesis, the effects of two Na+ ionophores, 
monensin and gramicidin, were evaluated. Monensin, is a polyether antibiotic 
isolated from Streptomyces cinnamonensis; ionophore properties of monensin are 
related to the preference of crown ethers to form complexes with monovalent 
cations, such as Li+, Na+, K+, Rb+, Ag+, and Ti+, thus conferring these ions the 
possibility to cross lipid cell membranes in both electrogenic and electroneutral (i.e. 
non-depolarizing) conditions (Huczyński et al., 2012). Na+ influx caused by 
monensin may favor Na+/Ca2+ exchange and Ca2+-induced activation of PLC (Wang 
et al., 1999), yet this mechanism is negligible under extracellular null Ca2+ 
conditions, as in this study. Gramicidin is a heterogeneous mixture of three linear 
pentadecapeptide antibiotic compounds, gramicidins A, B and C, obtained from the 
soil bacterial species Bacillus brevis. Gramicidin chains assemble inside of the 
hydrophobic interior of the cellular lipid bilayer to form a β-helix, which then 
dimerizes to form the elongated channel that spans the whole membrane. Its mode 
of action results from increasing cell membrane permeability selectively to inorganic 
monovalent cations, like Na+, which travel unrestricted through the channel in a 
single file coordinated with the same number of water molecules thereby destroying 
the ion gradient between the cytoplasm and the extracellular environment (Burkhart 
et al., 1999). Interestingly, divalent cations, like Ca2+, block the channel by binding 
near its mouth, so gramicidin channel is essentially impermeable to divalent cations; 
it also excludes anions, like Cl−, because its hydration shell is thermodynamically 
stronger than that of most monovalent cations. Figure 9 shows that the inhibitory 
effect of BzATP (3-300 µM) was mimicked by monensin (0.1-1µM) and gramicidin 
(0.1-1µM), although the ATP analogue exhibited a lesser potency. At 1 µM 
concentration, the two Na+ ionophores, monensin and gramicidin, decreased 
[3H]GABA uptake by 36.7±2.0% and 56.7±4.3% (Figure 9A) and [14C]glutamate 
uptake by 35.3±2.3% and 31.7±4.6% (Figure 9B), respectively. 
 
Purinergic modulation of neurotransmitter transporters in human MTLE  
Original research papers 
68 
 
 
 
 
Figure 9 - Intracellular Na+-accumulation decreases GABA and glutamate uptake. Illustrated is the 
role of two Na+ ionophores, monensin (0.1-1µM) and gramicidin (0.1-1µM), on [3H]GABA (A) and 
[14C]glutamate (B) uptake into rat cortical synaptosomes carried out during 90 seconds. The effect 
of BzATP (3-300 µM) is also shown for comparison. The results are expressed as mean ± SEM; the 
vertical bars represent SEM and they are expressed when they exceed the symbols in size; the n 
number of individual experiments is shown in the graphs. *P<0.05 (one way ANOVA followed by 
Bonferroni’s multiple comparison test) represents significant differences as compared to the control 
situation; BzATP, monensin and gramicidin were incubated 10 min before addition of [3H]GABA or 
[14C]Glutamate.  
 
We, then evaluated whether manipulation of intracellular Na+-levels could 
modulate GABA and glutamate uptake, using for this purpose two drugs with distinct 
mechanisms of action: ouabain (an inhibitor of Na+/K+-ATPase) and veratridine (an 
activator of voltage-sensitive Na+ channels). Activation of voltage-gated Na+ 
channels with veratridine (1-10 µM) concentration-dependently decreased the 
uptake of [3H]GABA (Figure 10A) and [14C]glutamate (Figure 10B). The inhibitory 
effects produced by 10 µM veratridine (77.1±1.3% and 43.7±1.5%, for GABA and 
glutamate respectively) were prevented by blocking voltage-gated Na+ channels 
with TTX (1 µM; Figures 10A and 10B), while the inhibitory effects produced by 100 
µM BzATP on the uptake of [3H]GABA and [14C]glutamate were not significantly 
altered by TTX (1 µM; data not shown). On its own TTX (1 µM) did not influence the 
uptake of both neurotransmitters. The inhibitory effects of 100 μM BzATP on 
[3H]GABA and [14C]glutamate uptake (37.7±2.3% and 36.3±2.0%, respectively) 
were still visible when the P2X7 agonist was applied on top of 1 µM veratridine, 
which on its own decreased the uptake of [3H]GABA by 26.5±1.0% and 
[14C]glutamate by 21.5±2.3%. The uptake inhibition of both neurotransmitters by 100 
μM BzATP becomes less apparent upon increasing the concentration of veratridine 
to 3 or 10 µM applied together with the P2X7 receptor agonist (Figures 10A and 
10B). 
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Figure 10 - Increase in intracellular Na+-levels attenuates the inhibitory effect of BzATP on GABA 
and glutamate uptake. Top panels show the inhibitory effect of veratridine (1-10 µM), an activator of 
voltage-gated Na+-channels, on [3H]GABA (A) and [14C]glutamate (B) uptake into rat cortical 
synaptosomes evaluated in the absence and in the presence of BzATP (100 μM). The effect of 
veratridine 10 µM was inhibited by the voltage-gated Na+-channel blocker, TTX (1 μM). On its own, 
TTX (1 µM) did not influence GABA nor glutamate uptake. Bottom panels show the inhibitory effect 
of the Na+/K+-ATPase inhibitor, ouabain (50 µM), on [3H]GABA (C) and [14C]glutamate (D) uptake 
into rat cortical synaptosomes carried out during 90 seconds as a function of the time of incubation 
(2-40 min) measured in the absence and in the presence of BzATP (100 μM). The results are 
expressed as mean ± SEM; the vertical bars represent SEM; the n number of individual experiments 
is shown in the graphs. *P<0.05 (one way ANOVA followed by Bonferroni’s multiple comparison test) 
represents significant differences as compared to the control situation; #P<0.05 (one way ANOVA 
followed by Bonferroni’s multiple comparison test) represents significant differences as compared to 
the effect of veratridine (top panels) or ouabain (bottom panels) alone; ns, non-significant. BzATP 
and veratridine were incubated 10 min before addition of [3H]GABA or [14C]Glutamate and ouabain 
was incubated for 2, 20 and 40 min before addition of [3H]GABA or [14C]Glutamate. TTX was 
incubated 10 min before veratridine application. 
 
Inhibition of Na+/K+ ATPase with 50 µM ouabain progressively decreased the 
uptake of [3H]GABA (to a maximum of 88.2±1.0%; Figure 10C) and [14C]glutamate 
(to a maximum of 47.4±3.2%; Figure 10D) depending on the time of incubation with 
this drug (2-40 min). Different incubation times with ouabain were used in order to 
promote a gradual increase of intracellular Na+ levels until full collapse of the Na+-
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gradient. The inhibitory effect of 50 µM ouabain incubated for 2 minutes (52.2±1.5% 
and 7.5±3.5%, for GABA and glutamate respectively) was amplified by 100 μM 
BzATP (to 60.3±0.8% and 32.5±1.8%, respectively). The effect of 100 µM BzATP 
on [3H]GABA and [14C]glutamate uptake was significantly attenuated by prolonging 
to 20 min the exposure time of the synaptosomes to 50 µM ouabain (85.8±1.2% and 
33.9±2.6%, for GABA and glutamate respectively; Figure 10C and 10D).  
To exclude the participation of hemichannels on the inhibitory effect of BzATP 
on [3H]GABA and [14C]glutamate uptake by rat cortical synaptosomes, we 
performed interaction experiments with carbenoxolone (10 µM, a non-selective 
inhibitor of Cx26, Cx30, Cx43 and Cx46, which also blocks pannexin-1 
hemichannels) and H1152 (3 µM, a Rho kinase inhibitor that affects hemichannels 
pore permeability) (see e.g. Pinheiro et al., 2013; Timóteo et al., 2014), which were 
added to the incubation solution 10 minutes before the P2X7 agonist. Neither of 
these compounds affected (P>0.05) the BzATP (100 µM)-induced downmodulation 
of [3H]GABA and [14C]glutamate uptake by synaptosomes of the rat cerebral cortex 
(Figure 11).  
 
 
Figure 11 – Hemichannels do not participate in the inhibitory effect of BzATP. Top panels show that 
the inhibitory effect of BzATP (100 μM) on [3H]GABA (A) and [14C]glutamate (B) uptake into rat 
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cortical synaptosomes is not altered by carbenoxolone (10 μM), a non-selective inhibitor of Cx26, 
Cx30, Cx43 and Cx46, which can also block pannexin-1. On its own, carbenoxolone (10 µM) 
decreases GABA, but not glutamate uptake. Bottom panels show that the inhibitory effect of BzATP 
(100 μM) on [3H]GABA (C) and [14C]glutamate (D) uptake into rat cortical synaptosomes is not altered 
by H-1152 (3 μM), a Rho kinase inhibitor that affects hemichannels pore permeability. On its own, 
H-1152 (3 µM) decreases GABA uptake and increases glutamate uptake. The results are expressed 
as mean ± SEM; the vertical bars represent SEM; the n number of individual experiments is shown 
in the graphs. *P<0.05 (one way ANOVA followed by Bonferroni’s multiple comparison test) 
represents significant differences as compared to the control situation; #P<0.05 (one way ANOVA 
followed by Bonferroni’s multiple comparison test) represents significant differences as compared to 
the effect of BzATP alone; £ P<0.05 (one way ANOVA followed by Bonferroni’s multiple comparison 
test) represents significant differences as compared to the effect of H-1152 alone; ns, non-significant. 
BzATP was incubated 10 min before addition of [3H]GABA or [14C]Glutamate. Carbenoxolone and 
H-1152 were incubated 10 min before BzATP application. 
 
All together these results suggest that increasing intracellular Na+ 
concentration, i.e. by partial collapsation of the Na+-gradient, downmodulates GABA 
and glutamate uptake similarly to that occurring with the activation of the P2X7 
receptor. Furthermore, P2X7 downmodulation of amino acids transport closely 
accompany the thermodynamic changes operated by increasing intracellular Na+ 
concentration.  
 
Blockage of Na+-influx through P2X7 receptors prevents the inhibitory effect 
of BzATP on the uptake of [3H]GABA and [14C]glutamate  
Next, we evaluated whether manipulation of the extracellular Na+ 
concentration could modulate GABA and glutamate uptake. Substitution of 
extracellular Na+ by NMDG+, so that the concentration of Na+ in the reaction 
chamber decreased from 129 mM to 101, 69 and 9 mM, also diminished the uptake 
of [3H]GABA (Figure 12A) and [14C]glutamate (Figure 12B) by synaptosomes of the 
rat cerebral cortex; the collapse of the Na+-gradient (9 mM plus 120 mM NMDG+) 
reduced [3H]GABA and [14C]glutamate uptake by 92.6±0.7% and 73.3±2.6%, 
respectively. Interestingly, the inhibitory effect of the P2X7 receptor agonist, BzATP 
(100 μM), on the uptake of [3H]GABA and [14C]glutamate was significantly 
attenuated upon decreasing the amount of Na+ in the reaction fluid from 129 mM to 
101 and 69 mM (Figure 12A and 12B), reinforcing the idea that P2X7 
downmodulation of GABA and glutamate transport closely accompanies the 
dynamics of the Na+ transport. 
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Figure 12 - Blockage of Na+-entry through the P2X7 receptor pore prevents the inhibitory effect of 
BzATP on GABA and glutamate uptake. Shown is the inhibitory effect of BzATP (100 μM) on the 
uptake of [3H]GABA (A) and [14C]glutamate (B) carried out during 90 seconds upon decreasing the 
extracellular concentration of Na+ by its replacement by NMDG+. Inhibition of [3H]GABA and 
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[14C]glutamate uptake by the P2X7 receptor agonist, BzATP (100 μM), was significantly attenuated 
upon decreasing the amount of Na+ in the reaction fluid from 129 mM to 101 and 69 mM. Panels (C) 
and (D) illustrate the blockage of the inhibitory effect of BzATP (100 μM) on the uptake of [3H]GABA 
(C) and [14C]glutamate (D) in the absence and in the presence of calmidazolium (1 µM), which inhibits 
small cation currents through the P2X7 receptor pore but not the permeation of the channel by 
organic molecules. On its own, calmidazolium (1 µM) did not influence GABA nor glutamate uptake. 
In panels (E) and (F), shown is that the effect of BzATP (100 µM) is not significantly changed by the 
cell-permeant fast Ca2+-chelator, BAPTA-AM (5 µM). Experiments shown in panels (A-F) were 
performed in Ca2+-free conditions. Bottom panels show that downmodulation of [3H]GABA (G) and 
[14C]glutamate (H) uptake caused by P2X7 receptors activation with BzATP (100-300 µM) is also 
verified in the presence of external CaCl2 (2.2 mM). Under these physiologically relevant conditions, 
the selective P2X7 receptor antagonist, A-438079 (3 µM), prevented the effect of BzATP (100 µM), 
which was still not modified by BAPTA-AM (5 µM). On their own, A-438079 (3 µM) and BAPTA-AM 
(5 µM) were devoid of effect on GABA and glutamate uptake. The results are expressed as mean ± 
SEM; the vertical bars represent SEM; the n number of individual experiments is shown in the graphs. 
*P<0.05 (one way ANOVA followed by Bonferroni’s multiple comparison test) represents significant 
differences as compared to the control situation; #P<0.05 (one way ANOVA followed by Bonferroni’s 
multiple comparison test) represents significant differences as compared to the effect of BzATP 100 
µM alone; ns, non-significant. BzATP was incubated 10 min before addition of [3H]GABA or 
[14C]Glutamate; calmidazolium and A-438079 were incubated 10 min before BzATP application. 
BAPTA-AM was incubated for 33.5 min before addition of [3H]GABA or [14C]Glutamate. 
 
To confirm that the inhibitory effect of BzATP on the transport of GABA and 
glutamate is mediated by Na+-influx, calmidazolium was tested. This drug inhibits 
small cation currents through the P2X7 receptor pore, without affecting permeation 
of hydrophilic organic molecules with a mass up to 900 Da (Virginio et al., 1997). 
The results show that the inhibitory effects produced by 100 µM BzATP (14.1±1.1% 
and 24.0±0.8%, for GABA and glutamate respectively) were significantly attenuated 
by calmidazolium (1 µM), which was incubated with synaptosomes 10 minutes 
before the addition of BzATP (Figure 12C and 12D). In the absence of BzATP, 
calmidazolium (1 µM) did not influence the uptake of neurotransmitters. The fact 
that blocking Na+-influx through the P2X7 receptor attenuates the inhibitory action 
of BzATP on the GABA and glutamate uptake suggests that the effect of the P2X7 
receptor activation is mediated by Na+-permeation through the receptor pore. 
Knowing that calmidazolium also inhibits calmodulin-regulated enzymes, and 
to prove that observed BzATP effects on the high-affinity transport of GABA and 
glutamate are directly mediated by Na+-influx and not by possible recruitment of 
intracellular Ca2+, BAPTA-AM (5 µM; a cell-permeant fast Ca2+-chelator) was tested. 
The results show that the inhibitory effects produced by 100 µM BzATP were not 
significantly (P>0.05) modified by BAPTA-AM, despite this drug has been pre-
incubated with synaptosomes for as long as 33.5 min to ensure high intracellular 
free BAPTA guaranteeing strong intracellular Ca2+-chelation (Figure 12E and 12F). 
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On its own BAPTA-AM did not influence the uptake of both neurotransmitters. These 
experiments demonstrate that Ca2+-signaling was not involved in calmidazolium 
blockade of BzATP effect on neurotransmitter uptake. Moreover, the fact that under 
our experimental conditions BzATP effect was unchanged in presence of BAPTA-
AM also rules-out the involvement of intracellular Ca2+-triggered cytosolic GABA or 
glutamate release proposed recently by Romei et al. (2015).   
Taking into consideration our findings showing that Na+-dependent 
downmodulation of [3H]GABA and [14C]glutamate transport was observed in Ca2+-
free media, we questioned ourselves whether it could also occur under 
physiologically-compatible conditions where extracellular Ca2+ was present. In the 
presence of 2.2 mM external CaCl2, the inhibitory effects of BzATP (300 µM) on 
[3H]GABA (12.6±1.3%) (Figure 12G) and [14C]glutamate (21.2±1.9%) (Figure 12H) 
uptake were about the same magnitude to those obtained in the Ca2+-free conditions 
(Figure 7A and 7B, respectively). Likewise, downmodulation of [3H]GABA and 
[14C]glutamate uptake in the presence of 2.2 mM external CaCl2 was fully prevented 
by the selective P2X7 antagonist, A-438079 (3 µM). Please note that the fast 
intracellular Ca2+ chelator, BAPTA-AM (5 µM) was also devoid of effect on BzATP-
induced downmodulation of amino acid uptake in the presence of external Ca2+ 
(Figures 12G and 12H).  
 
Activation of the P2X7 receptor triggers Na+ influx into cortical synaptosomes 
To ultimately prove that activation of the P2X7 receptor promotes an 
elevation of intrasynaptosomal Na+-levels, we used the cell-permeant sodium 
selective fluorescent indicator, SBFI-AM, to estimate plasma membrane Na+-
gradients. Results show that BzATP (100-300 µM) causes a concentration-
dependent increase in intrasynaptosomal Na+-levels (Figure 13), being the effect of 
100 µM BzATP (25.7±1.7%) fully prevented by the selective P2X7 receptor 
antagonist, A-438079 (3 µM; Figure 13). On its own A-438079 (3 µM) did not 
influence intrasynaptosomal Na+-levels. These results confirm the hypothesis that 
Na+-influx through the P2X7 receptor pore decreases the transport energetic for the 
uptake of GABA and glutamate by decreasing the Na+ gradient across the 
synaptosomal membrane. 
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Figure 13 - Activation of the P2X7 receptor 
increases the intrasynaptosomal Na+-
concentration. Illustrated is the effect of BzATP 
(100 and 300 µM) on Na+ influx into synaptosomes 
of  the rat cerebral cortex loaded with the cell-
permeant sodium selective fluorescent indicator, 
SBFI-AM, either in the absence or in the presence 
of the P2X7 receptor antagonist, A-438079 (3 µM). 
The results are expressed as mean ± SEM; the 
vertical bars represent SEM; the n number of 
individual experiments is shown in the graphs. 
*P<0.05 (one way ANOVA followed by 
Bonferroni’s multiple comparison test) represents 
significant differences as compared to the control situation; #P<0.05 (one way ANOVA followed by 
Bonferroni’s multiple comparison test) represents significant differences as compared to the effect of 
BzATP 100 µM applied alone. BzATP was applied 10 min before addition of [3H]GABA or 
[14C]Glutamate; A-438079 was incubated for 10 min before BzATP application. On its own A-438079 
(3 µM) did not influence intrasynaptosomal Na+ levels.  
 
The higher inhibitory effect of BzATP on [14C]glutamate uptake may stem from 
a concomitant leakage of the neurotransmitter directly through the P2X7 
receptor pore 
As mentioned above, BzATP inhibition was preferential on [14C]glutamate 
uptake, whereas changes in the transmembrane Na+ gradient (caused by 
veratridine and ouabain) were more effective in decreasing the uptake of [3H]GABA 
(Figure 7A and 7B). One possibility to explain these findings may be that repeated 
or prolonged activation of the P2X7 receptor opens a non-selective pore allowing 
the permeation of large molecular weight hydrophilic organic cations up to 900 Da 
(Virginio et al., 1997) providing a route for the release of glutamate (Duan et al., 
2003; Marcoli et al., 2008; Cervetto et al., 2013; Fu et al., 2013; Sperlágh and Illes, 
2014). In keeping with this hypothesis, we found that rat cortical synaptosomes 
challenged with BzATP (100-300 µM) in Ca2+-free media release five-fold more 
[14C]glutamate than [3H]GABA when neurotransmitter release amounts were 
normalized by the stimulatory effect of veratridine (10 µM) under the same 
experimental conditions (Figure 14). It is worth noting that [14C]glutamate release 
produced by BzATP (100 µM) was prevented in the presence of the P2X7 receptor 
antagonist, A-438079 (3 µM) and it was not altered by the glutamate transport 
inhibitor, DL-TBOA (100 µM; Figure 14B). These results suggest that the higher 
potency of the P2X7 receptor-induced decline in [14C]glutamate uptake may be owe 
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to concurrent non-vesicular [14C]glutamate leakage from rat cortical synaptosomes 
through the P2X7 receptor pore. This hypothesis may also explain why blockage of 
Na+ currents, but not permeation of organic molecules, through activated P2X7 
receptors with calmidazolium was unable to fully prevent the inhibitory effect of 
BzATP on [14C]glutamate uptake (Figure 12D), in contrast to that observed with the 
uptake of [3H]GABA under the same experimental conditions (Figure 12C). 
 
 
Figure 14 – Activation of the P2X7 receptor with BzATP exerts a predominant facilitory role on 
[14C]glutamate compared to [3H]GABA release from synaptosomes of the rat cerebral cortex. The 
radioactivity of superfusates was measured by liquid scintillation spectrometry in 2-min fractions 
collected automatically during 34 min. Ten min after initiation of fraction collection, synaptosomes 
retained in fibre glass filters were challenged during 2 min with BzATP (100 or 300 µM) or veratridine 
(10 µM) in Ca2+-free media by changing the inlet tube from one flask to another containing the test 
drug. The P2X7 receptor antagonist, A-438079 (3 µM) and inhibitors of the high-affinity GABA and 
glutamate transport, SKF 489976A (40 µM) and DL-TBOA (100 µM), were added to the superfusion 
solution from the beginning of the release period, i.e. 10 min before BzATP. For comparison 
purposes, [3H]GABA and [14C]glutamate release produced by BzATP was normalized by the 
stimulatory effect of veratridine (10 µM) under the same experimental conditions (Drug/VT). Data are 
expressed as mean ± SEM; the vertical bars represent SEM. The n number of individual experiments 
is shown in the graphs. *P<0.05 (one way ANOVA followed by Bonferroni’s multiple comparison test) 
represents significant differences as compared to the control situation; #P<0.05 (one way ANOVA 
followed by Bonferroni’s multiple comparison test) represents significant differences as compared to 
the effect of BzATP 100 µM applied alone; ns, non-significant.  
 
Discussion and conclusions 
This study was performed to evaluate, in parallel and under the same 
experimental conditions, the role of P2X7 receptor activation on [3H]GABA and 
[14C]glutamate uptake by synaptosomes of the rat cerebral cortex, which are highly 
enriched in nerve terminals expressing P2X7 receptors as we demonstrated by 
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Western blot analysis and immunofluorescence confocal microscopy (Miras-
Portugal et al., 2003; Alloisio et al., 2008; Marín-García et al., 2008). Results 
indicate that, either in the presence or in the absence of extracellular Ca2+ ions, 
stimulation of the P2X7 receptor downmodulates Na+-dependent high-affinity GABA 
and glutamate transport into rat cortical synaptosomes, being this effect more 
evident for the glutamate uptake. This suggests that transient P2X7 receptor 
activation following ATP release by high-frequency stimulus (Cunha et al., 1996b; 
Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 2013) may constitute a 
mechanism facilitating local glutamatergic neurotransmission while promoting, 
albeit to a lesser extent, the endurance of GABAergic neurotransmission ensuring 
tonic and more diffuse neuro-inhibition following intense stimulus. This mechanism 
may be particularly relevant in processes such as memory and learning where 
transient glutamate endurance in the synaptic cleft may facilitate the induction of 
LTP while preventing excytotoxicity by the concomitant promotion of diffuse 
GABAergic inhibition.  
Stimulation of the P2X7 receptor decreases the maximum transport capability 
(Vmax) of rat cortical synaptosomes to take up GABA and glutamate, keeping virtually 
unaltered the affinity for the substrates (Km). A similar result was observed regarding 
the uptake of glutamate by primary cultures of the rat spinal microglia (Morioka et 
al., 2008), yet in this case a metabotropic pathway seems to involve activation of 
the extracellular signal-regulated kinase cascade and production of anti-oxidants via 
a mechanism independent on extracellular Na+ and Ca2+ ions. It is, however, 
uncertain whether the same occurs in CD11b positive microglial cells of the rat 
cerebral cortex expressing the P2X7 receptor (see Figure 7). Taking into account 
that (1) the slowly-desensitizing P2X7 receptor works as a non-selective cationic 
channel promoting the influx of Na+ under low Ca2+ conditions (Jarvis and Khakh, 
2009), (2) GABA and glutamate uptake are crucially dependent on plasma 
membrane Na+-gradient (Kanner, 2006), and (3) extracellular Ca2+ was withdrawn 
from the reaction medium in the majority of the experiments, it is probable that the 
transportation decline (Vmax) caused by the P2X7 agonist may be owed to an 
impairment of the transport energetics, i.e. to the partial disruption of the Na+-
gradient via the activation of a low-affinity high-capacity ATP signal. Moreover, the 
fact that transport inhibition by BzATP was observed in the absence of intra and 
extracellular Ca2+ excludes any effects requiring Ca2+ activation, like: (1) exo- and 
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endocytosis (amenable to alter transporter membrane density), (2) Ca2+-dependent 
neurotransmitter release, or (3) the activation of Ca2+-dependent enzymatic 
cascades. In agreement with this hypothesis, we showed that (1) the inhibitory effect 
of BzATP on neurotransmitter transport was mimicked by two Na+ ionophores, 
gramicidin and monensin; (2) the increase in intracellular Na+ concentration via 
voltage-sensitive Na+ channels activation with veratridine or through inhibition of 
Na+/K+ ATPase with ouabain downmodulates the transport of both 
neurotransmitters; (3) the decrease in extracellular Na+ concentration by 
substitution with NMDG+ also downmodulates the transport of both 
neurotransmitters as predicted by the changes in transporter reversal potentials 
(Richerson and Wu, 2003; Allen et al., 2004); (4) the inhibitory effect of BzATP was 
attenuated when Na+-gradient was disrupted in accordance with changes in Na+-
equilibrium; and, finally, (5) the activation of P2X7 receptors significantly increased 
intrasynaptosomal Na+-levels. Moreover, when Na+-entry through the P2X7 
receptor pore was selectively blocked with calmidazolium the effect of BzATP on 
GABA and glutamate uptake was prevented, thus giving a strong indication that 
BzATP effects were mainly (if not exclusively) mediated by lowering the Na+-coupled 
transporter driving-force. Hence, our results point towards a novel mechanism 
implicated in the decrease of GABA and glutamate uptake by synaptic nerve 
terminals, which might depend on the decline of the Na+ driving-force necessary for 
amino acid transportation across the plasma membrane operated by P2X7 receptor 
activation (Wonnemann et al., 2000; Richerson and Wu, 2003; Kanner, 2006; Lo et 
al., 2008; Yu et al., 2010). A similar dependence on transmembrane Na+-gradient 
was also observed for the glutamate uptake by the RBA-2 astrocytic cell line (Lo et 
al., 2008). Contrarily to what happens in cell cultures, it seems that the P2X7 protein 
density found in astrocytes in situ is below immunofluorescence detection while both 
nerve terminals and microglia exhibit clear P2X7 immunoreactivity (see Figure 7) 
(Deuchars et al., 2001.; Sperlágh et al., 2002; Miras-Portugal et al., 2003; Cavaliere 
et al., 2004). 
As previously mentioned, activation of P2X7 receptors requires high ATP 
concentrations, since this receptor has low affinity for its endogenous ligand (Jarvis 
and Khakh, 2009). Thus, under basal conditions, P2X7 receptors are probably 
dormant, but they may become unmasked after high-frequency stimuli (Cunha et 
al., 1996b; Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 2013) or 
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under pathologic brain activity, such as during prolonged or repeated seizures 
(Engel et al., 2012a; Henshall et al., 2013). Different studies have demonstrated that 
Ca2+ concentration in the extracellular milieu drops progressively to as much as 90% 
under strong, yet physiological, stimulus as well as in pathological conditions, such 
as epilepsy (Heinemann et al., 1977; Borst and Sakmann, 1999; Engelborghs et al., 
2000; Stanley, 2000; Massimi and Amzica, 2001; Rusakov and Fine, 2003; Engel 
et al., 2012a; Poornima et al., 2012; Torres et al., 2012; Zhou et al., 2012; Jimenez-
Pacheco et al., 2013). Under such low extracellular Ca2+ conditions, Ca2+-
dependent neurotransmitter release is significantly diminished while Na+ 
conductance via P2X7 receptors is largely enhanced (Virginio et al., 1997; Jiang, 
2009; Yan et al., 2011) and synaptic ATP is highest. So, it seems plausible to admit 
that the mechanism unraveled in this work might play a role in physiological 
conditions by potentiating neurotransmission under both normal (high extracellular 
Ca2+) and low quantal content (low extracellular Ca2+) conditions. Such a typically 
short temporal-spanning amplification mechanism might gain a different meaning 
under excitotoxic conditions like during epileptic seizures, since in the latter situation 
the extracellular Ca2+ concentration falls during prolonged periods of time in 
synchrony with ATP endurance and the expression of P2X7 receptors is increased 
resulting in a predominantly pro-epileptic action (Burnstock et al., 2011b; Engel et 
al., 2012a; Jimenez-Pacheco et al., 2013). 
Besides epileptic seizures, there is an explosion of data indicating that P2X7 
receptors are involved in the pathophysiology of several neurological syndromes 
(e.g. stroke, neurotrauma, neuropathic pain, multiple sclerosis, amyotrophic lateral 
sclerosis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease) and 
psychiatric mood disorders (reviewed in Sperlágh and Illes, 2014). This may be due 
to the release of large quantities of ATP following any kind of cell injury and its 
widespread involvement as a key regulator of the inflammasome complex. It is 
possible that the decrease in the driving-force for neurotransmitters uptake caused 
by Na+-influx via P2X7 receptors occurs synchronously to other Na+-triggered 
events, like the activation of Na+/Ca2+-exchangers and subsequent activation of 
Ca2+-dependent neurotransmitter exocytosis following a significant increase in 
intracellular Na+ concentration that is a characteristic event associated with tissue 
injury (Yu et al., 2010; Romei et al., 2015). 
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In summary, data from this study suggest that Na+-influx through activated 
P2X7 receptors on synaptic nerve terminals may disrupt plasma membrane Na+-
gradient, which is the driving-force for the uptake of GABA and glutamate by brain 
cells. Hence, downmodulation of Na+-dependent high-affinity uptake of amino acids 
may constitute a novel mechanism by which ATP might influence neuronal 
excitation and, thus, synaptic transmission in the CNS, in particular when the 
extracellular concentration of the nucleotide increases to levels high enough to 
stimulate low affinity ionotropic P2X7 receptors, such as during high-frequency 
nerve firing or under pathological conditions leading to increased nerve activity 
and/or neuroinflammation. 
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Abstract 
Recently, we demonstrated that nerve terminals from the rat cerebral cortex 
express ATP-sensitive P2X7 receptors, whose activation downmodulates high-
affinity GABA and glutamate uptake by decreasing the transmembrane Na+ 
gradient. Increasing evidences made in several animal models point towards a 
significant role of P2X7 receptor in the pathophysiology of epilepsy. Increased 
expression of the P2X7 receptor was also observed by us in the hippocampus and 
neocortex of patients with drug-resistant MTLE. In this context, we aimed at 
understanding the pathological significance of the alterations of the P2X7 receptor-
mediated downmodulation of GABA and glutamate uptake in the pilocarpine-
induced epileptic rat model, which is most frequently used to compare with MTLE in 
humans. Results demonstrate that the P2X7 receptor-induced inhibition of GABA 
and glutamate uptake by synaptosomes of epileptic rats were not different from their 
control littermates. In contrast to that observed in human epileptic patients, we 
detected no significant changes in the density of P2X7 receptors in cortical slices of 
epileptic rats compared to control animals, thus indicating that the pilocarpine-
induced animal model might not reproduce drug-resistant MTLE in humans at least 
under the present experimental conditions.       
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Introduction 
Epilepsy is an old and prevalent disorder, still unresolved, with a great 
negative impact in the quality of life of patients, mainly for those patients in which 
seizures are not controlled by the currently available drugs. Despite intense 
research during the last decades,  few new AEDs were approved for clinical practice 
(Madsen et al., 2010). Only a subset of drug-refractory patients meet the criteria for 
surgical ablation of damaged tissue as last resource treatment, leaving remaining 
patients with an unmet medical need. Therefore, it is urgent to find new 
pharmacological targets to control seizures and prevent epileptogenesis. 
In a recent study, we showed that activation of the P2X7 receptor 
downmodulates GABA and glutamate uptake by nerve terminals (synaptosomes) of 
the rat cerebral cortex (Paper 1; Barros-Barbosa et al., 2015b). Despite the P2X7 
receptor-mediated inhibition being preferential on glutamate uptake, which may 
stem from a concomitant leakage of the neurotransmitter directly through the P2X7 
receptor pore, downmodulation of GABA uptake was by some means unexpected 
given the pro-convulsive actions of the P2X7 receptor in most literature reports 
(Vianna et al., 2002; Fernandes et al., 2009; Padrão et al., 2011; Engel et al., 2012a; 
Jimenez-Pacheco et al., 2013). At this point, it is worth mentioning that during 
prolonged and/or repetitive seizures increases in the extracellular levels of GABA 
might not have a protective role but, conversely, may exert a pro-epileptic one due 
to GABAergic “rundown” (Cohen et al., 2002; D’Antuono et al., 2004; Ragozzino et 
al., 2005; Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 2012). This can be 
defined as a decrease in GABAergic inhibition or even transient excitatory 
GABAergic actions, resultant from desensitization of GABAA receptor upon 
repetitive stimulation (Ragozzino et al., 2005; Palma et al., 2007; Mazzuferi et al., 
2010) or due to depolarization stemming from changes in Cl- homeostasis 
(D’Antuono et al., 2004; Miles et al., 2012). 
The present study was designed to understand the pathological significance 
of the alterations of the P2X7 receptor-mediated downmodulation of the uptake of 
GABA and glutamate in the pilocarpine-induced epileptic rat model, which is most 
frequently used to compare with drug-resistant MTLE in humans (Sharma et al., 
2007; Curia et al., 2008; O'Dell et al., 2012). Pilocarpine is a muscarinic 
acetylcholine receptor agonist that reproduces many morphological and clinical 
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aspects of MTLE in rodents (Sharma et al., 2007). Using a suitable animal model 
will guide us in the work we plan to execute with samples obtained from the brain of 
drug-resistant MTLE and non-MTLE patients submitted to neurosurgery for ablation 
of the epileptic focus, as human tissue available for research is very scarce.  
 
Experimental procedures 
Drugs and solutions 
HEPES and triton X-100 were from Merck Millipore (Darmstadt, Germany). 
GABA, SDS, 2-mercaptoethanol, sodium deoxycholate, Tris, BSA, bromophenol 
blue, glycerol, tween 20, BzATP, scopolamine methyl bromide, pilocarpine and 
AOAA were obtained from Sigma-Aldrich (St. Louis, MO). L-Glutamic acid, A-
438079 and DL-TBOA were from Tocris Bioscience (Bristol, UK); SKF89976A 
hydrochloride was from Abcam (Cambridge, UK); [14C]Glutamate and [3H]GABA 
were from American Radiolabeled Chemicals, Inc. (St. Louis, MO). All stock 
solutions were stored as frozen aliquots. Dilutions of stock solutions were made 
daily and appropriate solvent controls were done. No statistically significant 
differences between control experiments, made in the absence or in the presence 
of the solvents at the maximal concentrations used, were observed. 
 
Animals  
Animal care and experimental procedures were carried out in accordance 
with the UK Animals (Scientific Procedures) Act 1986 and followed the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and the 
National Institutes of Health Guide for Care and Use of Laboratory animals (NIH 
Publications No. 80-23) revised 1996. This study was done in accordance with 
ARRIVE guidelines (McGrath et al., 2010). All efforts were made to minimize animal 
suffering and to reduce the number of animals used. Wistar rats (150-200 g) of either 
sex (Charles River, Barcelona, Spain) were kept at a constant temperature (21 ºC) 
and a regular light (06.30–19.30 h)–dark (19.30–06.30 h) cycle, with food and water 
ad libitum.  
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Pilocarpine-induced epileptic rat model 
The generation of the epilepsy model was made as previously described 
byCardoso et al. (2011). Ten-week old rats were pretreated with scopolamine 
methyl bromide (1 mg/kg, subcutaneous) to minimize peripheral cholinergic side 
effects of pilocarpine. Thirty minutes later, the rats received a single high-dose of 
pilocarpine (350 mg/kg, intraperitoneal). The onset of SE was defined as the 
appearance of behavioral symptoms corresponding to stage 4 or 5 seizures on the 
Racine scale (Racine, 1972), i.e. rearing, falling and generalized convulsions. SE 
onset was detected usually 30–60 min following the pilocarpine injection. It has been 
previously reported that pilocarpine-induced SE, if lasting several hours, can be 
associated with high mortality rates ranging between 15 and 50% depending on the 
dose of pilocarpine and other experimental conditions. Therefore, special efforts 
were made to improve the survival rate of the animals. To this end, the rats were 
injected with diazepam (2.5 mg/kg, intraperitoneal) 2 h after the beginning of SE in 
order to cease convulsions. Albeit considerably reduced in severity seizure activity 
was only abrogated after an additional dose of diazepam (2.5 mg/kg) given to the 
rats 30 min after the first injection. During the first 24 h of the recovery period, the 
animals were periodically hydrated with saline injected subcutaneously. Following 
the induction of SE by a single-injection of pilocarpine, the rats were observed daily 
for spontaneous behavioral seizures at random times between 08:00 h and 20:00 
h. Animals exhibiting spontaneous seizures were used for the experimental work, 
which was performed 2 months after pilocarpine injection. 
 
Preparation of synaptosomes from the rat cerebral cortex 
Synaptosomes were isolated as previously described by Helme-Guizon et al. 
(1998) and then modified by Bancila et al. (2009). Briefly, the cerebral cortex was 
dissected out and gently homogenized in cold oxygenated (95% O2 and 5% CO2) 
Krebs solution (in mM: glucose 5.5, NaCl 136, KCl 3, MgCl2 1.2, Na2HPO4 1.2, 
NaHCO3 16.2, CaCl2 0.5, pH 7.40). Homogenates were filtered through a nylon filter 
(mesh size 100 µm). The filtrate was left to sit during 30–45 min until formation of a 
pellet, which was re-suspended into Krebs solution and left at room temperature. 
Protein concentration determined by the BCA method (PierceTM, Thermoscientific, 
Rockford USA) was adjusted to 6.25 mg protein mL-1. 
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[3H]GABA and [14C]glutamate uptake experiments 
[3H]GABA uptake by synaptosomes was measured as described elsewhere 
(Cordeiro et al., 2003; Barros-Barbosa et al., 2015a; Barros-Barbosa et al., 2015b). 
[3H]GABA (0.25 μCi mL-1; 70 Ci mmol-1) uptake reactions were initiated by adding 
[3H]GABA (0.5 μM) to media containing synaptosomes (0.25 mg protein mL-1), at 30 
ºC. Uptake reactions were performed in media containing (in mM) NaCl 128, MgCl2 
1.2, KCl 3, glucose 10, HEPES–Na 0.01 (pH 7.4), EGTA 0.1 and AOAA 0.01 (used 
to prevent GABA metabolism by GABAT). Experiments were performed in the 
absence of extracellular Ca2+, in order to focus research on the energetics of Na+-
coupled transport. The reactions were stopped by rapid filtration through glass fibre 
prefilters (Merck Millipore, Cork, IRL), prewashed with cold sucrose 320 mM, Tris–
HCl 10 mM (pH 7.4) and EGTA 0.1 mM. The filters were then washed with the same 
medium and plunged into vials containing scintillation cocktail (Insta-Gel Plus, 
Perkin Elmer, Boston, USA) for radioactivity measurement by liquid scintillation 
spectrometry (TriCarb2900TR, Perkin Elmer, Boston, USA). The values for 
[3H]GABA taken up by synaptosomes were expressed as pmol mg protein-1 after 
subtraction of blank values obtained by filtering reaction medium aliquots. 
[14C]Glutamate uptake (0.25 μCi mL-1; 0.270 Ci mmol-1) by synaptosomes was 
measured as described above for [3H]GABA uptake but using [14C]glutamate (10 
μM) without adding AOAA (10 μM) to the medium. Unless stated otherwise, uptake 
assays were carried out during 90 seconds since this time is in the linear phase of 
[3H]GABA and [14C]Glutamate accumulation. 
All modifier drugs tested were allowed to equilibrate with the synaptosomes 
at least for 10 min before adding the test drug, which was applied 10 min before 
addition of the radioactive neurotransmitter. Control samples were incubated for the 
same amount of time in the absence of drugs.  
 
Immunofluorescence staining and confocal microscopy   
Brain samples were fixed in 4% paraformaldehyde in phosphate-buffered 
saline (PBS; in mM: NaCl 137, KCl 2.6, Na2HPO4 4.3, KH2PO4 1.5; pH=7.4) for 
about 48 h (4 ºC), cryopreserved in 30% sucrose in PBS and stored in a tissue 
freezing medium at -80 ºC. 
Free floating 30 μm brain slices were incubated for 1 h, at room temperature, 
with blocking buffer I (foetal bovine serum 10%, BSA 1%, triton X-100 0.5%, NaN3 
Purinergic modulation of neurotransmitter transporters in human MTLE  
Original Research Papers 
87 
 
 
 
0.05%) and subsequently incubated overnight, at 4 ºC, with the primary antibodies 
diluted in blocking buffer II (foetal bovine serum 5%, BSA 0.5%, triton X-100 0.5%, 
NaN3 0.05% in PBS): rabbit anti-P2X7 receptor (1:50, #APR004, Alomone, 
Jerusalem, Israel), goat anti-VAMP-1 (1:20, R&D Systems, Minneapolis, MN), 
mouse anti-GFAP (1:350, Chemicon, Temecula, CA). Sections were rinsed in PBS 
supplemented with triton X-100 0.5% (3 cycles of 10 min) and incubated for 120 min 
with species specific secondary antibodies conjugated with fluorescent dyes 
(donkey anti-rabbit IgG Alexa Fluor 488, donkey anti-mouse IgG Alexa Fluor 568; 
donkey anti-goat Alexa 633) diluted in blocking buffer II, at room temperature. After 
rinsing in PBS, slices were mounted on optical-quality glass slides using 
VectaShield (Vector Labs, Peterborough, UK) as mounting media. Observations 
were performed with a laser scanning confocal microscopy (Olympus FV1000, 
Tokyo, Japan). Controls were performed by following the same procedure but 
replacing the primary antibodies with the same volume of blocking buffer II. Images 
were analyzed using the Olympus Fluoview 4.2 Software (Olympus FV1000, Tokyo, 
Japan). Co-localization was assessed by calculating the staining overlap and the ρ 
for each confocal micrograph stained with two fluorescent dyes. Both parameters 
were automatically calculated per image with the Olympus Fluoview 4.2 Software 
(Olympus FV1000, Tokyo, Japan). Overlap between two stainings gives a value 
between +1 and 0 inclusive, where 1 is total overlap and 0 is no overlap. ρ is a 
measure of the linear correlation between two variables (stainings), giving a value 
between +1 and −1 inclusive, where 1 is total positive correlation, 0 is no correlation, 
and −1 is total negative correlation.  
 
SDS-PAGE and Western blot analysis  
Synaptosomes of the rat cerebral cortex were homogenized in RIPA buffer 
containing: Tris-HCl (pH 7.6) 25 mM, NaCl 150 mM, sodium deoxycholate 1%, 
triton-X-100 1%, SDS 0.1%, EDTA 5 mM and a protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO). The protein content of the samples was evaluated using the 
BCA method. Samples were solubilized at 70 °C in SDS reducing buffer (Tris-HCl 
(pH 6.8) 125 mM, SDS 4%, bromophenol blue 0.005%, glycerol 20%, and 2-
mercaptoethanol 5%) for 10 min, subjected to electrophoresis in 12.5% SDS-
polyacrylamide gels and electrotransferred onto PVDF membranes (Merck 
MilliPore, Temecula, CA). Membranes were blocked for 1 h in Tris-buffered saline 
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(TBS; in mM: Tris-HCl 10 (pH 7.6), NaCl 150) containing Tween 20 0.05% and BSA 
5% and, subsequently, incubated overnight, at 4 ºC, with primary antibodies: rabbit 
anti-P2X7 receptor (1:300, #APR004, Alomone, Jerusalem, Israel) and rabbit anti-
β-actin antibody (1:2500, Abcam, Cambridge, UK). Membranes were washed three 
times for 10 min in 0.05% Tween 20 in TBS and then incubated with horseradish 
anti-rabbit or anti-mouse peroxidase-conjugated secondary antibodies for 120 min, 
at room temperature. The antigen-antibody complexes were visualized by 
chemiluminescence with the Immun-Star WesternC Kit (Biorad Laboratories, 
Hercules, CA) using the ChemiDoc MP imaging system (Bio-Rad Laboratories, 
Hercules, CA). To test for specificity of the bands corresponding to P2X7 receptor, 
the anti-P2X7 receptor antibody was pre-adsorbed with a control peptide antigen 
corresponding to the amino acid residues 576-595 of the intracellular C-terminus of 
the rat P2X7 receptor, before incubation with the membrane. Gel band image 
densities were quantified with Image J (National Institute of Health, USA). 
 
Data presentation and statistical analysis 
The uptake of [3H]GABA and [14C]glutamate by synaptosomes of the rat 
cerebral cortex was expressed as a percentage of control values obtained in the 
same synaptosomal batch without adding any drug. Results are expressed as mean 
± SEM, with n (showed in graphs) indicating the number of individual experiments 
performed in a given situation. Because of limited inter-individual variation, randomly 
chosen groups of at least three animals of the same strain and weight (Wistar rats 
of 150-200 g) were considered sufficient to replicate each experimental protocol; 
individual uptake experiments were performed in triplicate.  Statistical analysis of 
data was carried out using GraphPad Prism 6.04 software (La Jolla, CA, USA). 
Unpaired Student’s t-test with Welch correction was used for statistical analysis 
when parametric data was considered. For multiple comparisons, one-way ANOVA 
followed by Bonferroni's Multiple Comparison Test was used. For multiple 
comparisons between multiple groups, two-way ANOVA followed by Bonferroni´s 
Multiple Comparison Test was used.  P < 0.05 values were considered to show 
significant differences between means.  
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Results 
[3H]GABA and [14C]glutamate uptake by cortical nerve terminals isolated from 
both control and epileptic animals is mediated by high-affinity transporters 
First, we evaluated if the uptake of both neurotransmitters, [3H]GABA and 
[14C]glutamate, into isolated nerve terminals from the cerebral cortex of control and 
epileptic rats occurs through Na+-dependent high affinity transporters. Figure 15 
shows that selective inhibition of GAT1 with SKF89976A (40 µM) decreased 
(P<0.05) [3H]GABA uptake by cortical nerve terminals of control and epileptic rats 
by 96.4±0.2% and 96.8±0.3%, respectively (Figure 15A). Likewise, the non-
selective glutamate transporter inhibitor, DL-TBOA (100 µM), decreased 
[14C]glutamate uptake by cortical nerve terminals from control and epileptic rats by 
89.3±1.1% and 95.3±0.8%, respectively (Figure 15B). These results suggest that 
the uptake of [3H]GABA and [14C]glutamate by rat cortical nerve terminals occurs 
predominantly via high-affinity amino acid transporters.  
 
 Figure 15 – Nerve terminals isolated 
from the cerebral cortex of control and 
epileptic rats take up [3H]GABA and 
[14C]glutamate through Na+-dependent 
high-affinity transporters. Shown is the 
inhibition of Na+-coupled high-affinity 
transport of [3H]GABA (panel A) and 
[14C]glutamate (panel B) with 
SKF489976A (40 µM; GAT1 selective 
inhibitor) and DL-TBOA (100 µM; non-
specific inhibitor of the EAAT), 
respectively, into nerve terminals of 
control and pilocarpine-induced 
epileptic rats. SKF 489976A and DL-
TBOA contacted with nerve terminals 
for 20 min before application of 
[3H]GABA and [14C]glutamate into the 
reaction chamber. Data are expressed 
as mean ± SEM; the n number of experiments is shown below each bar. *P < 0.05 (Student’s t-test 
with Welch correction) represents significant differences as compared to the situation where no drugs 
were added.  
 
Downmodulation of GABA and glutamate uptake produced by activation of 
the P2X7 receptor is kept unchanged in epileptic rats 
Like that observed in isolated nerve terminals of the cerebral cortex of control 
rats (Paper1; Barros-Barbosa et al., 2015b), the prototypic P2X7 receptor agonist, 
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BzATP (1-300 µM), downmodulates [3H]GABA (Figure 16A) and [14C]glutamate 
uptake by cortical synaptosomes of epileptic animals (Figure 16B). The magnitude 
of the inhibitory effect of BzATP was dependent on the concentration; 
downmodulation of [3H]GABA and [14C]glutamate uptake was more evident at 
concentrations within the range (20-300 µM), indicating that the nucleotide activates 
preferentially low-affinity P2X7 receptors (North, 2002; Jarvis and Khakh, 2009); the 
negative modulation of [3H]GABA and [14C]glutamate uptake by BzATP was roughly 
similar in control and epileptic animals (Figure 16A and 16B).  
 
 
Figure 16 – Downmodulation of GABA and glutamate uptake caused by the P2X7 receptor agonist, 
BzATP, has about the same magnitude in cortical synaptosomes of control and pilocarpine-induced 
epileptic rats. Panels A and B illustrate the effect of BzATP (3-300 µM) on [3H]GABA and 
[14C]glutamate uptake by nerve terminals isolated from the cerebral cortex of control and epileptic 
rats. The selective P2X7 receptor antagonist, A-438079 (3 µM), prevented BzATP (100 µM)-induced 
inhibition of [3H]GABA  (C) and [14C]glutamate (D) uptake by cortical synaptosomes of control and 
epileptic rats. BzATP contacted with nerve terminals for 10 min before application of [3H]GABA and 
[14C]glutamate into reaction chamber; A-438079 was added 10 min before BzATP. Data are 
expressed as mean ± SD; the n number of animals per experimental condition is shown below each 
bar. §P < 0.05 (two way ANOVA followed by Bonferroni´s Multiple Comparison Test) represents 
significant differences as compared to control group. *P < 0.05 and #P< 0.05 (one-way ANOVA 
followed by Bonferroni´s Multiple Comparison Test) represents significant differences as compared 
to the situation where no drugs were added and to the effect of BzATP (100 µM) alone, respectively.  
 
Purinergic modulation of neurotransmitter transporters in human MTLE  
Original Research Papers 
91 
 
 
 
When used in the low micromolar range, BzATP increased (12%) rather than 
decreased the uptake of [14C]glutamate into isolated cortical nerve terminals of 
epileptic rats but not in control animals (Figure 16B), an effect that may be mediated 
by a distinct P2 purinoceptor (North, 2002; Jarvis and Khakh, 2009). Conversely, 
the nucleotide failed to inhibit the uptake of [3H]GABA into cortical synaptosomes of 
epileptic rats when used in a 3-µM concentration (Figure 16A), suggesting either 
that (1) another purinoceptor activated by BzATP may be counteracting the P2X7 
receptor-mediated inhibition, or that (2) the P2X7 receptor agonist lost its potency 
in epileptic rats. 
The selective P2X7 receptor antagonist, A-438079 (3 µM), prevented 
(P<0.05) the inhibitory effects of BzATP (100 µM) on the uptake of [3H]GABA (Figure 
15C) and [14C]glutamate (Figure 16D) into synaptosomes of the cerebral cortex of 
control and epileptic rats. These results strengthen our assumption that the P2X7 
receptor is equally involved in the inhibition of high-affinity GABA and glutamate 
uptake by cortical nerve terminals produced by BzATP in both control and epileptic 
rats.  
 
No changes were observed in the cellular localization and expression density 
of P2X7 receptors in the cerebral cortex of control and epileptic rats 
Using immunofluorescence confocal microscopy and Western blot assays, 
we showed that the P2X7 receptor is predominantly localized in cortical nerve 
terminals of healthy rats (Paper1; Barros-Barbosa et al., 2015b). Our results are in 
keeping with reports from other authors suggesting the presence of functional P2X7 
receptors on nerve terminals of the rat cerebral cortex (Miras-Portugal et al., 2003; 
Alloisio et al., 2008; Marcoli et al., 2008; Marín-García et al., 2008). Here, we 
evaluated if the same occurs in the cerebral cortex of pilocarpine-injected epileptic 
rats and whether one could detect changes in the density of expression of the P2X7 
receptor in these animals.  
The analysis of confocal micrographs shown in Figure 17 indicates that the 
antibody directed against the P2X7 receptor (green) co-localizes with the synaptic 
nerve terminal marker, VAMP-1 (red, Figure 17A), whereas no significant co-
localization was detected with the astrocytic cell marker, GFAP (red, Figure 17B), 
within the same brain region. Co-localization was assessed by evaluating the 
Pearson´s coefficient (ρ) and staining overlap obtained by merging the two 
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fluorescent channels (yellow staining). Data suggest that no changes were observed 
in the cellular localization of the P2X7 receptor in slices of the cerebral cortex of 
both control and epileptic rats; the dominant localization of the P2X7 receptor in 
cortical nerve terminals was kept unaltered in epileptic animals assayed after two 
months of pilocarpine injection.  
 
 
Figure 17– Immunoreactivity against the P2X7 receptor in nerve terminals isolated from the cerebral 
cortex of epileptic rats is similar to that found in control rats. Panels A and B illustrate confocal 
micrographs of rat cortical slices from control and epileptic rats stained against the P2X7 receptor. 
Synaptic nerve terminals were identified with VAMP-1 antibody, whereas astrocytes were stained 
with an antibody against the GFAP. Note that VAMP-1-positive nerve terminals (red) are endowed 
with the P2X7 receptor (green) (panel A), but no significant co-localization was observed between 
P2X7 receptor (green) and GFAP (red) (panel B). Data below confocal micrographs correspond to 
staining overlap and Pearson´s Coefficient (ρ) and were used to estimate co-localization of P2X7 
receptor and type-specific cell markers (yellow staining). Panel C illustrates representative blots of 
the P2X7 receptor immunoreactivity in synaptosomes of the cerebral cortex of control and epileptic 
rats; gels were loaded with 75 µg of protein. Please note that both bands are specific as they 
disappeared after pre-adsorption of antibody with the control peptide antigen (negative control; lane 
3). β-actin was used as a reference protein. Data are expressed as mean ± SEM and the number of 
animals per group is shown below each bar. ns (Student’s t-test with Welch correction) represents 
non-significant differences as compared to control rats. Scale bars = 50 µm. 
 
Regarding the expression density of the P2X7 receptor in the cerebral cortex 
of control and pilocarpine-injected epileptic rats, Western blot analysis  shows that 
the P2X7 receptor expression normalized by β-actin was kept fairly constant in the 
two animal groups (Figure 17C). Like that observed in cortical synaptosomes of 
control rats, two bands corresponding to the P2X7 receptor appear at ~72 kDa 
(Künzli et al., 2007; Jimenez-Pacheco et al., 2013; Yu et al., 2013) in the samples 
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isolated from epileptic animals. Please note that both bands disappeared after pre-
adsorption of the antibody against P2X7 receptor with excess of the control peptide 
antigen corresponding to amino acid residues 576-595 of the intracellular C-
terminus of the rat P2X7 receptor, confirming the specificity of the antibody used in 
this study (Figure 17C, lane 3, Negative Control). 
 
Discussion and conclusions 
Despite the fact that P2X7 receptor has been considered the P2 receptor 
more committed to epilepsy, controversy still exists regarding its pro- or 
anticonvulsant effects in distinct animal models. Pilocarpine-induced seizures were 
increased in mice lacking the P2X7 receptor, although no such effect was observed 
in the kainate epilepsy model (Kim and Kang, 2011). In vitro studies also argue that 
the P2X7 receptor activation can be inhibitory. These include a report showing that 
presynaptic P2X7 receptor reduce neurotransmitter release in hippocampal slices 
(Armstrong et al., 2002). Conversely, increasing evidences suggest that the P2X7 
receptor may be upregulated in the hippocampus and cerebral cortex of rodents 
with temporal lobe epilepsy induced either with pilocarpine or kainate; these findings 
were observed both in acute and chronic phases of the disorder (Avignone et al., 
2008; Doná et al., 2009; Jimenez-Pacheco et al., 2013). Nevertheless, it might 
happen that the P2X7 receptor expression may transiently decrease to control levels 
in the latent phase of the disease (Doná et al., 2009) and this finding may complicate 
interpretation of the results obtained by various research groups. An increase in the 
density of the P2X7 receptor was also observed in the neocortex from patients with 
drug-resistant temporal lobe epilepsy (Jimenez-Pacheco et al., 2013), as well as in 
the hippocampus of patients with temporal lobe epilepsy associated with 
hippocampal sclerosis (abstracts published by Fernandes et al., 2009; Padrão et 
al., 2011). Manipulation of the P2X7 receptor tone with the selective antagonist, A-
438079, exerts an anticonvulsant effect in rodent models of epilepsy (Engel et al., 
2012a; Engel et al., 2012b; Henshall et al., 2013; Jimenez-Pacheco et al., 2013).  
In this study, we show for the first time that activation of the P2X7 receptor in 
isolated nerve terminals of the rat cerebral cortex downregulates high-affinity GABA 
and glutamate uptake by a similar extent in epileptic rats and healthy control 
littermates when the former where tested 2 months after induction of the SE by 
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injecting pilocarpine. Immunofluorescence confocal microscopy data and Western 
blot analysis show that the P2X7 receptor is highly enriched in nerve terminals of 
the rat cerebral cortex labeled with VAMP1, with no immunoreactivity being 
observed in GFAP-positive astrocytes. In contrast to previous findings (Avignone et 
al., 2008; Doná et al., 2009; Jimenez-Pacheco et al., 2013), we observed no 
significant differences in the P2X7 receptor expression density normalized by β-
actin in synaptosomes isolated from healthy controls and epileptic rats. This may 
explain why no changes were detected in the magnitude of the inhibitory effect of 
BzATP on GABA and glutamate uptake by synaptosomes of the cerebral cortex of 
the two groups of animals, when the nucleotide was tested in the high micromolar 
concentration range. Whether these contradictory findings regarding the role of the 
P2X7 receptor in different animal models of epilepsy are attributed to changes in the 
receptor expression and function along the disease progression (Doná et al., 2009) 
and/or to the underlying epileptogenic process remains to be elucidated.  
In fact, the use of animal models for studying epilepsy has been associated 
with many limitations (Kandratavicius et al., 2014), which are mainly due to (1) 
anatomical and functional differences between species, (2) the chronicity of the 
disease stage, and/or (3) the origin and neuronal network adaptation to the initial 
cause of the disease. It is, therefore, plausible that under the present experimental 
conditions, epileptic animals used 2 months after induction of the SE with pilocarpine 
require extra time to develop measurable changes in cortical P2X7 receptor 
expression and function comparable to those found in the neocortex of more severe 
epileptic animal models and, eventually, of MTLE patients, as for the latter the 
epileptogenic process lasts several years (see original data in the following two 
papers).  
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Abstract 
Thirty percent of epileptic patients are refractory to medication. The majority 
of these patients have MTLE. This prompts for new pharmacological targets, like 
ATP-mediated signaling pathways, since the extracellular levels of the nucleotide 
dramatically increase during in vitro epileptic seizures. In this study, we investigated 
whether sodium-dependent GABA and glutamate uptake by isolated nerve 
terminals of the human neocortex could be modulated by ATP acting via slow-
desensitizing P2X7 receptor. 
Modulation of [3H]GABA and [14C]glutamate uptake by ATP, through 
activation of the P2X7 receptor, was investigated in isolated nerve terminals of the 
neocortex of cadaveric controls and drug-resistant epileptic (non-MTLE and MTLE) 
patients submitted to surgery. Tissue density and distribution of the P2X7 receptor 
in the human neocortex was assessed by western blot analysis and 
immunofluorescence confocal microscopy. 
The P2X7 receptor agonist, BzATP (3-100 µM) decreased [3H]GABA and 
[14C]glutamate uptake by nerve terminals of the neocortex of control and epileptic 
patients. The inhibitory effect of BzATP (100 µM) was prevented by the selective 
P2X7 receptor antagonist, A-438079 (3 µM). Downmodulation of [14C]glutamate 
uptake by BzATP (100 µM) was roughly similar in control and epileptic patients, but 
the P2X7 receptor agonist inhibited more effectively [3H]GABA uptake in the 
epileptic tissue. Neocortical nerve terminals of epileptic patients express higher 
amounts of the P2X7 receptor protein than control samples.  
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High-frequency cortical activity during epileptic seizures releases huge 
amounts of ATP, which by acting on low-affinity slowly-desensitizing ionotropic 
P2X7 receptor, leads to downmodulation of neuronal GABA and glutamate uptake. 
Increased P2X7 receptor expression in neocortical nerve terminals of epileptic 
patients may, under high-frequency firing, endure GABA signaling and increase 
GABAergic rundown, unbalancing glutamatergic neuroexcitation. This study 
highlights the relevance of the ATP-sensitive P2X7 receptor as an important 
negative modulator of GABA and glutamate transport and prompts for novel anti-
epileptic therapeutic targets. 
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Introduction 
Epilepsy is the second most common neurological disorder, affecting ~50 
million people worldwide (Pitkänen and Lukasiuk, 2011). Nearly 30% of epileptic 
patients are drug refractory and most of them exhibit MTLE with unknown etiology 
(Pitkänen and Lukasiuk, 2011). Amygdalohyppocampectomy surgery is the last 
resource treatment for some, leaving remaining patients with an unmet medical 
need. This prompts for new pharmacological tools to control seizures and/or 
epileptogenesis (Pitkänen and Lukasiuk, 2011).  
Sodium-coupled high-affinity GABA and glutamate transporters located in 
the plasma membrane of both neurons and glial cells emerge as potential targets, 
since they are crucial in terminating amino acid neurotransmission and synaptic 
excitability by removing neurotransmitters from the synaptic cleft. In order to 
adapt the uptake of amino acids to the synaptic environment, transporters should 
be rapidly modulated. However, little is known about the signaling molecules 
responsible for fast regulation of GABA and glutamate transport in the epileptic 
human brain. 
ATP is a likely candidate, since in vitro studies have shown that the 
extracellular levels of this nucleotide dramatically increase during high-frequency 
neuronal firing and/or pathologic brain activity, such as prolonged or repeated 
seizures (Cunha et al., 1996b; Frenguelli et al., 2007; Heinrich et al., 2012). ATP 
exerts its action through the activation of P2X and P2Y receptors. Increasing 
evidences have implicated the participation of ionotropic P2X7 receptor in 
epilepsy (Vianna et al., 2002; Fernandes et al., 2009; Padrão et al., 2011; Engel 
et al., 2012a; Jimenez-Pacheco et al., 2013). It has been shown that P2X7 
receptor levels increase after SE in hippocampus and cortex of mice (Engel et 
al., 2012a; Jimenez-Pacheco et al., 2013) and other animal models (Vianna et 
al., 2002). Increased neocortical expression of the P2X7 receptor has also been 
demonstrated in human patients with pharmaco-resistant temporal lobe epilepsy 
(Jimenez-Pacheco et al., 2013), as well as in the hippocampus of patients with 
temporal lobe epilepsy associated with hippocampal sclerosis (published in 
abstract form) (Fernandes et al., 2009; Padrão et al., 2011). Additionally, an 
anticonvulsant effect of P2X7 receptor antagonists has been observed in animal 
models of epilepsy (Engel et al., 2012a; Jimenez-Pacheco et al., 2013). 
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Although P2X7 receptor shows low affinity (0.1–1 mM) for its agonist 
(Jarvis and Khakh, 2009), high levels of ATP released during intense and/or high-
frequency stimuli (Cunha et al., 1996b; Frenguelli et al., 2007; Heinrich et al., 
2012; Wall and Dale, 2013) activate this receptor leading to spatial-temporal 
coincidence of high concentrations of ATP, glutamate and GABA at the synapse. 
Additionally, under conditions of high-frequency nerve firing extracellular Ca2+ 
drops (Heinemann et al., 1977; Rusakov and Fine, 2003; Engel et al., 2012a; 
Torres et al., 2012; Jimenez-Pacheco et al., 2013) allowing for full receptor 
activation, since Ca2+ is a negative modulator of these P2X7 receptor (Virginio et 
al., 1997; Yan et al., 2011). Full opening of the P2X7 receptor pore leads to 
extensive Na+-influx, which might dissipate the Na+-gradient across the plasma 
membrane and, thus, the transport driving force for GABA and glutamate (Lo et 
al., 2008; Yu et al., 2010). Astrocytic and neuronal P2X7 receptor activation may 
also contribute to neuronal damage by promoting the release of ATP, glutamate 
and GABA, unbalancing excitability (Tian et al., 2005) and/or causing a direct 
neurotoxic effect (Volonté et al., 2003).  
Given our previous study showing that the P2X7 receptor activation 
downmodulates Na+-dependent high-affinity GABA and glutamate transport into 
rat brain cortical synaptosomes (Paper 1; Barros-Barbosa et al., 2015b) , here 
we investigated if this modulation also occurs in the neocortex of cadaveric 
controls and epileptic (non-MTLE and MTLE) human patients. Taking into 
consideration the overall antagonistic effects of GABA and glutamate on synaptic 
networking, the uptake of the two amino acids was evaluated in parallel, i.e. under 
the same modulatory conditions, in order to appreciate putative differential effects 
caused by activation of the P2X7 receptor in control and epileptic tissue. 
 
Experimental procedures 
Drugs and solutions 
HEPES and triton X-100 were from Merck Millipore (Darmstadt, Germany); 
GABA, SDS, 2-mercaptoethanol,  sodium deoxycholate, Tris, BSA, bromophenol 
blue, glycerol, tween 20, BzATP, ouabain, EGTA, NMDG, protease inhibitors and 
AOAA were from Sigma-Aldrich (St. Louis, MO, USA); L-Glutamic acid, A-438079 
and DL-TBOA were from Tocris (Bristol, UK); SKF89976A was from Abcam 
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(Cambridge, UK); [14C]Glutamate and [3H]GABA were from American 
Radiolabeled chemicals (St. Louis, MO, USA).  
No statistical differences between control experiments, made in the 
absence or in the presence of the solvents at the maximal concentrations used, 
were observed. 
 
Subjects 
Human epileptic brain samples were obtained from patients undergoing 
surgery at the Department of Neurosurgery of the Centro Hospitalar do Porto – 
Hospital Geral de Santo António (CHP-HGSA). This study and all its procedures 
were approved by the Ethics Committees of CHP-HGSA and Instituto de Ciências 
Biomédicas Abel Salazar – Universidade do Porto. All epileptic patients signed 
an informed consent for using the biological material. The amount of tissue 
removed did not differ from the strict amount necessary for successful surgery 
practice. Resected tissue was kept in cold artificial cerebral-spinal fluid (in mM: 
glucose 10, NaCl 124, KCl 3, MgCl2 1, NaH2PO4 1.2, NaHCO3 26, CaCl2 2, pH 
7.40) and used within 2-6 hours after collection. Surgical specimens were divided 
into two groups: MTLE and non-MTLE (composed by patients that have epilepsy 
other than MTLE). 
Control brain samples were obtained from four human cadavers, with no 
previous history of neurological disease, submitted to forensic autopsy performed 
within 4-7 hours post-mortem, which corresponds to the tissue viability window 
for functional assays. Previous experiments from our group demonstrated that 
Ca2+ influx into nerve terminals of the human neocortex depolarized by veratridine 
(10 µM) decreases drastically (P<0.05) when brain samples are collected more 
than 7 hours after death, reaching zero activity 8h post-mortem (manuscript in 
preparation); due to legal constrains, it is virtually impossible to obtain forensic 
brain samples within the first 4 hours post-mortem. Brain samples were made 
available by the Instituto Nacional de Medicina Legal e Ciências Forenses – 
Delegação do Norte (INMLCF-DN), according to Decree-Law 274/99, of 22 July, 
published in Diário da República - 1st SERIE A, No. 169, of 22-07-1999, Page 
4522, regarding the regulation on the ethical use of human cadaveric tissue for 
research. After collection, brain tissue was kept in cold artificial cerebral-spinal 
fluid until usage.  
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Clinical information on the composition of the control and epileptic groups 
is provided in Table 6. The investigation conforms to the principles outlined in The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
Table 6 – Comparison of clinical variables of the three groups: control, non-MTLE 
and MTLE 
  Control Non-MTLE MTLE   
  Age (years) ± SD 60.5 ± 16.3 29.0 ± 22.6 43.4 ± 6.0   
  Male : Female 3 : 1 6 : 3 4 : 6   
  Epilepsy onset (years) ± SD NA 10.1 ± 15.5 11.05 ± 9.2   
  Duration (years) ± SD NA 19.0 ± 19.4 32.35 ± 11.6   
  pmi (h) ± SD 5.1 ± 1.3 NA NA   
  
Pathology 
Acute myocardial 
infarction (4) 
Dysplasia (6), 
Dystrophy (1), 
Ganglioma (1), 
Cavernous angiome (1) 
MTLE 
  
  NA= not applicable; pmi= post mortem interval; SD=standard deviation   
 
Isolation of nerve terminals from human neocortex 
Nerve terminals (synaptosomes) from the human neocortex were isolated 
as previously described (Bancila et al., 2009). Briefly, the neocortex was gently 
homogenized in cold oxygenated (95% O2 /5% CO2) Krebs solution (in mM: 
glucose 5.5, NaCl 136, KCl 3, MgCl2 1.2, Na2HPO4 1.2, NaHCO3 16.2, CaCl2 0.5, 
pH 7.40). Homogenates were filtered through a nylon filter (mesh size 100 µm). 
The filtrate was left to sit until pellet formation, which was re-suspended into 
Krebs solution and left at room temperature.  Protein concentration determined 
by the BCA method (PierceTM, Thermoscientific, Rockford USA) was adjusted to 
6.25 mg protein mL-1. In order to take full advantage of scarce cadaveric human 
brain tissue meeting the criteria for inclusion in this study (Table 6), we used re-
sealed nerve terminal membranes in some control experiments required to 
implement the technique for using human neocortex in our lab (Cordeiro et al., 
2000; Cordeiro et al., 2003). Compared to synaptosomes, isolation of re-sealed 
nerve terminal membranes of the human neocortex allowed processing larger 
amounts of tissue while taking up [3H]GABA and [14C]glutamate via Na+-
dependent high-affinity transporters with a similar kinetics. 
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[3H]GABA and [14C]glutamate uptake experiments 
  [3H]GABA uptake was measured as described elsewhere (Cordeiro et al., 
2000; Cordeiro et al., 2003; Barros-Barbosa et al., 2015b). [3H]GABA (0.25 µCi 
ml-1; 0.5 μM) uptake reactions, carried out at 30 ºC, were initiated by adding either 
synaptosomes or re-sealed nerve terminal membranes to the reaction media 
containing AOAA, which prevents GABA metabolism by GABAT. Reactions were 
stopped by rapid filtration through glass-fiber prefilters (Merck Millipore, Cork, 
IRL), prewashed with cold saline. The filters were washed with the same medium 
and the radioactivity was measured by liquid scintillation spectrometry 
(TriCarb2900TR, Perkin Elmer, Boston, USA). [3H]GABA uptake values were 
expressed as pmol mg protein-1 after subtraction of blank values. Assays were 
performed in triplicates. All experiments were performed in the absence of 
extracellular Ca2+ (Barros-Barbosa et al., 2015b). 
[14C]glutamate uptake (0.25 µCi mL-1) was measured as described above 
for [3H]GABA uptake, but using [14C]glutamate at 10 µM and without AOAA.  
Ninety seconds was set as the incubation time in all experiments, so that 
[3H]GABA and [14C]glutamate uptake were measured in the linear accumulation 
phase. When the influence of a modifier drug was assayed, it equilibrated with 
the synaptosomes for 10 min before the addition of the test drug, which was 
added 10 min before the beginning of reaction. Control samples were incubated 
for the same amount of time in the absence of drugs.  
 
Immunofluorescence confocal microscopy  
Brain samples were fixed in 4% paraformaldehyde in PBS, cryopreserved 
in 30% sucrose and stored in a tissue freezing medium at -80ºC. Free floating 30 
μm brain sections were incubated for 1 h, with blocking buffer  (foetal bovine 
serum 10%, BSA 1%, triton X-100 0.5%, NaN3 0.05%) and incubated overnight 
with the primary antibodies: rabbit anti-P2X7 receptor (1:50, Alomone #APR-004, 
Jerusalem, Israel), goat anti-VAMP-1 (1:20, R&D Systems #AF4828, 
Minneapolis, MN, USA) and mouse anti-GFAP (1:200, Chemicon #MAB360, 
Temecula, CA, USA). Sections were rinsed and incubated 2 h with species 
specific secondary antibodies (donkey anti-rabbit Alexa Fluor 488, goat anti-
mouse Alexa Fluor 633 and donkey anti-goat Alexa Fluor 633; Molecular Probes, 
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Eugene, OR). After mounting, sections were observed and analyzed with a laser 
scanning confocal microscope (Olympus FV1000, Tokyo, Japan).  
Co-localization was assessed by calculating the staining overlap and the 
ρ for each confocal micrograph using the Olympus Fluoview 4.2 Software 
(Olympus FV1000, Tokyo, Japan). Overlap between two colors gives values 
between +1 (total overlap) and 0 (no overlap); the ρ is a measure of the linear 
correlation between two variables (stainings), giving values between +1 and −1 
inclusive, where 1 is total positive correlation, 0 is no correlation, and −1 is total 
negative correlation. 
 
Western blot analysis 
Total membrane lysates and synaptosomes of the human cerebral 
neocortex were homogenized in RIPA buffer (Tris-HCl 25 mM (pH 7.6), NaCl 150 
mM, sodium deoxycholate 1%, Triton-X-100 1%, SDS 0.1%, EDTA 5 mM and 
protease inhibitors). Samples were solubilized in SDS buffer (Tris-HCl 125 mM 
(pH 6.8), SDS 4%, bromophenol blue 0.005%, glycerol 20%, and 2-
mercaptoethanol 5%), subjected to electrophoresis in SDS-polyacrylamide gels 
and electrotransferred onto PVDF membranes (Merck Millipore, Darmstadt, 
Germany). Membranes were blocked in Tris-buffered saline (in mM: Tris-HCl 10 
(pH 7.6), NaCl 150) containing Tween 20 0.05% and BSA 5% and incubated with 
the primary antibodies: mouse anti-GFAP (1:500, Chemicon, Temecula, CA), 
mouse anti-synaptophysin (1:750, Chemicon, Temecula, CA), mouse anti-
postsynaptic density-95 (PSD95) (1:600, Chemicon, Temecula, CA) and rabbit 
anti-P2X7 receptor (1:200; Alomone #APR-004, Jerusalem, Israel). Membranes 
were washed and incubated with horseradish peroxidase-conjugated secondary 
antibody. 
 For normalization purpose, membranes were incubated with rabbit anti-β-
actin antibody (1:1000; Abcam, Cambridge, UK), rabbit anti-β-tubulin antibody 
(1:2500; Abcam, Cambridge, UK) or mouse anti-glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) antibody (1:200; Santa Cruz Biotechnology, Dallas, 
TX) following the procedures described above. The antigen-antibody complexes 
were visualized using the ChemiDoc MP imaging system (Bio-Rad Laboratories, 
Hercules, CA). Gel band image densities were quantified with Image J (National 
Institute of Health, USA). To test for specificity of the bands corresponding to 
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P2X7 receptor, the anti-P2X7 receptor antibody was pre-adsorbed with a control 
peptide antigen corresponding to the amino acid residues 576-595 of the 
intracellular C-terminus of the P2X7 receptor.  
 
Data presentation and statistical analysis 
The uptake of [3H]GABA and [14C]glutamate was expressed in percentage 
of control values obtained in the same batch without adding any drug. P2X7 
receptor density was expressed as fold change of control individuals. Results are 
expressed as mean ± SD. n shown in graphs represent the total number of 
replicas in a given situation.  Statistical analysis was carried out using Graph Pad 
Prism 6.04 software (La Jolla, CA, USA). Unpaired Student’s t-test with Welch 
correction was used for statistical analysis when parametric data was considered. 
For multiple comparisons, one-way ANOVA followed by Dunnett's Multiple 
Comparison Test was used. For multiple comparisons between multiple groups, 
two-way ANOVA followed by Bonferroni´s Multiple Comparison Test was used. 
P < 0.05 values were accepted as significant.  
 
Results 
Human neocortical synaptosomes are enriched in synaptic nerve terminals 
Western blot analyses (Figure 18) indicate that synaptosomes isolated 
from the neocortex of human cadaveric controls (Figure 18B) and MTLE patients 
(Figure 18A and 18C) present lesser (P<0.01) amounts of the astrocytic marker, 
GFAP, compared to total lysates. Similar levels of the postsynaptic density 
marker, PSD95, were found in synaptosomes and total lysates of the neocortex 
of control individuals and MTLE patients. More importantly, synaptosomes 
isolated from the neocortex of control individuals (Figure 18B) and MTLE patients 
(Figure 18A and 18C) using our methodology are highly enriched (P<0.001) in 
synaptic nerve terminals specifically labelled with synaptophysin compared to 
total lysates of the same brain region. 
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Figure 18 – Synaptosomes isolated from the neocortex of cadaveric controls and MTLE patients 
are enriched in synaptic nerve terminals. Panel A illustrates representative blots of GFAP, 
synaptophysin and PSD95 immunoreactivity (bands inside black boxes) in total lysates and 
synaptosomes of the neocortex of an MTLE patient. Bottom panels illustrate the average 
composition in GFAP, synaptophysin and PSD95 of total lysates and synaptosomes from three 
controls (B) and four MTLE (C) individuals. Data are expressed as mean ± SD. *P < 0.05, **P < 
0.01 and ***P < 0.001 represents significant differences as compared to total lysates (two way 
ANOVA followed by Bonferroni´s Multiple Comparison Test); ns, non-significant.  
 
[3H]GABA and [14C]glutamate uptake by isolated nerve terminals of the 
human neocortex is mediated by high-affinity transporters 
Figure 19 (panels A and B) shows that isolated nerve terminals from the 
neocortex of cadaveric controls take up [3H]GABA and [14C]glutamate over time. 
Selective inhibition of the GABA transporter 1 (GAT1) with SKF89976A (40 µM) 
significantly decreased [3H]GABA uptake by neocortical nerve terminals from 
cadaveric controls (85.0±6.1%), non-MTLE (94.4±1.7%) and MTLE (95.2±2.0%) 
patients (Figure 19C). Likewise, [14C]glutamate uptake was significantly inhibited 
by DL-TBOA (100 µM) in neocortical nerve terminals from cadaveric controls 
(65.8±7.3%), non-MTLE (95.5±3.1%) and MTLE (90.4±4.2%) patients (Figure 
19D); here, we used a non-selective inhibitor because subtype-specific glutamate 
transport inhibitors are still lacking. Data suggest that the uptake of [3H]GABA 
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and [14C]glutamate by human neocortical nerve terminals occurs mainly via high-
affinity transporters, a situation that is even more obvious in epileptic patients 
where transport blockers reduced the uptake of both amino acids by more than 
90%. 
 
 
Figure 19 – Nerve terminals isolated from the human neocortex take up [3H]GABA and 
[14C]glutamate through Na+-dependent high-affinity transporters. Illustrated is the accumulation of 
[3H]GABA (A) and [14C]glutamate (B) into nerve terminals from the neocortex of control individuals 
over time (0-20 min). Panels C and D show the inhibition of Na+-coupled high-affinity transport of 
[3H]GABA and [14C]glutamate with SKF489976A (40 µM; GAT1 selective inhibitor) and DL-TBOA 
(100 µM; non-specific inhibitor of the EAAT), respectively, into nerve terminals of control 
individuals and epileptic (non-MTLE and MTLE) patients. SKF 489976A and DL-TBOA contacted 
with nerve terminals for 20 min before application of [3H]GABA and [14C]glutamate into the 
reaction chamber. Data are expressed as mean ± SD; the n number of replicas is shown below 
each bar. *P < 0.05 and ***P < 0.001 (Student’s t-test with Welch correction) represents significant 
differences as compared to the situation where no drugs were added. ## P < 0.01 and ### P < 
0.001 (one way ANOVA followed by Dunnett's Multiple Comparison Test) represents significant 
differences when compared to control individuals. 
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Neocortical nerve terminals of epileptic patients express higher levels of 
P2X7 receptor 
The existence of functional P2X7 receptors on cortical nerve terminals of 
the rat has been previously demonstrated by microfluorimetric intracellular Ca2+-
concentration measurements and immunochemical staining (Miras-Portugal et 
al., 2003; Barros-Barbosa et al., 2015b). Here, we evaluated by 
immunofluorescence confocal microscopy if the P2X7 receptor is also present in 
nerve terminals of the human cerebral neocortex.  
Figure 20A shows that the antibody directed against P2X7 receptor 
(green) co-localizes with the synaptic nerve terminal marker, VAMP-1 (red), in 
the three groups of individuals, controls, non-MTLE and MTLE, but no significant 
co-localization was detected with the astrocytic cell marker, GFAP; this was 
observed despite intense astrogliosis is documented in the epileptic brain (Figure 
20B). Co-localization was assessed by evaluating the Pearson´s coefficient (ρ) 
and staining overlap obtained by merging the two fluorescent channels (yellow 
staining). These results are presented on the right-hand side of confocal 
micrographs (Figure 20A and 20B).  
Co-localization of the P2X7 receptor with VAMP-1 was significantly higher 
in the neocortex of epileptic patients as compared to controls (Figure 20A), giving 
the impression that epileptic nerve terminals express more P2X7 receptor 
compared to control individuals. We confirmed this hypothesis by Western blot 
analysis. Figure 20D shows that the P2X7 receptor protein density increased five-
fold in neocortical synaptosomes of MTLE patients compared to cadaveric 
controls, as previously described in the literature (Jimenez-Pacheco et al., 2013). 
Enrichment of the P2X7 receptor protein density in neocortical nerve terminals of 
non-MTLE tissue was intermediate between control and MTLE patients (Figure 
20D). Disappearance of P2X7 receptor bands after pre-adsorption with excess of 
the corresponding antigen peptide sequence confirmed the specificity of the 
antibody used in this study (Figure 20D, lane 4). 
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Figure 20 – Immunoreactivity 
against the P2X7 receptor is 
higher in nerve terminals 
isolated from the neocortex of 
epileptic patients than in control 
individuals. Panels A and B 
illustrate confocal micrographs 
of human neocortical slices 
from control, non-MTLE and 
MTLE individuals stained 
against the P2X7 receptor. 
Synaptic nerve terminals were 
identified with VAMP-1 
antibody, whereas astrocytes 
were stained with an antibody 
against the GFAP. Note that 
VAMP-1-positive nerve 
terminals (red) are endowed 
with the P2X7 receptor (green) 
(panel A), but no significant co-
localization was observed 
between P2X7 receptor (green) 
and GFAP (red) (panel B). Data 
on the right-hand side 
correspond to staining overlap 
and Pearson´s Coefficient (ρ) 
parameters calculated from 3-4 
confocal micrographs per 
individual; at least three 
individuals from each group, 
control, non-MTLE and MTLE, 
were analyzed. These 
parameters were automatically 
calculated per image with the 
Olympus Fluoview 4.2 Software 
(Olympus FV1000, Tokyo, 
Japan) and were used to 
estimate co-localization of P2X7 receptor and type-specific cell markers (yellow staining). Panel 
C shows negative controls resulting from the incubation of human neocortical slices from control, 
non-MTLE and MTLE individuals with the anti-rabbit secondary antibody without previous addition 
of the rabbit anti-P2X7 receptor primary antibody (#APR-004); DIC image is shown for 
comparison. Panel D illustrates representative blots of the P2X7 receptor immunoreactivity in 
synaptosomes of the human neocortex of control, non-MTLE and MTLE patients; gels were 
loaded with 100 µg of protein. Please note that the band corresponding to the molecular weight 
of native P2X7 receptor (~69 kDa) disappeared after pre-adsorption of the primary antibody 
(#APR-004) with a control peptide antigen equivalent to the amino acid residues 576-595 of the 
intracellular C-terminus of the P2X7 receptor (lane 4 - negative control); β-actin was used as a 
reference protein. Data are expressed as mean ± SD and the number of individuals per group is 
shown below each bar. *P < 0.05, **P < 0.01 and ***P < 0.001 (two way ANOVA followed by 
Bonferroni´s Multiple Comparison Test (panels A and B) and one way ANOVA followed by 
Dunnett's Multiple Comparison Test (panel D) represents significant differences as compared to 
control individuals. Scale bars = 50 µm. 
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Activation of the P2X7 receptor inhibits more potently the uptake of 
[3H]GABA than of [14C]glutamate by nerve terminals of the human epileptic 
neocortex 
The prototypic P2X7 receptor agonist, BzATP (3-300 µM), concentration-
dependently decreased [3H]GABA (Figure 21A) and [14C]glutamate (Figure 21B) 
uptake by neocortical nerve terminals of control individuals and epileptic patients. 
While downmodulation of [14C]glutamate uptake by BzATP (100 µM) was roughly 
similar in control, non-MTLE and MTLE patients (Figure 21B), the P2X7 receptor 
agonist inhibited more effectively [3H]GABA uptake in neocortical nerve terminals 
isolated from both non-MTLE and MTLE patients than from control individuals 
(Figure 21A). The selective P2X7 receptor antagonist, A-438079 (3 µM), 
significantly (P<0.05) attenuated the inhibitory effects of BzATP (100 µM) on 
[3H]GABA (Figure 21C) and [14C]glutamate (Figure 21D) uptake in epileptic 
patients, further confirming the involvement of the P2X7 receptor on BzATP-
induced downmodulation of high-affinity GABA and glutamate uptake by human 
neocortical nerve terminals. 
 
 
Figure 21 – Downmodulation of GABA, but not of glutamate, uptake by P2X7 receptor activation 
is upregulated in the neocortex of epileptic patients. Panels A and B illustrate the effect of BzATP 
(3-300 µM) on [3H]GABA and [14C]glutamate uptake by nerve terminals isolated from the 
neocortex of control, non-MTLE and MTLE patients. The selective P2X7 receptor antagonist, A-
438079 (3 µM) prevented BzATP (100 µM)-induced inhibition of [3H]GABA  (C) and [14C]glutamate 
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(D) uptake by neocortical synaptosomes of non-MTLE and MTLE patients. BzATP contacted with 
nerve terminals for 10 min before application of [3H]GABA and [14C]glutamate in to reaction 
chamber; A-438079 was added 10 min before BzATP. Data are expressed as mean ± SD; the n 
number of replicas is shown below each bar. *P < 0.05 and ***P < 0.001 (Student’s t-test with 
Welch correction) represents significant differences as compared to the situation where no drugs 
were added; §P < 0.05 and §§§P < 0.001 (Student’s t-test with Welch correction) represents 
significant differences as compared to BzATP (100 µM) alone; #P < 0.05 and ###P < 0.001 (two 
way ANOVA followed by Bonferroni´s Multiple Comparison Test) represents significant 
differences as compared to control individuals.  
 
P2X7-induced downmodulation of [3H]GABA and [14C]glutamate uptake by 
human neocortical nerve terminals parallels the collapse of the 
transmembrane Na+-gradient 
Taking into consideration that (1) the P2X7 receptor works as a 
nonselective cationic channel promoting Na+ entry under low Ca2+ conditions 
(Jarvis and Khakh, 2009), (2) GABA and glutamate uptake is critically dependent 
on transmembrane Na+-gradient (Kanner, 2006), (3) extracellular Ca2+ was 
removed from the reaction medium (Barros-Barbosa et al., 2015b), and (4) Na+ 
influx through P2X7 receptor and subsequent dissipation of the Na+ gradient is 
responsible for the downmodulation of GABA and glutamate transport in rat 
cortex synaptosomes (Barros-Barbosa et al., 2015b), we evaluated if a similar 
mechanism could justify the P2X7-induced decrease of GABA and glutamate 
uptake in human neocortical nerve terminals. 
Manipulation of intracellular Na+ levels with ouabain (50 µM), an inhibitor 
of Na+/K+-ATPase, progressively decreased the uptake of [3H]GABA (to a 
maximum of 97.1±2.0%; Figure 22) and [14C]glutamate (to a maximum of 
51.4±8.2%; Figure 22B) depending on the time of incubation with this drug (2-40 
min). The inhibitory effects of ouabain (50 µM) incubated for 2 minutes 
(51.7±4.6% and 23.9±9.2% for GABA and glutamate, respectively) and for 20 min 
(93.9±2.1% and 42.2±6.0% for GABA and glutamate, respectively) were 
amplified in the presence of BzATP (100 μM). Magnification of ouabain (50 µM)-
induced inhibition by BzATP (100 µM) decreased over time of incubation with the 
Na+/K+-ATPase inhibitor.  
Furthermore, the substitution of extracellular Na+ by NMDG+, so that the 
Na+ concentration in the reaction chamber decreased from 129 mM to 101, 69 
and 9 mM, also diminished the uptake of [3H]GABA (Figure 22C) and 
[14C]glutamate (Figure 22D) by MTLE synaptosomes. Collapsing the Na+ gradient 
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across the plasma membrane by reducing the extracellular Na+ concentration to 
9 mM (plus 120 mM NMDG+) decreased the uptake of [3H]GABA and 
[14C]glutamate by 94.2±5.0% (Figure 22C) and 83.4±2.6% (Figure 22D), 
respectively. The inhibitory effect of BzATP (100 μM) on [3H]GABA and 
[14C]glutamate uptake diminished upon decreasing the amount of Na+ in the 
reaction fluid from 129 mM to 101 mM and to a concentration (69 mM) below 
which no significant difference (P>0.05) from the control situation was observed, 
which in accordance with both Na+-gradient and Na+-coupled transport 
thermodynamics. 
 
 
Figure 22 – P2X7 receptor-induced downmodulation of [3H]GABA and [14C]glutamate uptake by 
human neocortical nerve terminals parallels the collapse of transmembrane Na+-gradient.  Shown 
is the inhibitory effect of BzATP (100 µM) on [3H]GABA (A and C) and [14C]glutamate (B and D) 
uptake into neocortical synaptosomes of MTLE patients in the presence of the Na+/K+ ATPase 
inhibitor, ouabain (50 µM, applied for 2-40 min) (A and B) or after substituting extracellular Na+ 
with NMDG+, so that the Na+-concentration in the reaction chamber decreased from 129 mM to 
101, 69 and 9 mM, respectively (C and D). BzATP contacted with nerve terminals for 10 min 
before application of [3H]GABA and [14C]glutamate in to reaction chamber; ouabain was added 2, 
20 and 40 min before BzATP. Data are expressed as mean ± SD; the n number of replicas is 
shown below each bar. *P < 0.05 and ***P < 0.001 (Student’s t-test with Welch correction) 
represents significant differences as compared to the situation where no drugs were added; §P < 
0.05 and §§§§P < 0.001 (Student’s t-test with Welch correction) represents significant differences 
when comparing the effect of BzATP with the modifier alone; ns, non-significant differences. 
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All together these results suggest that increasing intracellular Na+-
concentration or decreasing extracellular Na+-concentration, i.e. collapsing the 
Na+-gradient, downmodulates [3H]GABA and [14C]glutamate uptake by nerve 
terminals of the human neocortex under low extracellular Ca2+ conditions, 
similarly to that occurring upon activation of the P2X7 receptor. Thus, P2X7 
receptor-induced downmodulation of GABA and glutamate transport closely 
accompany the thermodynamic changes associated with Na+-gradient across 
nerve terminal membranes.  
 
Discussion and conclusions 
This work demonstrates that neocortical nerve terminals isolated from 
drug-resistant epileptic human patients express higher-than-control amounts of 
P2X7 receptor, which negatively modulate Na+-dependent high-affinity GABA 
and glutamate uptake. Additionally, our findings show for the first time that an 
increase in the density of P2X7 receptor in isolated nerve terminals of the 
epileptic neocortex correlates with a more potent P2X7 receptor-induced 
downmodulation of GABA uptake, but no significant changes were observed 
concerning downmodulation of the glutamate uptake. The minor difference in the 
P2X7 receptor protein density among MTLE and non-MTLE patients had no 
repercussion in the magnitude of the inhibitory effect of BzATP on [3H]GABA and 
[14C]glutamate uptake, suggesting that deregulation of the P2X7 receptor is 
characteristic of the epileptic neocortex independently of brain lesion 
characteristics.  
Changes in the P2X7 receptor-mediated downmodulation of [3H]GABA 
and [14C]glutamate uptake were assessed in the absence of extracellular Ca2+ in 
order to mimic conditions that occur under high-frequency neuronal firing and/or 
pathologic brain activity, such as prolonged or repeated seizures (Engel et al., 
2012a). Under these conditions the extracellular Ca2+ concentration falls up to 
90% (Heinemann et al., 1977; Rusakov and Fine, 2003; Engel et al., 2012a; 
Torres et al., 2012; Jimenez-Pacheco et al., 2013) and Na+ conductance through 
the P2X7 receptor is largely enhanced, as this receptor is highly sensitive to 
changes in the extracellular concentration of divalent cations (Virginio et al., 1997; 
Yan et al., 2011). Spatial-temporal coincidence of ATP, GABA and glutamate at 
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the synapse is possible, given that high levels of the nucleotide are released 
during intense and/or high-frequency neuronal activity (Cunha et al., 1996b; 
Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 2013) reaching high 
enough concentrations to activate low-affinity P2X7 receptor (Jarvis and Khakh, 
2009). Performing experiments in low extracellular Ca2+ conditions also excludes 
the involvement of Ca2+ regulation of amino acid transporters (directly or via 
plasmalemmal and mitochondrial Na+/Ca2+ exchangers), as well as the 
interference of Ca2+-activated neurotransmitter release (Cordeiro et al., 2000; 
Cordeiro et al., 2003; Romei et al., 2015). It also allows focusing our research on 
alterations of the Na+ driving-force for neurotransmitters uptake. Under these 
circumstances, downmodulation of [3H]GABA and [14C]glutamate uptake seems 
to occur almost exclusively through the decrease in the Na+ driving-force 
available for transporters, as previously observed in the rat neocortex (Barros-
Barbosa et al., 2015b). This is concluded because: 1) increases in intracellular 
Na+ concentration or decreases in extracellular Na+ concentration 
downmodulated the uptake of both neurotransmitters, and 2) the magnitude of 
the inhibitory effect of BzATP, was lowered upon reducing the Na+ gradient as 
predicted by changes in transporters reversal potentials (Kanner, 2006; Lo et al., 
2008; Yu et al., 2010). However, we cannot rule-out that minute amounts of 
P2X7-mediated GABA and glutamate release might also occur under our 
experimental conditions (Barros-Barbosa et al., 2015b). Furthermore, data using 
the Na+/K+-ATPase inhibitor, ouabain (Figure 22), indicate that [3H]GABA uptake 
was more sensitive to variations in the intracellular Na+-concentration, i.e. 
reduction of the transmembrane Na+ gradient, compared to [14C]glutamate. Our 
results may be of clinical interest because significant increases in intracellular 
Na+ concentration constitute a characteristic event associated with tissue injury 
in epilepsy (Wang et al., 1996; Yu et al., 2010). Thus, we may speculate whether 
increases in Na+ conductance leading to enhanced levels of the intracellular Na+ 
concentration might be correlated with excessive ATP signals conveyed through 
up-regulated P2X7 receptor in nerve terminals of the epileptic neocortex.  
The cellular localization of P2X7 receptor in the CNS of diverse animal 
species has been intensively investigated, but scarce information is available in 
the human brain (Narcisse et al., 2005; Fu et al., 2013; Rodrigues et al., 2015). 
Moreover, there is a gap in our knowledge concerning the presence of the P2X7 
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receptor in neurons of the human brain besides a couple of preliminary accounts 
suggesting that its levels increase in the hippocampus and neocortex of patients 
with TLE (Fernandes et al., 2009; Padrão et al., 2011; Jimenez-Pacheco et al., 
2013). Here we show that the P2X7 receptor co-localizes with the synaptic nerve 
terminal marker, VAMP-1, in human neocortex, with only vestigial staining on 
GFAP-positive glial cells. Interestingly, the increase in staining overlap between 
P2X7 receptor and VAMP-1 did not occur with GFAP in the epileptic neocortex, 
despite the astrogliosis that usually accompanies epileptic brain lesions. This is 
apparently unexpected because astrocytes release ATP and P2X7 receptor have 
been reported to be present on astrocytes, yet no transcriptional activation of the 
P2X7 receptor was detected in astrocytes either after SE or in chronic epilepsy 
in mice (Engel et al., 2012a; Jimenez-Pacheco et al., 2013). Western blot data 
confirmed that isolated nerve terminals from epileptic human neocortices express 
increased amounts of P2X7 receptor, which is also compatible with previous 
findings (Fernandes et al., 2009; Padrão et al., 2011; Jimenez-Pacheco et al., 
2013). While data from the present study do not exclude the putative participation 
of astrocytic and microglial P2X7 receptor towards unbalanced neuronal 
excitability and damage in epilepsy, gain of function of neuronal P2X7 receptor 
under the present experimental conditions deserve a leading role in deregulating 
GABA and glutamate uptake by nerve terminals of the epileptic neocortex.  
It, thus, seems that under physiological conditions, transient P2X7 
receptor activation following ATP release by high-frequency neuronal firing 
(Cunha et al., 1996b; Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 
2013) may engage a mechanism that equally facilitates local glutamatergic 
neurotransmission while promoting the endurance of GABAergic signals, 
ensuring tonic and more diffuse neuroinhibition. This mechanism may be relevant 
in processes such as learning and memory, where transient glutamate endurance 
in the synaptic cleft may facilitate the induction of long term potentiation, while 
preventing excytotoxicity by concomitant promotion of diffuse GABAergic 
inhibition. In epileptic conditions, controversy still exists in the literature 
concerning the pro- or anticonvulsant effects of the P2X7 receptor in distinct 
animal models. Kang and colleagues reported that pilocarpine-induced seizures 
were increased in mice lacking the P2X7 receptor, although they found no 
influence of the receptor in the kainate model (Kim and Kang, 2011). Some in 
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vitro studies also argue that the P2X7 receptor activation can be inhibitory, 
including work showing that presynaptic P2X7 receptor on mossy fibres reduce 
neurotransmitter release in hippocampal slices (Armstrong et al., 2002). 
Conversely, Jimenez-Pacheco’s group reported increased neocortical 
expression of the P2X7 receptor after SE induced by injecting kainic acid into the 
amygdala of mice and showed that the P2X7 receptor antagonist, A-438079, 
exerts an anticonvulsant effect (Engel et al., 2012a; Engel et al., 2012b; Jimenez-
Pacheco et al., 2013). These apparently contradictory findings may suggest that 
the contribution of the P2X7 receptor may change along the disease stage and 
the underlying epileptogenic process.  
In epileptic conditions, the increased downmodulation of GABA uptake 
might not have a protective role but, conversely, a pro-epileptic one due to 
GABAergic “rundown” (Cohen et al., 2002; D’Antuono et al., 2004; Ragozzino et 
al., 2005; Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 2012). This is a 
phenomenon defined as decreases in GABAergic inhibition or even transient 
GABAergic mediated excitation, resultant from desensitization of GABAA receptor 
upon repetitive stimulation (Ragozzino et al., 2005; Palma et al., 2007; Mazzuferi 
et al., 2010) or even due to depolarization stemming from changes in Cl- 
homeostasis (D’Antuono et al., 2004; Miles et al., 2012). There are evidences 
that GABAergic rundown promotes synchronous neuronal discharges underlying 
focal seizures in refractory TLE (Cohen et al., 2002; D’Antuono et al., 2004; 
Ragozzino et al., 2005; Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 
2012). This implies that instead of GABAergic signaling counterbalancing the 
depolarizing effects of glutamate, it may also contribute to the excitatory tone. So, 
it is possible that the pro-epileptic role of the P2X7 receptor activation (Engel et 
al., 2012a; Engel et al., 2012b; Jimenez-Pacheco et al., 2013) may be explained 
by an increase in the downmodulation of GABA uptake contributing to GABAergic 
rundown in epileptic patients (Cohen et al., 2002; D’Antuono et al., 2004; 
Ragozzino et al., 2005; Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 
2012). This hypothesis requires further investigations, which are being 
undertaken by our group. This study fills a gap regarding the pro-epileptic role of 
extracellular ATP in the human brain neocortex and led us to hypothesize, in line 
with previous suggestions from animal studies (Vianna et al., 2002; Engel et al., 
2012a; Jimenez-Pacheco et al., 2013; Rodrigues et al., 2015), that targeting the 
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P2X7 receptor with selective brain-permeant antagonists, such as the recently 
characterized JNJ-42253432, which displays high affinity and selectivity for the 
P2X7 receptor (Lord et al., 2014), may constitute a valuable alternative to drug-
resistant epilepsy treatment.  
In summary, while the mechanism of the P2X7 receptor-mediated amino 
acid transporters downmodulation reported here in the human neocortex appears 
to have a plausible role under physiological conditions by potentiating 
neurotransmission, it might gain a different meaning during epileptic seizures. 
Under epileptic conditions, the extracellular Ca2+-concentration falls in parallel to 
increases in the amount of released ATP (Engel et al., 2012b; Jimenez-Pacheco 
et al., 2013). Up-regulated P2X7 receptor bolsters ATP signals to a scenario that 
promotes GABA-mediated neurotransmission endurance, which combined with 
altered GABAA receptor subunit composition, might originate GABAergic 
rundown (Cohen et al., 2002; D’Antuono et al., 2004; Ragozzino et al., 2005; 
Palma et al., 2007; Mazzuferi et al., 2010; Miles et al., 2012). The parallel P2X7 
receptor-induced glutamate transmission boost under epileptic conditions may 
ultimately lead to neuronal excytotoxicity. Data points towards Na+-coupled high-
affinity amino acid transport modulators, like the P2X7 receptor selective 
antagonists, as being putative new anti-epileptic drug targets.
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Abstract 
Most patients with MTLE are refractory to common AEDs or to the 
combinatorial usage of such medications. This prompts for the urgent need to find 
new and more accurate pharmacological targets to control seizures and/or the 
epileptogenic process. The adenosine A2A receptor emerges as an interesting 
pharmacological target since the excitatory nature of this receptor partially 
counteracts the dominant antiepileptic role of endogenous adenosine acting via the 
most abundant inhibitory A1 receptor in the brain. Gain of function of the excitatory 
A2A receptor has been implicated in a significant number of CNS pathologies 
commonly characterized by neuronal excitotoxicity, such as Alzheimer’s disease, 
Parkinson’s disease, trauma, also including epilepsy. In this study, we investigated 
changes in the expression and cellular localization of the A2A receptor in the 
hippocampus of control and MTLE human patients, in order to understand whether 
this receptor plays a role in human epilepsy. 
The expression of the A2A receptor was evaluated by Western blot analysis 
in total lysates and in isolated nerve terminals of the hippocampus of cadaveric 
controls and MTLE patients submitted to amygdalohippocampectomy for ablation of 
the epileptic focus. The distribution of the A2A receptor in the human hippocampus 
was assessed by immunofluorescence confocal microscopy. 
Results showed that hippocampi from MTLE patients exhibit higher amounts 
of the A2A receptor protein than the control group. Immunoreactivity against the A2A 
receptor colocalizes this receptor with the astrocytic cell marker, GFAP. No 
colocalization of the A2A receptor was observed with the nerve terminal marker, 
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synaptotagmin 1/2, neither with axon neurofilament 200 (NF200). Moreover, results 
also show that astrogliosis that is characteristic of MTLE with sclerosis of the 
hippocampus is accompanied by an upregulation of the A2A receptor density. 
Whether this feature contributes to an overall excitatory tone facilitating seizure 
occurrence in drug-resistant MTLE, remains to be elucidated by functional studies. 
In this context, our working hypothesis is that selective blockade of the adenosine 
A2A receptor may be a useful therapeutic approach to control drug-refractory 
seizures in MTLE patients.  
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Introduction 
MTLE is the most common and devastating form of human epilepsy (Pitkänen 
and Lukasiuk, 2011). This disorder is characterized by irreversible biochemical and 
structural changes in the hippocampus and several neocortical regions (Bartolomei 
et al., 2005; O'Dell et al., 2012; Biagini et al., 2013). Despite the extensive research 
of the last decades resulting in the discovery of new AEDs introduced into the clinical 
practice, most MTLE patients remain refractory to medication. The leading cause 
for this concern is our relative ignorance regarding the underlying mechanisms 
responsible for the transformation of brain networks into hyperexcitable connections 
more prone to intense and/or prolonged neuronal discharges. The last resource 
treatment for some drug-refractory patients is still the surgical ablation of defective 
tissue to curb epileptic crisis. Yet, a significant number of MTLE patients do not fill 
the requirements for this surgical procedure and are faced with an unmet medical 
need. This calls for the urgent need to find new and more accurate pharmacological 
targets to control seizures and/or the epileptogenic process (Pitkänen and Lukasiuk, 
2011).  
Increasing evidences show that the extracellular levels of ATP and adenosine 
dramatically increase during high-frequency neuronal firing and/or pathologic brain 
activity, such as prolonged or repeated seizures (Heinrich et al., 2012; Wall and 
Dale, 2013; Sims and Dale, 2014). Once in the extracellular space, adenosine, 
released directly from cells or produced from the extracellular catabolism of ATP 
(Heinrich et al., 2012; Wall and Dale, 2013; Sims and Dale, 2014), exerts its action 
through the activation of four types of adenosine receptors, A1, A2A, A2B and A3. The 
most relevant adenosine receptors in the brain are inhibitory A1 and excitatory A2A 
receptors (Boison, 2008). Recently, numerous studies have shown the contribution 
of A2A receptor to control neuronal excitability and synaptic plasticity (Kanno and 
Nishizaki, 2012; Matos et al., 2012; Valadas et al., 2012; Matos et al., 2013). 
Involvement of this receptor subtype in diverse pathologies of the CNS, including 
epilepsy, has been demonstrated (Chen et al., 2007; Hosseinmardi et al., 2007; El 
Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Li et al., 2012; 
Huicong et al., 2013; Orr et al., 2015). Most studies implicating the adenosine A2A 
receptor in epilepsy were performed in rodents, both in mice (El Yacoubi et al., 2008, 
2009; Orr et al., 2015; Rombo et al., 2015) and rats (Hosseinmardi et al., 2007; 
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Fukuda et al., 2011; Rosim et al., 2011; Li et al., 2012; Huicong et al., 2013). Results 
from these investigations suggest that adenosine A2A receptor antagonists might 
offer protection against diverse epileptic syndromes, such as temporal lobe 
epilepsy, highlighting the idea that the A2A receptor may be an attractive 
pharmacological target for the treatment of epilepsy. To our knowledge, there are 
no studies investigating changes in the expression and function of the A2A receptor 
in the brain of drug-resistant MTLE human patients, as we did in this work. 
Though it was believed that the adenosine A2A receptor was mostly located 
in neurons at the synaptic region (Rebola et al., 2005; Rodrigues et al., 2015), recent 
evidences showed that this receptor is also expressed in glial cells, both astrocytes 
and microglia (Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013; 
Orr et al., 2015). The astrocytic A2A receptor seems to be critical for the modulation 
of glutamate transport, either by decreasing the uptake (Matos et al., 2012; Matos 
et al., 2013) or by increasing the release (Kanno and Nishizaki, 2012) of glutamate. 
In view of this, astrocytic A2A receptor have been implicated in memory formation 
(Orr et al., 2015). Furthermore, the same group demonstrated that astrocytic A2A 
receptor levels are upregulated in humans with Alzheimer’s disease, as well as in 
epileptic mice injected with kainate (Orr et al., 2015).  
Given the excitatory (pro-convulsive) nature of the adenosine A2A receptor 
activation in the brain and the need for clarification of its role in drug-resistant human 
epilepsy, we designed this study to investigate changes in the expression and 
cellular localization of the A2A receptor in the hippocampus of control and MTLE 
human patients.  
 
Experimental procedures 
Subjects 
Human MTLE brain samples were obtained from patients undergoing 
amygdalohippocampectomy at the Department of Neurosurgery of the CHP-HGSA. 
This study and all its procedures were approved by the Ethics Committees of CHP-
HGSA and Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto. 
All MTLE patients signed an informed consent for using the biological material. The 
amount of tissue removed did not differ from the strict amount necessary for 
successful epileptic focus ablation surgery.  
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Control brain samples were obtained from four human cadavers submitted to 
forensic autopsy performed within 4-7 hours post-mortem (Barros-Barbosa et al., 
2015a). Brain samples were made available by the Instituto Nacional de Medicina 
Legal e Ciências Forenses – Delegação do Norte (INMLCF-DN), according to 
Decree-Law 274/99, of 22 July, published in Diário da República - 1st SERIE A, No. 
169, of 22-07-1999, Page 4522, regarding the regulation on the ethical use of 
human cadaveric tissue for research.  
Clinical information on the composition of control and MTLE groups is 
provided in Table 1. The investigation conforms to the principles outlined in The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
Table 7 – Comparison of clinical variables of control and MTLE patients. 
 Control MTLE 
Age (years) ± SD 60.5 ± 16.3 38.9 ± 9.0 
Male : Female 3 : 1 5 : 3 
Epilepsy onset (years) ± SD NA 9.9 ± 6.7 
Duration (years) ± SD NA 28.9 ± 12.8 
pmi (h) ± SD 5.1 ± 1.3 NA 
Cause of death Acute myocardial infarction (4) NA 
NA= not applicable; pmi= post mortem interval; SD=standard deviation 
 
Isolation of nerve terminals from human hippocampus 
Nerve terminals (synaptosomes) from the human hippocampus were isolated 
as previously described (Bancila et al. 2009; Paper 1, Barros-Barbosa et al., 2015b; 
Paper 3; Barros-Barbosa et al., 2015a). Briefly, the hippocampus was gently 
homogenized in cold oxygenated (95% O2 /5% CO2) Krebs solution (in mM: glucose 
5.5, NaCl 136, KCl 3, MgCl2 1.2, Na2HPO4 1.2, NaHCO3 16.2, CaCl2 0.5, pH 7.40). 
Homogenates were filtered through a nylon filter (mesh size 100 µm). The filtrate 
was left to sit during 30–45 min until pellet formation, which was re-suspended into 
Krebs solution and left at room temperature.   
 
Western blot analysis 
Western blot analysis was performed as previously described (Paper 1; 
Barros-Barbosa et al. 2015b). Total lysates and synaptosomes of the human 
cerebral hippocampus were homogenized in RIPA buffer. Samples were solubilized 
in SDS reducing buffer, subjected to electrophoresis in SDS-polyacrylamide gels 
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and electrotransferred onto PVDF membranes. Membranes were blocked in Tris-
buffered saline containing Tween 20 0.05% and BSA 5% and incubated with the 
primary antibodies: mouse anti-GFAP (1:500, Chemicon, Temecula, CA), mouse 
anti-synaptophysin (1:750, Chemicon, Temecula, CA), mouse anti-PSD95 (1:600, 
Chemicon, Temecula, CA) and rabbit anti-A2A receptor (1:250; Alpha Diagnostic, 
San Antonio, TX). Membranes were washed and incubated with horseradish 
peroxidase-conjugated secondary antibody.  For normalization purpose, 
membranes were incubated with rabbit anti-β-tubulin antibody (1:2500; Abcam, 
Cambridge, UK) or mouse anti-GAPDH antibody (1:200; Santa Cruz Biotechnology, 
Dallas, TX) following the procedures described above. The antigen-antibody 
complexes were visualized using the ChemiDoc MP imaging system (Bio-Rad 
Laboratories, Hercules, CA). Gel band image densities were quantified with Image 
J (National Institute of Health, USA). To test for specificity of the bands 
corresponding to A2A receptor, the anti-A2A receptor antibody was pre-adsorbed with 
a control/blocking peptide (# A2aR21-P, Alpha Diagnostic, San Antonio, TX).  
 
Immunofluorescence confocal microscopy  
Immunofluorescent staining and confocal microscopy analysis was 
performed as previously described (Paper 1; Barros-Barbosa et al. 2015b). Free 
floating 30 μm brain sections were incubated for 1 h, with blocking buffer and 
incubated overnight with the primary antibodies: mouse anti-A2A receptor (1:300, 
Chemicon, Temecula, CA), rabbit anti-synaptotagmin 1/2 (1:500, Synaptic Systems 
GmbH, Goettingen, D), rabbit anti-GFAP (1:500, Dako, Glostrup, DK) and rabbit 
anti-NF200 (1/900, Abcam, Cambridge, UK). Sections were rinsed and incubated 2 
h with species specific secondary antibodies: donkey anti-rabbit Alexa Fluor 488 
and goat anti-mouse Alexa Fluor 633 (Molecular Probes, Eugene, OR). After 
mounting, sections were observed and analyzed with a laser scanning confocal 
microscope (Olympus FV1000, Tokyo, JP). Co-localization was assessed by 
calculating the staining overlap and the Pearson´s Coefficient (ρ) for each confocal 
micrograph using the Olympus Fluoview 4.2 Software (Olympus FV1000, Tokyo, 
JP).  
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Data presentation and statistical analysis 
Results are expressed as mean ± SD. n shown in graphs represent the 
number of individuals in a given situation.  Statistical analysis was carried out using 
Graph Pad Prism 6.04 software (La Jolla, CA, USA). Unpaired Student’s t-test with 
Welch correction was used for statistical analysis when parametric data was 
considered. For multiple comparisons, one-way ANOVA followed by Dunnett's 
Multiple Comparison Test was used. For multiple comparisons between multiple 
groups, two-way ANOVA followed by Bonferroni´s Multiple Comparison Test was 
used. P < 0.05 values were accepted as significant.  
 
Results 
Human hippocampal synaptosomes are enriched in synaptic nerve terminals 
Figure 23 shows that synaptosomes isolated from the hippocampus of MTLE human 
patients present less amounts (P<0.001) of the astrocytic cell marker, GFAP, when 
compared to total lysates. Similar levels of the postsynaptic density marker, PSD95, 
were found in synaptosomes and total lysates of the hippocampus of MTLE patients. 
More importantly, synaptosomes isolated from the hippocampus of MTLE patients 
(Figure 23) using our methodology are highly enriched (P<0.001) in synaptic nerve 
terminals specifically labelled with synaptophysin compared to total lysates of the 
same brain region. 
 
Figure 23 – Synaptosomes isolated from 
the hippocampus of MTLE human patients 
are enriched in synaptic nerve terminals. At 
the top of the figure are illustrated 
representative blots of GFAP, 
synaptophysin and PSD95 immuno-
reactivity in total lysates and synaptosomes 
of the hippocampus of an MTLE patient. 
GAPDH and β-tubulin were used as 
reference proteins. At the bottom, it is 
illustrated the average composition in 
GFAP, synaptophysin and PSD95 of total 
lysates and synaptosomes from four MTLE 
patients. Data are expressed as mean ± 
SD. ***P < 0.001 represents significant 
differences as compared to total lysates 
(two way ANOVA followed by Bonferroni´s 
Multiple Comparison Test); ns, non-
significant.  
 
Purinergic modulation of neurotransmitter transporters in human MTLE  
Original Research Papers 
125 
 
 
 
The A2A receptor expression is upregulated in the hippocampus of MTLE 
human patients 
Data from Western blot analysis show that the A2A receptor protein (~46 kDa) 
levels are significantly (P<0.001) increased (by about three fold) in total lysates of 
the hippocampus of MTLE patients as compared to control individuals (Figure 24A). 
Please note that the bands corresponding to the A2A receptor protein disappeared 
after pre-adsorption of the antibody with the control peptide (Figure 24A; negative 
control). It is worth noting that upregulation of the A2A receptor protein in the 
hippocampus of MTLE patients compared to control individuals is more notorious 
(P<0.01) in total lysates than in isolated nerve terminal (synaptosomal) fractions, 
suggesting that the A2A receptor is localized predominantly in non-neuronal cells, 
probably glial cells (Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 
2013; Orr et al., 2015). 
 
Figure 24 – The A2A receptor protein density is greatly increased in the hippocampus of drug-
refractory MTLE human patients. Panel A illustrates representative Western blots of the A2A receptor 
immunoreactivity in total lysates and synaptosomes of the hippocampus of control and MTLE human 
patients; gels were loaded with 100 µg of protein. Please note that the bands corresponding to the 
molecular weight of native A2A receptor (~46 kDa) disappeared after pre-adsorption of the primary 
antibody with a control peptide (lane 5; negative control); GAPDH was used as a reference protein. 
Data are expressed as mean ± SD and the number of individuals per group is shown below each 
bar. ***P < 0.001 (two way ANOVA followed by Bonferroni´s Multiple Comparison Test). Panel B 
shows representative confocal microscopy images from different regions of the human hippocampus 
demonstrating that immunoreactivity against the A2A receptor (green) is more notorious in the 
hippocampus of MTLE patients than that from control individuals; nuclei are labeled with 4',6-
diamidino-2-phenylindole (DAPI; blue); DIC images are shown for comparison; 2 confocal 
micrographs were obtained per individual; 3 individuals from each group (control and MTLE) were 
analyzed; scale bars = 300 µm. 
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Upregulation of the adenosine A2A receptor expression in the hippocampus 
of MTLE patients compared to control individuals detected by Western blot analysis 
(Figure 24A) is supported by immunofluorescence confocal microscopy (Figure 
24B). Confocal micrographs of the hippocampus of MTLE patients show increases 
in the A2A receptor density (labelled in green) in all its regions, CA1, CA2, CA3 and 
DG/CA4, when compared to control individuals. Due to hippocampal sclerosis, the 
boundaries of each region are less evident in hippocampi of MTLE patients than of 
control individuals and this can be appreciated using the DIC images for 
comparison.  
Altogether these results show that the adenosine A2A receptor is upregulated 
(by about 3-fold) in the hippocampus of drug-refractory MTLE patients compared to 
control individuals. 
 
Upregulated expression of adenosine A2A receptors are mainly localized in 
astrocytes of the hippocampus of MTLE human patients 
Results obtained by comparing A2A receptor protein levels in total lysates and 
synaptosomal fractions of the human hippocampus (Figure 24A) led us to reach the 
conclusion that the A2A receptor is localized predominantly in non-neuronal cells. 
Using immunofluorescence confocal microscopy, we show in Figure 25 that the 
adenosine A2A receptor (green) colocalizes extensively with the astrocytic cell 
marker, GFAP (red), in all regions of the human hippocampus, including Cornu 
Ammonis, CA1, CA2, CA3, CA4, and dentate gyrus (DG). Co-localization between 
A2A receptor and GFAP immunostainings detected by the yellow staining when 
merging the two fluorescence channels (Figure 25A, right-hand side of the image) 
was confirmed by the elevated scores obtained by calculating the staining overlap 
(overlap > 0.6) and the Pearson´s Coefficient (ρ > 0.4) in different areas of the 
human hippocampus (Figure 25B). Overlap between two colors gives values 
between +1 (total overlap) and 0 (no overlap) and the ρ value is a measure of the 
linear correlation between two variables (stainings), giving values between +1 and 
−1 inclusive, where 1 is total positive correlation, 0 is no correlation, and −1 is total 
negative correlation. 
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Figure 25 – The A2A receptor 
is predominantly present in 
astrocytes. Panel A illustrates 
representative confocal 
micrographs of different 
regions of human 
hippocampus from MTLE 
patients stained against the 
A2A receptor (green) and the 
astrocytic cell marker, GFAP 
(red). Co-localization is shown 
by the yellow labeling 
appearing when merging the 
two fluorescent channels 
(right-hand side of the image). 
Panel B shows the staining 
overlap and Pearson´s 
Coefficient (ρ) parameters 
(mean ± SD) calculated from 
2-4 confocal micrographs per 
MTLE individual of 3 
individuals. These parameters 
were automatically calculated 
per image and were used to 
quantify the co-localization of 
A2A receptor and GFAP 
(yellow staining) in different 
hippocampal regions. Scale 
bars = 50 µm. 
 
 
 
 
 
 
 
 
 
Conversely, we obtained reduced scores of colocalization when calculating 
the staining overlap (overlap < 0.25) and the Pearson´s Coefficient (ρ < 0.03) when 
we evaluated the colocalization of the A2A receptor with the nerve terminal marker, 
synaptotagmin 1/2 (Figure 26), and the axonal marker, NF200 (Figure 27). Under 
these conditions, we could hardly see the yellow staining when merging the two 
fluorescent channels in any regions of the hippocampus of MTLE patients. 
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Figure 26 – The A2A receptor 
does not co-localize with the 
synaptic nerve terminal marker, 
synaptotagmin 1/2. Panel A 
shows representative confocal 
micrographs of different regions 
of the hippocampus of MTLE 
human patients labeled with 
antibodies against the A2A 
receptor (green) and 
synaptotagmin 1/2 (red). The 
absence of colocalization is 
shown by the non-appearance 
of the yellow staining when 
merging the two fluorescent 
channels (right-hand side of the 
image). Panel B shows the 
staining overlap and the 
Pearson´s Coefficient (ρ) 
parameters (mean ± SD) 
calculated from 2-4 confocal 
micrographs per MTLE 
individual of 3 individuals. 
These parameters were 
automatically calculated per 
image and were used to 
quantify the co-localization of 
A2A receptor and synaptotagmin 
1/2 in different hippocampal 
regions. Scale bars = 50 µm. 
 
 
 
 
 
 
 
 
These results suggest that the adenosine A2A receptor is present 
predominantly in astrocytes of the hippocampus from MTLE patients, thus 
confirming our suspicion due to differences in the density of Western blot bands 
obtained with total lysates and synaptosomal fractions of the human hippocampus 
(Figure 24A). Our results are also in keeping with those obtained in the 
hippocampus of Alzheimer patients (Orr et al., 2015).  
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Figure 27 – The A2A receptor 
does not co-localize with the 
axonal marker, NF200. Panel A 
shows representative confocal 
micrographs of different 
regions of the hippocampus of 
MTLE human patients labeled 
with antibodies against the A2A 
receptor (green) and NF200 
(red). The absence of 
colocalization is shown by the 
non-appearance of the yellow 
staining when merging the two 
fluorescent channels (right-
hand side of the image). Panel 
B illustrates the staining 
overlap and the Pearson´s 
Coefficient (ρ) parameters 
(mean ± SD) calculated from 2-
3 confocal micrographs per 
MTLE individual of 2 
individuals. These parameters 
were automatically calculated 
per image and were used to 
quantify the colocalization of 
A2A receptor and NF200 in 
different hippocampal region. 
Scale bars = 50 µm. 
 
 
 
 
 
 
 
 
Discussion and conclusions 
The present study shows, for the first time, that the adenosine A2A receptor 
is upregulated (by about 3-fold) in the hippocampus of drug-resistant MTLE human 
patients compared to control individuals. This feature is in agreement with previous 
studies showing that the A2A receptor exists at relative low levels in the hippocampus 
(Schiffmann et al., 1991; Dixon et al., 1996), but its amount may increase in the 
hippocampus of epileptic animal models (Huicong et al., 2013; Orr et al., 2015). As 
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a matter of fact, increasing evidences show that activation of the adenosine A2A 
receptor favors seizure activity in different epileptic syndromes (Hosseinmardi et al., 
2007; El Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Huicong 
et al., 2013). Activation of the A2A receptor has a pro-convulsive effect on piriform 
cortex kindled seizures in the rat (Hosseinmardi et al., 2007) and it decreases the 
seizure threshold of hyperthermia-induced convulsions in young rats (Fukuda et al., 
2011). Reduction of seizures occurrence has been verified in rat models of temporal 
lobe epilepsy (induced by pilocarpine or by kindling) either by selective inhibition of 
the A2A receptor with SCH58261 or ZM241385 (Rosim et al., 2011; Li et al., 2012) 
or by genetic deletion (knockdown) of the A2A receptor (El Yacoubi et al., 2008, 
2009). Curiously, deletion of the A2A receptor does not protect against maximal 
electroshock-induced seizures that are originated from brainstem structures (El 
Yacoubi et al., 2008, 2009).  
It is worth noting that increases in the extracellular levels of ATP and, 
consequently, augmentation of the levels of its metabolite, adenosine, that has been 
reported during high-frequency neuronal firing and/or during prolonged or repeated 
epileptic seizures (Heinrich et al., 2012; Wall and Dale, 2013; Sims and Dale, 2014), 
may be critical for the activation of the A2A receptor. This is because adenosine 
resulting from the extracellular catabolism of released ATP, via CD73, preferentially 
activates the excitatory A2A receptor in the hippocampus (Cunha et al., 1996a). 
Additionally, the CD73 enzyme seems to be increased in rat models of temporal 
lobe epilepsy induced by kainate or pilocarpine (Bonan et al., 2000).  
Despite adenosine has been considered the main endogenous antiepileptic 
molecule, via the activation of inhibitory A1 receptors, and some studies had 
proposed that augmentation of adenosine levels may be a solution to resolve drug-
refractory epilepsies, this must be taken carefully since increased extracellular 
levels of adenosine may not only activate the inhibitory A1 receptor, but can also 
trigger A2A receptor-mediated excitation (Boison, 2008). Activation of the excitatory 
A2A receptor is more likely to occur in epileptic patients, as this receptor is 
upregulated in the human epileptic hippocampus (this study, see e.g. Figure 24). 
According to the results described in this study, it is therefore advisable when 
proposing adenosine augmenting strategies for treating epilepsy to consider 
simultaneous inhibition of the A2A receptor to prevent adenosine-induced excitability. 
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Another important finding from this study concerns the demonstration that the 
A2A receptor is upregulated predominantly in GFAP-positive astrocytes of the 
hippocampus of drug-resistant MTLE patients. A recent study reached the same 
conclusion using epileptic rats injected with kainate, as well as hippocampi from 
patients with Alzheimer’s disease (Orr et al., 2015). Data from our study revealed a 
low density score for colocalization of the A2A receptor with immunoreactive 
neuronal markers, like synaptotagmin 1/2 and NF200, in the hippocampus of MTLE 
human patients. Whether upregulation of the A2A receptor accompanies astrogliosis 
that is characteristic of hippocampal sclerosis observed in MTLE patients in 
detriment of neuronal loss and/or mossy fibers sprouting deserves further 
elucidation. Nevertheless, the astrocytic localization of the A2A receptor highlights a 
role of these cells in epilepsy, which relevance may be associated with the proposed 
modulation of glutamate transport and release via the activation of astrocytic A2A 
receptors (Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013) and, 
subsequent, increase in the extracellular levels of this excitatory neurotransmitter 
resulting in neuronal excitation and/or excitotoxicity. The mechanism underlying the 
A2A receptor-mediated control of glutamate release by astrocytes seems to involve 
the activation of PKA and intracellular Ca2+ mobilizations (Kanno and Nishizaki, 
2012), while the mechanism underlying the A2A receptor-mediated downmodulation 
of glutamate uptake seems to involve the decrease of the Na+/K+-ATPase activity, 
and, thereby, the disruption of transmembrane Na+ gradient (Matos et al., 2013). 
Although the intracellular transduction pathway implicated in the A2A receptor-
mediated inhibition of glutamate uptake in astrocytes may differ, the final result (i.e. 
collapse of the Na+-driving force to take up glutamate) is quite similar to what we 
found to be involved in the P2X7 receptor-mediated downmodulation of glutamate 
uptake in cortical nerve terminals (Barros-Barbosa et al., 2015a; Barros-Barbosa et 
al., 2015b).  
In conclusion, our results suggest that inhibition of upregulated A2A receptors 
localized in hippocampal astrocytes of drug-resistant MTLE human patients using 
selective antagonists may prevent neuronal excitation and confer neuroprotection, 
as previously demonstrated in epileptic animal models (Rosim et al., 2011; Li et al., 
2012; Valadas et al., 2012; Rombo et al., 2015). Therefore, our hypothesis is that 
the hippocampal A2A receptor may be an attractive pharmacological target for the 
treatment of drug-resistant MTLE. The mechanism by which the A2A receptor 
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promotes excitability in epileptic patients remains unknown. However, it is possible 
that modulation of the glutamate transport operated by activation of astrocytic A2A 
receptors (Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013) might 
be involved, as it results in the augmentation of extracellular glutamate levels and, 
thus, promote neuronal excitability/excitotoxicity.   
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CHAPTER 4: DISCUSSION 
AND CONCLUSIONS
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The main aim of this work was to contribute to the discovery of novel 
pharmacological targets to control drug-resistant epileptic seizures and/or 
epileptogenesis. Given that imbalance between GABAergic and glutamatergic 
neurotransmission leading to over synchronized neuronal firing has long been 
considered the hallmark of epilepsy, we investigated endogenous regulators that 
could fine-tuning modulate the extracellular levels of GABA and glutamate. Our 
focus was on ATP and adenosine whose extracellular accumulation rapidly increase 
in the brain during high-frequency neuronal firing or under pathological conditions 
(Cunha et al., 1996b; Frenguelli et al., 2007; Heinrich et al., 2012; Wall and Dale, 
2013) allowing the spatial and temporal cohabitation of these two purines with GABA 
and glutamate neurotransmitters. Limitations in the use of animal models of epilepsy 
(Kandratavicius et al., 2014) encouraged us to address the changes in purinergic 
receptor-mediated modulation of Na+-coupled neurotransmitter transporters directly 
on human tissue obtained from drug-resistant epileptic patients and from cadaveric 
controls. Despite the use of human brain samples, another major advantage of our 
approach compared with previous studies in the literature was the possibility of 
measuring simultaneously the transport of [3H]GABA and [14C]glutamate into 
isolated nerve terminals. However the scarcity of the human brain tissue and the 
difficulty in its achievement due to obvious ethical reasons and inherent complexity 
in coordinating clinical work and laboratory timings, lead us to first expand our 
evaluation about the mode of action of the purines on GABA and glutamate uptake 
in isolated nerve terminals (synaptosomes) of the cerebral cortex of control and 
epileptic Wistar rats injected with pilocarpine. This animal model was chosen 
because its clinical features and pathological characteristics most frequently 
compare with drug-resistant MTLE in humans (Sharma et al., 2007; Curia et al., 
2008; O'Dell et al., 2012).  
Taking into consideration previous findings suggesting that the ionotropic 
P2X7 receptor may be a potential target to control seizures and that it is able to 
modulate the extracellular levels of amino acid neurotransmitters (Neal et al., 1998; 
Lo et al., 2008; Morioka et al., 2008), we drew our attention to the study of the role 
of ATP acting via the P2X7 receptor on synchronized modulation of GABA and 
glutamate uptake into isolated cortical nerve terminals. Results clearly showed that 
activation of the ATP-sensitive P2X7 receptor downregulates Na+-coupled high-
affinity GABA and glutamate uptake by nerve terminals (synaptosomes) isolated 
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from the cerebral cortex of control rats and human patients. The mechanism 
underlying downregulation of amino acid transporters seems to be common for the 
two neurotransmitters and, in accordance with our initial hypothesis, it involves the 
partial collapse of the Na+ driving-force for neurotransmitters uptake caused by the 
influx of Na+ through the P2X7 receptor channel. It is worth to note that most of the 
experiments presented in this work were done in low extracellular Ca2+ conditions 
in order to mimic the synaptic ambience under strong physiological nerve firing or 
during epileptic seizures (Heinemann et al., 1977; Borst and Sakmann, 1999; 
Engelborghs et al., 2000; Stanley, 2000; Massimi and Amzica, 2001; Rusakov and 
Fine, 2003; Engel et al., 2012a; Poornima et al., 2012; Torres et al., 2012; Zhou et 
al., 2012; Jimenez-Pacheco et al., 2013). That is, under pathological epileptic 
conditions, the Ca2+ concentration in the extracellular milieu declines to a maximum 
of 90% and synaptic ATP is high enough to activate low-affinity P2X7 receptors 
(Jarvis and Khakh, 2009) in a situation where GABA and/or glutamate levels are 
maximal. This strategy allowed us to focus our research on alterations of the Na+ 
driving-force for amino acids transportation, while excluding (1) the involvement of 
Ca2+ in the regulation of amino acid transporters either directly or via plasmalemmal 
and/or mitochondrial Na+/Ca2+ exchangers, and (2) the interference of Ca2+-
activated neurotransmitter release (Cordeiro et al., 2000; Cordeiro et al., 2003; 
Romei et al., 2015).  
Data using rat cortical synaptosomes show that besides decreasing GABA 
and glutamate uptake under low Ca2+ conditions, activation of the P2X7 receptor 
also favors the release of both neurotransmitters. However, the magnitude and the 
mechanism underlying GABA and glutamate release triggered by the P2X7 receptor 
activation differ significantly. While activation of the P2X7 receptor causes the 
outflow of small amounts of GABA through reversal of the GAT1, glutamate is 
released in higher quantities through the P2X7 receptor pore (see also Marcoli et 
al., 2008; Cervetto et al., 2013). These differences may contribute to explain why 
the P2X7 receptor agonist, BzATP, was more potent in decreasing the uptake of 
glutamate by nerve terminals of the rat cerebral cortex, as compared to GABA 
uptake as the concomitant leakage of glutamate directly through the P2X7 receptor 
pore may downsize [14C]glutamate incorporation inside cortical synaptosomes.     
Contrary to our expectations, we found no differences in the P2X7 receptor 
expression and function on nerve terminals from the cerebral cortex of pilocarpine-
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induced epileptic rats compared to their control littermates. These findings contrast 
with our data using human cerebral cortices obtained from drug-resistant MTLE and 
non-MTLE patients. Under similar experimental conditions, we found that the P2X7 
receptor was upregulated in cortical nerve terminals isolated from epileptic patients 
compared to cadaveric controls. Moreover, increases in the P2X7 receptor density 
correlate with a higher potency of the P2X7 receptor agonist, BzATP, concerning 
inhibition of GABA, but not glutamate, uptake by nerve terminals isolated from the 
neocortex of MTLE patients. Thus, the absence of differences in the purinergic 
modulation between control and epileptic animals may be explained by shortage in 
the disease evolution after SE induced by pilocarpine, being this time insufficient to 
promote the morpho-functional changes observed in human patients with MTLE, 
where the disorder is allowed to develop for many years before last resource 
neurosurgery is indicated. 
Taking into consideration that epileptic activity also gives rise to large 
quantities of adenosine released to the extracellular milieu as such (via equilibrative 
nucleoside transporters) or generated by the catabolism of released ATP (via the 
CD73 pathway), creating the ideal conditions to activate excitatory adenosine A2A 
receptors counterbalancing the anti-epileptic role of the nucleoside via inhibitory A1 
receptors (see Cunha et al., 1996a), we thought it was appropriate to investigate for 
the first time the density of expression and cellular localization of the A2A receptor in 
human hippocampal samples from control and MTLE patients exhibiting 
hippocampal sclerosis. The results obtained showed that A2A receptors were 
upregulated in hippocampal astrocytes of MTLE patients. Interestingly, the 
astrocytic localization of surplus excitatory metabotropic A2A receptors in the 
hippocampus of MTLE patients clearly differ from that found for the ionotropic P2X7 
receptor, which was more abundant in neocortical nerve terminals of MTLE patients. 
Upregulation of astrocytic A2A receptors in the hippocampus of MTLE human 
patients is not different from that verified in the brain of epileptic animal models 
(Huicong et al., 2013; Orr et al., 2015), where activation of the A2A receptor promotes 
epileptiform activity under various disease conditions (Hosseinmardi et al., 2007; El 
Yacoubi et al., 2008, 2009; Fukuda et al., 2011; Rosim et al., 2011; Huicong et al., 
2013). Interestingly, data from our group demonstrated that adenosine resulting 
from the extracellular catabolism of released ATP, via the CD73 pathway, activates 
preferentially excitatory A2A receptors in the hippocampus (Cunha et al., 1996a), 
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and this enzyme is also significantly upregulated in rat models of temporal lobe 
epilepsy induced either by pilocarpine or kainate injections (Bonan et al., 2000). 
Astrocytic A2A receptors have been recently implicated in the control of the 
synaptic levels of glutamate by modulating both the release and the uptake of this 
neurotransmitter (Kanno and Nishizaki, 2012; Matos et al., 2012; Matos et al., 2013). 
Moreover, activation of the A2A receptor has been involved in the facilitation of GABA 
uptake by astrocytes, an effect requiring the synergism with BDNF (Vaz et al., 2011). 
Concerted actions of adenosine, via astrocytic A2A receptors, may favor neuronal 
excitation due to synaptic glutamate accumulation, whose effects may rapidly 
become unbalanced due to the A2A receptor-mediated promotion of GABA uptake 
by neighboring astrocytes.     
The mechanism underlying the A2A receptor-mediated downmodulation of 
glutamate uptake by astrocytes seems to involve partial disruption of the 
transmembrane Na+ gradient due to the decrease of the Na+/K+-ATPase activity 
(Matos et al., 2013). These authors described a physical association between the 
A2A receptor and the Na+/K+-ATPase in astrocytes of the cerebral cortex and 
suggested that there is a link to GLT-1 via the α2 subunit of the Na+/K+-ATPase, 
which may be crucial to regulate the glutamate transport in astrocytes. Furthermore, 
the prolonged activation of the A2A receptor may result in a cAMP/protein kinase A-
dependent reduction of GLT-1 and GLAST mRNA and protein levels, leading to a 
sustained decrease of glutamate uptake (Matos et al., 2013). Although the 
intracellular transduction elements implicated in the A2A receptor-mediated inhibition 
of glutamate uptake may differ, the final result (i.e. partial collapse of the Na+-driving 
force to take up glutamate) is quite similar to what we found to be involved in the 
modulation of glutamate uptake by activation of the ionotropic P2X7 receptor in 
cortical nerve terminals (Barros-Barbosa et al., 2015a; Barros-Barbosa et al., 
2015b). To our knowledge, downmodulation of GABA uptake produced by the A2A 
receptor-mediated decrease of Na+/K+ ATPase activity was not demonstrated yet, 
however it is plausible to assume that this modulation can also occur since the 
GABA transporters are expressed in astrocytes (Conti et al., 2004; Melone et al., 
2015) and their function is also dependent on extracellular Na+ levels (Allen et al., 
2004; Kanner, 2006). However, other studies demonstrated that the A2A receptor 
activation seems to be required to the potentiation of GABA uptake by BDNF in 
astrocytes (Vaz et al., 2011).  
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Taken together our results, in conjunction with the data from other authors, 
led us to anticipate that transient activation of P2X7 and A2A receptors by released 
ATP during high-frequency neuronal firing and its subsequent catabolism into 
adenosine in the extracellular milieu (Cunha et al., 1996b; Frenguelli et al., 2007; 
Heinrich et al., 2012; Wall and Dale, 2013; Sims and Dale, 2014)  may undertake 
facilitation of glutamatergic neurotransmission (Marcoli et al., 2008; Kanno and 
Nishizaki, 2012; Matos et al., 2013; Barros-Barbosa et al., 2015a; Barros-Barbosa 
et al., 2015b) while promoting, albeit to a lesser extent, the endurance of GABAergic 
neurotransmission ensuring tonic and more diffuse neuro-inhibition following an 
intense period of stimulation (Barros-Barbosa et al., 2015a; Barros-Barbosa et al., 
2015b). This mechanism may be particularly relevant in processes such as learning 
and memory where transient glutamate endurance in the synaptic cleft may facilitate 
the induction of LTP while preventing excytotoxicity by the concomitant promotion 
of diffuse GABAergic inhibition. As a matter of fact, several studies demonstrated 
that both P2X7 (Chu et al., 2010; Campos et al., 2014) and A2A receptors (Kessey 
et al., 1997; Almeida et al., 2003; Rebola et al., 2008) are essential players to 
promote long-term changes in synaptic plasticity.  
While fine-tuning modulation of extracellular concentrations of GABA and 
glutamate by endogenously released purines, namely ATP and adenosine, appears 
to have a significant role under physiological conditions by potentiating 
neurotransmission, it might gain a different meaning during epileptic discharges 
where the density of both P2X7 and A2A receptors is upregulated and the sequential 
activation of these two purinoceptors may constitute “an hazardous orchestra” 
(Rodrigues et al., 2015). Upregulation of P2X7 and A2A receptors located 
respectively in nerve terminals and astrocytes of the brain of drug-resistant epileptic 
(MTLE) patients, contributes to amplify ATP- and adenosine-mediated signals 
resulting in the impairment of the transmembrane Na+ gradient (see also Matos et 
al., 2013). This leads to a scenario where, besides the glutamatergic signaling 
endurance, the persistence of GABA-mediated neurotransmission owed to the 
decrease of GABA uptake may guide the GABAA receptor to rundown. Therefore, 
under pathological conditions, increases in the extracellular accumulation of GABA 
combined with impaired Cl- gradient and altered GABAA receptor subunit 
composition that has been described in drug-resistant epileptic patients, may 
convert GABAergic inhibition into a pro-convulsive action instigated by GABAergic 
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rundown (Cohen et al., 2002; D’Antuono et al., 2004; Ragozzino et al., 2005; Palma 
et al., 2007; Mazzuferi et al., 2010; Miles et al., 2012). The GABAergic rundown 
phenomenon is likely to occur during high-frequency neuronal stimulation and it has 
been linked either (1) to GABAA receptor desensitization (Ragozzino et al., 2005; 
Palma et al., 2007; Mazzuferi et al., 2010), or (2) to membrane depolarization 
stemming from changes in the way cells handle intracellular Cl- homeostasis 
(D’Antuono et al., 2004; Miles et al., 2012) (see Figure 28).  
 
 
Figure 28 – Schematic diagram representing the role of purines released by high-frequency nerve 
discharges. During epileptic seizures, the extracellular concentrations of ATP and its metabolite, 
adenosine, increase drastically reaching levels high-enough to activate low-affinity ionotropic P2X7 
and metabotropic A2A receptors, respectively, which expression is upregulated in drug-resistant 
epileptic patients. Activation of both receptors favors the imbalance in the extracellular levels of 
GABA and glutamate, through downmodulation of their reuptake system operated by the disruption 
of the transmembrane Na+ gradient. Under these conditions, inhibition of GABA uptake coupled to 
changes in Cl- homeostasis can affect the inhibitory nature of GABAA receptor-mediated 
transmission, leading to GABA mediated excitation. On the other hand, parallel promotion of 
glutamatergic neurotransmission by excess of glutamate at the synapse may ultimately lead to 
excitotoxicity and neuronal degeneration. This highlights the inhibition of both P2X7 and A2A 
receptors as relevant pharmacological targets to control drug-resistant human epilepsy. 
 
Nowadays, increasing evidences have shown that altered neuronal Cl- 
homeostasis in MTLE patients can affect the strength and even the signal of GABAA 
receptor-mediated neurotransmission, leading to a decrease in the efficacy of 
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GABAergic inhibition or even to GABA-mediated excitatory actions (Cohen et al., 
2002; Huberfeld et al., 2007; Ben-Ari et al., 2012; Miles et al., 2012; Pavlov et al., 
2013; Pallud et al., 2014). Interestingly, impairment of Cl- homeostasis has been 
associated with the downregulation of KCC2 and often with the upregulation of 
NKCC1 in patients with drug-refractory temporal lobe epilepsies and in animals with 
acquired focal epilepsies (Köhling, 2002; Huberfeld et al., 2007; Blaesse et al., 2009; 
Miles et al., 2012). This might explain why, sometimes, increasing extracellular 
GABA levels (using, for instance, vigabatrin or tiagabine) or administering GABA 
mimetic drugs (like benzodiazepines) may result in paradoxical clinical effects in 
some epileptic patients (Ben-Ari, 2014; Khazipov et al., 2015).  
Concurrently with the paradoxical excitatory effect resulting from the increase 
in extracellular GABA accumulation, parallel promotion of glutamatergic 
neurotransmission by decreases in the uptake of glutamate (Matos et al., 2013; 
Barros-Barbosa et al., 2015a; Barros-Barbosa et al., 2015b) may ultimately lead to 
excitotoxicity and neuronal degeneration. Findings from this study and other reports 
in the literature support the idea that the mechanisms underlying downmodulation 
of GABA and glutamate uptake by neuronal P2X7 and astrocytic A2A receptors in 
epileptic patients are quite similar and involve the collapse of Na+ gradient across 
plasma membranes (Matos et al., 2013; Barros-Barbosa et al., 2015a). Thus, 
activation of both purinoceptors lead to a common feature that is translated into (1) 
increases in the intracellular Na+ concentration, which was already described to 
occur at the time of tissue injury (Yu et al., 2010; Romei et al., 2015), and (2) 
increases in the extracellular glutamate concentration that is characteristic of the 
epileptic situation (Janjua et al., 1992; During and Spencer, 1993; Soukupova et al., 
2015). 
In summary, this study fills a gap in the understanding of the human epileptic 
brain, regarding the pro-epileptic role of both ATP and adenosine in the extracellular 
milieu, in conditions where the synaptic levels of these purines rapidly increase, 
such as during intense neuronal discharges (Cunha et al., 1996b; Frenguelli et al., 
2007; Heinrich et al., 2012; Wall and Dale, 2013). Altogether, the results obtained 
in this work and data from other authors (Kanno and Nishizaki, 2012; Matos et al., 
2012; Matos et al., 2013) indicate that purines, ATP and adenosine, acting 
respectively on neuronal P2X7 and astrocytic A2A purinoceptors can modulate the 
extracellular levels of GABA and glutamate, an effect that can dramatically increase 
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in drug-resistant epileptic patients where the expression of the two purinoceptors is 
upregulated. In view of this and in line with previous suggestions obtained from 
animal studies (Vianna et al., 2002; Hosseinmardi et al., 2007; El Yacoubi et al., 
2008; Engel et al., 2012a; Huicong et al., 2013; Jimenez-Pacheco et al., 2013; 
Rodrigues et al., 2015), we now propose that the pharmacological targeting of 
neuronal ATP-sensitive P2X7 and astrocytic adenosine A2A receptors with selective 
antagonists may constitute a novel and valuable therapeutic alternative to manage 
drug-resistant epileptic patients. We believe that the combined blockade of 
ionotropic P2X7 and metabotropic A2A receptors in the epileptic brain will avoid 
neuronal excitability and excitotoxicity, improving the quality-of-life and longevity of 
drug-refractory MTLE patients by restoring the extracellular levels of GABA and 
glutamate.  
Outside the epilepsy context, there is an explosion of data indicating that both 
P2X7 and A2A receptors are involved in the pathophysiology of several neurological 
syndromes, including neurotrauma (Kimbler et al., 2012), multiple sclerosis (Gu et 
al., 2015), amyotrophic lateral sclerosis (Yiangou et al., 2006), Alzheimer’s disease 
(McLarnon et al., 2006; Miras-Portugal et al., 2015; Orr et al., 2015; Sáez-Orellana 
et al., 2015), Parkinson’s disease (Uchida et al., 2015), Huntington’s disease (Díaz-
Hernández et al., 2009) and psychiatric mood disorders (Kongsui et al., 2014). It 
appears that there is a common feature among all these pathological conditions, 
which may be the rapid increase in extracellular ATP levels that is characteristic of 
brain cells injury with its subsequent catabolism into adenosine, thus creating the 
conditions required to over activate damage receptors, like P2X7 and A2A 
purinoceptors. Therefore, blockade of both P2X7 and A2A purinoceptors with 
selective antagonists may also present clinical benefits in non-epileptic 
neurodegenerative conditions to curb “dangerous signals” emanating from an 
underlying dysfunction of these two purinoceptors. 
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